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Magnetic nanoparticles have gained significant importance in the recent past for 
their use in biomedical applications such as drug delivery, imaging, diagnosis, and therapy. 
Magnetic nanoparticle hyperthermia is the selective heating of tumor tissue using magnetic 
nanoparticles which generate heat when exposed to an alternating magnetic field. It is a 
minimally invasive method which can cause effective and localized tumor thermal damage. 
The challenge to achieve consistent heating with this modality is the variable distribution 
upon delivery, which results in variable heat distribution in the tumor and surrounding 
normal tissue.  
In this thesis, using computational methods we explore optimization strategies to 
modulate magnetic field amplitude using limited temperature feedback to achieve 
clinically effective thermal dose in tumor and minimize healthy tissue damage. The 
magnetic field amplitude is modulated by using a Proportional-Integral-Derivative (PID) 
controller based on temperature feedback from tumor-healthy tissue boundary. We 
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consider nanoparticle distributions obtained from animal studies and idealized 
mathematical constructs. Two and three dimensional (2D & 3D) models of tumor and 
healthy tissue were considered. Temperature effects on perfusion were considered. Results 
of thermal damage, temperature distributions and thermal dose obtained from modulated 
power heating were then compared to constant power heating. It is shown that controlling 
the tumor-healthy tissue boundary temperature by modulating the heating power of the 
nanoparticles can compensate for variable nanoparticle distributions to deliver effective 
treatment. The strategy was then implemented in mouse models of liver cancer. Two 
nanoparticle distributions were generated by using two injection methods. It was shown 
that the temperature at the tumor-healthy tissue boundary can be consistently controlled for 
the two nanoparticle distributions. The challenges associated with implementation of our 
proposed strategy have been identified and future steps for further accurate testing have 
been presented. 
Another challenge for magnetic nanoparticle hyperthermia is the onset of eddy 
current heating when the treatment modality is applied to tumors in large organs. 
Monitoring of eddy current heating in in vivo studies is challenging. Hence, we developed 
a computational tool which couples thermal and electromagnetic modeling to predict the 
temperatures achieved due to eddy current heating. The model was verified with the 
analytical solution and validated with gel phantom experiments. We then implemented it 
to generate 3D liver model from computed tomography (CT) images of rabbit liver. The 
temperatures attained due to eddy current heating from exposure to alternating magnetic 
fields were calculated to demonstrate the utility of the model in estimating temperature 
during magnetic nanoparticle hyperthermia of large organs. 
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In the last chapter, we characterized the thermal and magnetic properties of dual 
contrast nanoparticle formulations used in image guided thermal therapy of liver cancer. 
Dual contrast nanoparticle formulations are magnetic iron oxide nanoparticles combined 
with lipiodol. The heating potential of these lipiodol nanoparticle formulations was 
extensively characterized by measuring their thermal properties at fixed frequency with 
different magnetic field amplitudes. These were then compared to original aqueous 
formulations for assessing the differences between both the formulations. Bulk magnetic 
properties of both the formulations was measured and compared. It is observed that when 
nanoparticles are mixed with lipiodol, the specific loss power of these particles is reduced. 
These results highlight the importance of evaluating the heating performance of new 
nanoparticle formulations. 
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Chapter 1                                        
Introduction 
1.1 Cancer 
Cancer is one of the major health problems worldwide and is the second leading 
cause of death in the United States [1].  In 2017, a projected 1.7 million new cancer cases 
and 0.6 million cancer deaths are expected to occur in the United States [1].  The World 
Health Organization estimated in 2011 that cancer causes more deaths than coronary heart 
disease or all stroke [2].  With the continuing global demographic and epidemiologic 
transitions, cancer burden is expected to increase across the world with over 20 million 
new cancer cases projected annually from 2025 [2]. In the coming decades, cancer is set to 
become the major source of morbidity and mortality across the whole world [3].  In the 
United States alone, nearly $125 billion was spent for cancer in 2010 which is expected to 
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go up to $156 billion in 2020 [4]. In the past century, significant research efforts have been 
focused on understanding cancer and developing treatments. The recently launched Cancer 
MoonshotSM [5] initiative launched by the National Cancer Institute to accelerate cancer 
research highlights this importance.  
Current standard therapies for cancer include surgery, radiation therapy, 
chemotherapy, or a combination. Surgery involves complete or partial removal of 
cancerous tumor from the body. Radiation therapy is the use of ionizing radiation such as 
x-rays, gamma rays, electron beams, or protons, to destroy cells by inflicting DNA damage 
[6]. Chemotherapy is the use of chemotherapeutic agents such as cisplatin, doxorubicin, 
for destroying cells by altering or damaging their DNA. They achieve this by binding to 
DNA resulting in crosslinking of DNA inhibiting replication, repair, and/or synthesis [7,8].  
These standard therapies have multiple drawbacks and have not been entirely successful in 
treatment of all types of cancers. For surgery, the location of tumor can pose difficulty in 
complete removal of cancerous tissue. Additionally, during or post-surgery, infections, 
blood clots and other complications are possible. Radiation therapy can cause damage to 
surrounding healthy tissue, resulting in fibrosis, fatigue, and has even the potential to cause 
secondary cancer [6]. Common side effects for chemotherapy include fatigue, pain, 
mucositis, diarrhea, hair loss, loss of appetite, and nerve damage, depending on the drug 
used. Also, cancer cells are known to develop resistance to chemotherapeutic drugs and 
sometimes a patient’s condition can preclude them from standard treatments. Thus, many 
research efforts are currently focused on developing alternative treatment strategies which 
can complement these standard therapies or can be stand-alone therapies. With advances 
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in science and technology, hyperthermia, one such alternative treatment strategy, has 
gained prominence. 
1.2 Hyperthermia 
Hyperthermia cancer therapy involves raising and sustaining the temperature of 
malignant tumors and adjacent tissues to about 41 - 45 ºC for 30-60 min, to achieve a 
therapeutic thermal effect (dose) [9,10]. While hyperthermia is generally defined as heat 
treatment in the temperature range of 41 – 45 °C, there are other definitions based on 
temperature that is applied. For temperatures in the range of 39 – 41 °C, it is defined as 
mild/low temperature hyperthermia and for temperatures > 45 °C, it is defined as thermal 
ablation [11,12].  
1.2.1 History of hyperthermia 
The benefits of heat as a therapeutic agent have been recognized since the early 
ages by Romans, Greeks, Indians, and Egyptians, and is probably one of the oldest cancer 
therapies known [13]. The earliest recorded application dates back to 5000 years ago, when 
Egyptians treated breast cancer with heat [13,14]. In 3000 BC, Indian physicians used 
hyperthermia as part of a five stage clinical process known as Panchakarma prescribed for 
purificatory, curative or nutritional purposes [15]. In ancient Rome, Cornelius Celsus 
Aulus, a Roman encyclopedic doctor (25 BC – 50 AD), was the first one to note that first 
stages of cancer are extremely thermosensible [16]. In the middle ages, fever was 
considered to be an agent of purification and detoxification of the body. However, this 
enthusiasm in hyperthermia diminished after Ambriose Paré reported the negative 
consequences due to cauterization of wounds in 1537. Later in the 17th century, many 
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instances of spontaneous tumor regression in patients with malaria, smallpox, influenza, 
tuberculosis, accompanied by fever, were reported [13,16].  
Interest in hyperthermia was again revived in the 19th century when Carl Busch 
published the first paper on hyperthermia claiming that fever caused by erysipelas cured 
the sarcoma on the face of a 43-year old woman [16]. Westermark was the first person to 
deliberately use hyperthermia for treatment of cancer, when he used circulating water 
cisterns at 42 - 44 °C to treat inoperable carcinomas of the uterus [13,16]. With reports 
from the 17th century and work by Busch, further studies were based on observations that 
febrile diseases can cause tumors to shrink. Based on this, Friedrich Fehleisen infected 
patients with bacteria causing erysipelas to treat cancer. William Coley then treated almost 
900 inoperable cancer patients with bacterial extracts called Coley’s toxins, inducing fever 
and achieving more than 60% regression rate and 20% cure rate [17]. Despite initial 
promise, the lack of better technologies and temperature measurement techniques reduced 
the use of hyperthermia for cancer treatment.  
However, the development of radiation therapy for cancer and the role of 
hyperthermia in increasing the sensitivity to radiation therapy, reinvigorated the interest in 
hyperthermia [12,14]. This led to multiple clinical and fundamental studies which resulted 
in new heating technologies being developed. Multiple in vitro and in vivo studies were 
carried out to show the potential of hyperthermia as a sensitizer for both radiation therapy 
and chemotherapy. The fundamental concepts of thermal dose and mechanisms of 
hyperthermia were developed. In the period 1981-1984, the three hyperthermic oncology 
societies in the United States, Europe, and Japan were formed [16]. This further catalyzed 
the interest in hyperthermia and led to multiple research studies. However, the lack of 
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proper heating equipment and temperature monitoring methods, led to ambiguous clinical 
reports dampening the interest in hyperthermia [14]. Since the start of the 21st century, 
advancements and availability of better technology led to a resurgence in hyperthermic 
research [14]. 
As mentioned hyperthermia is distinguished based on temperature as, mild/low 
temperature hyperthermia (39 – 41 °C), hyperthermia (41 – 45 °C), and ablation (> 45 °C). 
Other than temperatures, hyperthermia is also distinguished based which body part is 
treated. When the complete body is increased to an elevated temperature, usually in the 
mild hyperthermic temperature range, it is called as whole body hyperthermia. Regional 
hyperthermia is the increase of temperature regionally in an isolated part of body, such as 
body cavity, limb, or organ. Local hyperthermia is when only the tumor is heated [12]. 
Based on these distinctions multiple technologies have been developed. We review these 
technologies in the next subsection. Before reviewing the mechanisms to deposit heat at 
various tissue/organ levels, we need to understand the significance of hyperthermia as a 
potent sensitizer for radiation therapy and chemotherapy.  
 
1.2.2 Synergy with radiation therapy and chemotherapy 
Hyperthermia is one of the most effective radiation sensitizers known [13]. In in 
vitro studies, it has been shown that hyperthermia and radiation act in a synergistic way 
[18] and this happens in all cells, both normal and neoplastic [13]. This synergy is 
influenced by multiple factors such as temperature, heating time, sequence, and time 
interval between the two treatments. It has been shown that higher temperature results in 
larger sensitization to radiation while a similar increase effect with saturation was observed 
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for treatment time. Simultaneous hyperthermia and irradiation has proven to be most 
effective for cells and as the gap between radiation therapy and hyperthermia increases, the 
effect decreases [13]. The mechanism by which heat sensitizes cells to radiation damage is 
by interfering with the cells ability to repair DNA damage induced by radiation.   
In vivo hyperthermia sensitizes tumors to radiation therapy by inhibition of DNA 
repair processes and/or by tumor reoxygenation [13,19]. Tumor vascular structure is 
structurally and functionally abnormal when compared to the normal tissue [13]. It is 
characterized by oxygen depletion, high lactate levels, glucose deprivation, significant 
interstitial fluid flow, and pressure [20]. The imbalance between blood perfusion and 
consumption leads to hypoxic and anoxic conditions. Cells that survive in these conditions 
are referred to as hypoxic cells and have been known to have a significant negative effect 
on the tumor response to radiation therapy [13]. Hyperthermia increases the blood flow 
resulting in tumor reoxygenation, thereby sensitizing the tumor for radiation therapy [21]. 
Datta et al. [14] analyzed clinical outcomes from 38 clinical trials conducted between 1987 
and 2014, comparing radiotherapy with thermoradiotherapy (hyperthermia + radiation 
therapy) in various tumors sites namely: breast, cervix, head and neck, rectum, urinary 
bladder, esophagus, lung, skin, melanoma, choroidal melanoma, and other sites. They 
showed that an overall complete response of 54.9% was observed with thermoradiotherapy 
compared to 39.8% with radiation therapy alone [14]. No significant increase in acute or 
late toxicity was evident from these studies [14].  
Thermal enhancement ratio (TER) is often used to express the synergy between 
hyperthermia and radiation, and hyperthermia and chemotherapy. It is defined as the ratio 
of radiation or chemotherapy dose required to produce a given level of biological damage 
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with versus without heat [22]. Most clinical studies have reported a TER of 1.5 indicating 
the synergy of hyperthermia with radiotherapy and chemotherapy.  
Hyperthermia has also been known to significantly enhance the effectiveness of 
several chemotherapeutic drugs [21]. The proposed mechanisms for interaction between 
hyperthermia and chemotherapeutic drug action are increased drug uptake, increased DNA 
and protein damage, and other pharmacological changes [21]. The damage to cell 
membranes by hyperthermia results in increased permeability of the membranes leading to 
increased drug uptake. Additionally, as mentioned previously hypoxic tumor regions have 
less blood supply leading to lower uptake of cytotoxic drugs. These regions are more 
sensitive to hyperthermia, plus hyperthermia increases blood flow to these regions, 
resulting in increased drug uptake [19,23]. Hyperthermia is also known to have the ability 
to reverse the resistance to certain chemotherapeutic drugs such as methotrexate, cisplatin, 
and mitomycin-C [19]. In clinical studies, the efficacy of chemotherapy and loco regional 
hyperthermia was evaluated. The recurrence rate for 83 intermediate/high risk non-muscle 
invasive bladder cancers reduced from 80% treated with mytomycin-C alone to 40% 
treated with hyperthermia and mytomycin-C and disease free survival increased from 15% 
to 53% with thermochemotherapy [14]. These results show that combining hyperthermia 
with radiation therapy and/or chemotherapy enhances the effectiveness of both the 
treatments. 
1.2.3 Thermal dose 
For comparison of hyperthermic treatments, a thermal dose parameter needs to be 
defined. Hyperthermia treatments are performed at different temperatures and with 
different treatment times. An appropriate dose parameter is needed to compare the 
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effectiveness of these treatments [24]. The main requirements of a thermal dose parameter 
are that it should provide a means for predicting a treatment outcome as a function of 
applied hyperthermia treatment, allow for comparison of treatment responses at different 
temperatures and times, should be related to the biological mechanisms involved and 
should be a physical quantity which is measurable and well-defined [24]. The complexity 
of the biological effects of hyperthermia makes it difficult to define a single dose parameter 
that satisfies all the above requirements. However, two thermal dose models are 
extensively used in the hyperthermia community. Both of these models are based on the 
assumption that hyperthermia causes death of cells by an irreversible process, described by 
a first-order chemical reaction [25–27].  
The thermal isoeffective dose (TID) model was proposed by Sapareto et al. [25] 
based on their in vitro clonogenic survival experiments carried out on Chinese Hamster 
Ovary (CHO) cells exposed to heat. Clonogencity is the ability of cells to divide and form 
colonies and the clonogenic survival assay tests for the cell’s ability to divide [28]. The 
thermal isoeffective dose is a normalizing method for comparing the cytotoxic effects of 
different temperatures and times. It normalizes these thermal histories by converting heat 
exposures at different temperatures and exposure times, to an equivalent exposure time at 
43 °C. The reference temperature was chosen to be 43 °C, as their original measurements 
show a break point in the survival curves at that temperature [25]. This equivalent exposure 
time at 43 °C, referred to as cumulative equivalent minutes at 43 °C, CEM43 is given by 






where T(τ) is the temperature at any time τ and RCEM  is the ratio of exposure times required 
to result in the same survival for a 1°C rise in temperature [29]. The values of RCEM are 
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0.25 for T ≤ 43 °C and 0.5 for T > 43 °C, which were based on the CHO experiments [25]. 
The TID model only converts different thermal histories into equivalent minutes of 
exposure at 43 °C. It cannot predict the outcome or survival fraction after the treatment. 
For clinical application, minimum thresholds are often used for comparison. Since the 
temperatures throughout the tumor can vary significantly (ΔT ~ 4 – 5 °C) during a heat 
treatment, it is important to establish criteria to compare these treatments [30,31]. T90 is the 
criteria often used, where T90 is the temperature attained by 90% of tumor volume. A 
similar criteria CEM43T90 often used in clinical experiments for thermal dose comparison. 
The Arrhenius thermal damage model is based on the assumption that thermally 
induced cell injury is a first order irreversible kinetic process and the resultant cell survival 
fraction is given by, 
 𝑆 = 𝑒−∫ 𝑘𝑑𝜏
𝑡
0  (1.2) 
 





where S is the cell survival fraction after heating at temperature T (K), A is the frequency 
factor (s-1), ∆𝐸𝑎 the activation energy (J/mol) and R is the universal gas constant (8.314 J/ 
(mol-K)). Survival fraction is the ratio of the living cells at a given time point and the initial 
concentration. The parameters A and ∆𝐸𝑎 will need to be determined experimentally [27]. 
They are often determined by conducting multiple isothermal experiments and plotting the 
survival fraction with time to determine k and then plotting the natural logarithm of k versus 
the inverse of temperature. Then the two model parameters A and ∆𝐸𝑎can be determined 
by doing a linear fit with A being the intercept and ∆𝐸𝑎being the slope [27]. 
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Both thermal damage models have been extensively used for hyperthermia studies. 
The thermal isoeffective dose (TID) is the standard thermal dose measure for clinical 
studies [30,32]. The Arrhenius thermal damage is mostly used for predicting the survival 
fraction / thermal damage for thermal ablation [27]. Despite the different approaches, both 
models are based on the same assumptions that cell killing is a first-order irreversible 
chemical reaction [26,29,30]. The TID model is derived from the Arrhenius thermal 
damage model but leads to different results because of some assumptions and 
simplifications [25,27,30].  
There are several limitations for both the models. The models predict cell killing to 
be an irreversible first order chemical process. However, cell killing is a complex reaction 
with multiple pathways [24,29]. Moreover, the models neglect the initial shoulder region 
in the clonogenic survival and only model the exponential region. This can result in 
overestimation of thermal damage at lower temperatures. They also predict that cell killing 
can happen even at lower temperatures for long treatment times, whereas this has not been 
observed experimentally [24,29]. Various statistical and higher order models have been 
proposed to model thermal damage [29,33] which account for reversible thermal damage 
and thermotolerance. However, the difficulty in designing experiments to determine the 
parameters (often more than three) makes the implementation of these models challenging. 
Additionally, all the above models are based on in vitro experiments which are conducted 
in controlled conditions. In in vivo experiments, tumors are always in heterogeneous 
conditions with abnormal vasculature and hypoxic conditions. Thus, the application of 
these models in vivo is still questionable. However, clinical results do show a relationship 
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between the existing models for thermal dose measurement and the treatment outcome 
[34]. 
 
1.2.4  Mechanisms of heating 
There are hundreds of medical devices used for thermal treatment, but they are all 
based on three mechanisms of heat delivery to tissue: thermal conduction, mechanical 
losses, and electromagnetic losses [11,22]. 
Thermal conduction is the most fundamental mechanism of heat transfer, where 
heat flows from higher temperature to lower temperature. The rate of heat transfer is 
dependent on the temperature difference and the thermal properties of tissue. Examples of 
thermal conduction heat sources are heated fluids, heated air, or hot blankets. Thermal 
conduction is often used for whole body hyperthermia [11].  
Mechanical losses from molecular collisions induced by ultrasound pressure waves 
result in heating. The intensity of ultrasound waves attenuate exponentially with depth in 
soft tissue. For tissue heating, frequencies of 0.5 – 10 MHz which correspond to a 
wavelength of 0.1 – 3 mm are often used. These shorter wavelengths allow for more 
focused heating and the frequency range is low enough allowing for deeper penetration. 
One of the disadvantages of ultrasound therapy is that bone absorbs 50 times more energy 
compared to soft tissue. This restricts the usage of ultrasound if there is a bone in between 
the applicator and tissue [22]. 
Multiple technologies have been developed based on the interaction of electric and 
magnetic fields with tissue to generate heat. These technologies include radiofrequency 
ablation (RF ablation), microwave thermal therapy, laser or photothermal therapy, and 
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magnetic nanoparticle hyperthermia. RF ablation involves use of radiofrequency 
electromagnetic waves in the frequency range of 3 kHz to 300 GHz to generate heat by 
resistive or Joule heating. For RF ablation, frequencies in the range of 500 kHz are 
generally used [35]. It involves heating of tissue using inserted electrodes and application 
of radiofrequency currents. It is one of the leading hyperthermia techniques and is proven 
to be an effective treatment for primary liver cancer.  
Microwave therapy is the use of ultrahigh frequency electromagnetic waves (300 
MHz to 300 GHz) for heating the tissue. The heating is produced by oscillation of water 
molecules. Laser or photothermal therapy uses high intensity light waves to treat tumors 
directly. This method has been traditionally used for superficial tumors because of their 
ability to cause damage to normal healthy tissue for deep tumors. However, new interstitial 
therapy methods have been developed which use waves in the near infrared range (NIR) 
that have maximum transmissivity in normal tissue. These waves can be used to reach deep 
tumors injected with photosensitizers such as gold and silver nanoparticles to generate 
focused heat [36]. 
 
1.3 Magnetic nanoparticle hyperthermia 
Magnetic nanoparticle hyperthermia is the use of magnetic nanoparticles to 
generate heat. Magnetic nanoparticles generate localized heating when exposed to an 
alternating magnetic field. It has emerged as one of the promising hyperthermia modalities 
because of its ability to produce effective localized heating [37,38]. This modality offers 
benefits over the other modalities described above because the heat sources, i.e. 
nanoparticles, can be embedded within the target tissue. Once magnetic nanoparticles are 
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embedded into the tumour tissue, the region is exposed to an alternating magnetic field 
generating heat by the particles via hysteresis losses in the magnetic nanoparticles while 
minimal energy is deposited in the surrounding tissues because the AC magnetic fields 
(low radiofrequency) couple poorly with tissue [37–53]. Heat generated by the 
nanoparticles is then transferred to tissues/fluids of the tumor by convective and conductive 
processes within the tumour to realize efficient distribution, while offering potential to 
minimize energy deposition outside the treatment margins. Magnetic fields are long range 
in nature and can therefore act from a distance allowing for remotely controlled heating. 
Additionally, low frequency alternating magnetic fields show little attenuation in 
biological tissues. This allows for precisely controlled targeted heating of tumor tissue. 
Magnetic nanoparticle hyperthermia was first proposed by Gilchrist et al. [40] in 
their seminal paper published in 1957. With the emergence of new technology in the past 
two decades, especially in the manufacturing of high loss power nanoparticles, this method 
has gained more prominence [38].  Magnetic nanoparticle formulations typically consist of 
magnetic nanoparticles suspended in a carrier fluid (typically water). Iron based 
nanoparticles such as magnetite (Fe3O4) and maghemite (γ-Fe2O3) are the most commonly 
used nanoparticles because of their biocompatibility [54]. The typical sizes of these 
nanoparticles are in the range of 10 – 100 nm in diameter. They are usually coated with 
surfactants to prevent agglomeration. The two iron based nanoparticles used in this 
dissertation are: Bionised nano ferrite (BNF) nanoparticles [55,56] and Johns Hopkins 
University (JHU) nanoparticles [53]. BNF nanoparticles are synthesized by a high 
temperature and high pressure homogenization process [55]. JHU nanoparticles are 
synthesized by high gravity controlled precipitation process [53,57]. Different synthesis 
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methods are used to maximize the heating potential of the nanoparticles. The properties of 
magnetic nanoparticles that influence the high heating potential of nanoparticles and the 
physical mechanisms that result in magnetic nanoparticle heating are briefly reviewed here. 
1.3.1 Physics of magnetic nanoparticle heating 
Magnetism in a material is a result of the orbital and spin motions of electrons in 
atoms which produce an atomic magnetic moment [51]. In some materials, there exists a 
strong interaction among the individual atomic magnetic moments (exchange interaction) 
while in others no such interaction is present. Different types of magnetic materials are 
classified based on their net magnetic moment in zero field and their response to an 
externally applied magnetic field [51].  
Magnetic materials are colloquially referred to as “non-magnetic” and “magnetic” 
based on their net magnetic moment in zero field. “Non-magnetic” materials have no net 
magnetic moment in zero field [51]. These are scientifically classified into three classes of 
materials – diamagnets, paramagnets, and antiferromagnets. All materials have 
diamagnetic contributions since they have paired electrons. When a non-zero magnetic 
field is applied, the individual electrons oppose this field by changing their angular 
momentum. In diamagnets, a net negative response is obtained for an applied positive field. 
Paramagnetic materials have unpaired electrons which are oriented in all directions 
resulting in a zero net magnetic moment in zero field conditions [51]. When a positive 
magnetic field is applied, these unpaired electrons align with the applied field resulting in 
a net positive magnetic moment. This paramagnetic response dominates the diamagnetic 
response. Antiferromagnetic materials exhibit a temperature dependent positive exchange 
interaction. Below a critical temperature, called the Nèel temperature, the atomic moments 
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align themselves antiparallel to their neighbors due to this strong positive exchange 
interaction. Below this temperature, no net magnetization exists as the atomic moments 
cancel out each other [51]. Above this temperature, the thermal energy overcomes this 
interaction and the antiferromagnets act as a paramagnet.  
“Magnetic” materials have a non-zero magnetic moment in zero field. These 
materials are further scientifically classified into two classes – ferromagnetic and 
ferrimagnetic [51]. Ferromagnetic materials have a strong negative exchange interaction 
present resulting in the atomic moments aligning parallel to their neighbors. This dominates 
the diamagnetic response. Hence, they have non-zero magnetic moment at zero magnetic 
field, below the Curie temperature. Above the Curie temperature, the thermal energy is 
sufficient to overcome this exchange interaction and the material becomes a paramagnet 
[51]. When a saturating magnetic field is applied, all the moments align parallel to the 
applied field. Ferrimagnets are a special case of antiferromagnets, where the antiparallel 
atomic moments have different magnitudes. Because of unequal neighboring atomic 
magnetic moment magnitudes, ferrimagnets can have a net magnetic moment below the 
Nèel temperature. Under the application of a saturating applied magnetic field, the atomic 
moments spontaneously align with the applied field resulting in a net positive magnetic 
moment. The iron oxide nanoparticles used in magnetic nanoparticle hyperthermia, 
magnetite (Fe3O4) and maghemite (γ-Fe2O3) are both ferrimagnets [51]. 
Under an applied magnetic field, in addition to aligning their magnetic moments, 
magnetic nanoparticles exhibit certain additional characteristic features, shown in Figure 
1.1. When an alternating magnetic field is applied, the change in polarity results in change 
in the direction of magnetic moment of the material (related to the coercivity, Hc). In ferro-
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/ferri- magnets, Hc ≠ 0, resulting in energy being added to the material to reverse the 
magnetization. In addition, Hc is dependent upon the frequency of the alternating magnetic 
field, with Hc typically increasing with increase in magnetic field. This is called hysteresis 
and is always accompanied by losses, which manifest as heat [51].  Schematic of a 
hysteresis loop is shown in Figure 1.1.  
When the magnitude of the applied field is increased, the magnetization of the 
magnetic material increases until reaches a maximum value where all the magnetic 
moments in the material are aligned parallel to the direction of the applied magnetic field 
[51]. This maximum value is known as the saturation magnetization, denoted by MS in 
Figure 1.1. When the applied magnetic field is reduced to zero, the magnetization of the 
material does not necessarily return to zero. This remaining magnetization is called as 
remanent magnetization, denoted by MR in Figure 1.1. The magnetic field required to 
coerce the magnetization to zero is called the coercive field, HC. The anisotropy field HK, 
related to the energy needed to align the magnetic moments. Specifically, most magnetic 
materials have a preferred direction of orientation of the magnetic moments, which is 
referred to as magnetic anisotropy. This magnetic anisotropy is dependent on multiple 




where Q is heat. Assuming the material returns to the original state, and assuming there is 
no change in the internal energy of the material, implying that all work done by the external 
magnetic field on the magnetic material is manifested as heat [51]. Thus, during one 
traversal of hysteresis loop, the heat generated is equal to area of the hysteresis loop given 
by, 
 𝑄 = ∮ ?⃗? . 𝑑?⃗⃗?  (1.6) 
The power dissipated per unit volume of magnetic material 𝑃ℎ𝑦𝑠𝑡𝑒𝑟𝑒𝑠𝑖𝑠 is then given by (in 
S. I. units), 
 𝑃ℎ𝑦𝑠𝑡𝑒𝑟𝑒𝑠𝑖𝑠 =  𝜇𝑜𝑓∮ ?⃗? . 𝑑?⃗⃗?  (1.7) 
Here, f is the applied frequency and 𝜇𝑜 is the vacuum permeability (𝜇𝑜= 4π × 10-7 H/m). 
Calculation of area under the hysteresis loop given by equation (1.7) is not trivial [51]. No 
analytical model exists except for few simple cases so it is often determined by numerical 
simulations. Several theoretical models have been developed and are well known in the 
magnetic nanoparticle hyperthermia research community. However, most of them are 
simplified and are often freely applied without considering the inherent limiting 
assumptions [51,58]. The description of these models and their limitations are beyond the 
scope of this thesis and the readers are referred to excellent reviews given by Carrey et al. 
[58] and Dennis et al. [51]. 
1.3.2 Eddy currents 
When an electrically conducting material is exposed to an alternating magnetic 
field, eddy currents are induced due to Faraday’s law of induction. In the case of human 
body, this can lead to unwanted heating of healthy tissue, eliciting a thermoregulatory 
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response resulting in complex thermal gradients [38,61]. The power dissipated due to eddy 
currents is given by [62], 
 𝑃𝑒𝑑𝑑𝑦 = 𝜎𝑡 . 𝐺 (𝐻. 𝑓. 𝑟)2 (1.8) 
where 𝜎𝑡 is the electrical conductivity of the tissue, G is a geometric coefficient and r is 
the radius of the exposed tissue. Results from Atkinson et al. [61] show that the permissible 
limits for frequency and applied field for a 30 cm diameter torso is given by, 




For smaller exposure areas ( ~ 10 cm diameter), this limit can be exceeded by a factor of 
10, Dutz et al. [62] suggested an upper limit given by,  




These limits indeed pose a challenge on the heating performance of the magnetic 
nanoparticles as they are required to generate significant heating at low amplitudes and 
frequencies. It is therefore critical to consider eddy current heating effect when optimizing 
both magnetic nanoparticle properties and operating conditions for magnetic nanoparticle 
hyperthermia. In this thesis, we develop a computational tool that couples both 
electromagnetic and thermal effects in tissues to account for eddy current heating. This 
model can help predict the temperature distributions to gain a better insight and to develop 
new treatment strategies that can translate magnetic nanoparticle hyperthermia into the 
clinic. 
1.3.3 Delivery of nanoparticles 
Nanoparticles are primarily delivered by two methods – systemic delivery and 
direct delivery. In systemic delivery, magnetic nanoparticles are administered via a 
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systemic injection. The size of the nanoparticles allows for selective uptake by the tumors 
because of their leaky vasculature known as the enhanced permeability and retention effect 
(EPR). Compared to endothelial cells of normal tissue vasculature, tumor endothelial cells 
are often larger allowing particles of up to 1-2 µm to pass through [63]. However, not 
enough nanoparticles can be deposited in the tumor by this method. Another method of 
systemic delivery, is the use of targeted nanoparticles. Targeted nanoparticles are 
nanoparticles to which tumor selective ligands are attached to the surface of the 
nanoparticles which can then bind to specific biomarkers expressed by tumor cells. One 
example is the binding of Chimeric L6 (ChL6) to iron oxide nanoparticles by DeNardo et 
al. [49,50]. ChL6 is human mouse antibody chimera that reacts with an integral membrane 
glycoprotein expressed on human breast, ovary, colon, and lung carcinomas. Despite 
multiple efforts being undertaken for targeted nanoparticle delivery, it has still been 
challenging to achieve significant deposition of nanoparticles in the tumor [64]. 
Direct delivery of nanoparticles involves injection of nanoparticles directly into the 
tumors. It has been the most widely used method of nanoparticle delivery [65] for both in 
vivo studies [52,66] and in clinical trials [39,43,67]. The nanoparticle distribution and 
retention are dictated by both tumor physiological properties and injection parameters [52]. 
While multiple efforts have been made to optimize injection parameters for reproducible 
and repeatable nanoparticle distributions, [68,69], the applicability of these methods for 
different tumors is limited. Considering the heterogeneity of nanoparticle distributions and 
the resulting temperature distribution, clinical translation of magnetic nanoparticle 
hyperthermia has been challenged. In this thesis, we seek to develop methods to overcome 




In 2010, magnetic nanoparticle hyperthermia achieved clinical approval for 
treatment of glioblastoma multiforme in Europe [39]. Despite this, challenges remain and 
further work is needed to harness the full potential of magnetic nanoparticle hyperthermia 
in cancer therapy [65].  Delivery of substantial quantity of nanoparticles to the target 
region, distribution of nanoparticles in the tumor, identifying the safe combinations of 
alternating magnetic field magnitude and frequency to generate substantial heat in tumor 
and minimize off target heating, are some of the challenges for magnetic nanoparticle 
hyperthermia to become a clinical modality. For developing methods to address the above 
challenges, further work is necessary to understand the mechanisms of thermal damage, 
the physical principles of nanoparticle heating, and the bio-distribution and toxicity of 
nanoparticles. In this thesis, we present methods and develop tools to address some of the 
challenges identified above. 
 
1.4 Thermodynamics and heat transfer  
Heat is defined as the form of energy that is transferred across the boundary of a 
system at a given temperature to another system (or surroundings) at a lower temperature 
by virtue of temperature difference between two systems [70]. Heat transfer is the transport 
of energy due to a temperature difference between different amounts of matter. Before we 
review the different modes of heat transfer, the first law of thermodynamics is presented 
as it applies to all heat transfer processes. 
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The first law of thermodynamics [71] states that the rate of change in internal 
energy stored in a system is equal to summation of the net change in energy transferred 
into the system and the energy generated by the system. This is the law of conservation of 
energy expressed as, 
 𝑑𝑈
𝑑𝑡
=  ∑?̇? − ?̇? +∑?̇?(ℎ𝑖𝑛 − ℎ𝑜𝑢𝑡) + 𝑄𝑔𝑒𝑛̇  (1.11) 
 
Here U is the energy of the system, ∑ ?̇? is the sum of all heat flows, ?̇? is the work done 
by the system on the environment, ∑ ?̇?(ℎ𝑖𝑛 − ℎ𝑜𝑢𝑡) is the sum of all mass flows crossing 
the system boundary, each having an enthalpy h, as it enters and leaves the system, and  
𝑄𝑔𝑒𝑛̇  is the rate of energy generated by the system. 
 There are three basic modes of heat transfer – conduction, convection, and 
radiation [72]. Conduction may be viewed as the transfer of energy from the more energetic 
particles to the less energetic particles of a material due to interaction of particles. 
Conduction occurs in all phases of material: solids, liquids, and gases. Higher energy 
particles are associated with higher temperature and when these particles interact with 
lower energy particles via collision, energy transfer takes place. Thus, the diffusion of heat 
due to random of molecular motion is known as conduction. The fundamental expression 
that describes the conduction of heat is called the Fourier’s law given by: 




here 𝑞"𝑥  is the heat transferred per unit area (W/m2), x is the direction normal to the 
direction of heat transfer, k is the thermal conductivity and 𝑑𝑇
𝑑𝑥
 is the temperature gradient 
along the x direction.  
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Heat transfer by convection comprises of two mechanisms – diffusion and 
advection [72]. Diffusion as described previously is the energy transfer due to random 
molecular motion, while advection is the transfer of heat due to macroscopic or bulk motion 
of the fluid. Convection heat transfer takes place when a surface and a fluid at two 
temperatures come in contact with each other. The rate equation that describes convection 
is known as Newton’s law of cooling, given by: 
 𝑞" = ℎ(𝑇𝑠 − 𝑇∞) (1.13) 
where 𝑞" is the convective heat flux (W/m2), h is the convective heat transfer coefficient, 
𝑇𝑠 is the surface temperature and 𝑇∞is the fluid temperature. Convection heat transfer may 
be further classified into three types based on nature of flow. Forced convection occurs 
when the fluid is driven by an external force such as a fan, or a pump. Free convection 
occurs when the flow is driven by buoyancy forces, which are due to internal density 
differences caused by temperature variations in the fluid. Mixed convection occurs when 
heat transfers by both free and forced convection.  
The third mode of heat transfer is radiation. Thermal radiation is the energy emitted 
by matter at a non-zero temperature [72]. These emissions can occur for all forms of matter 
and may be attributed to the changes in electron configurations of the constituent atoms or 
molecules. The energy is transmitted via electromagnetic waves and this mode of heat 
transfer does not require a medium unlike conduction and convection. The rate of thermal 
energy emitted is given by the Stefan Boltzmann law, 
 𝐸𝑏 = 𝜖𝜎𝑅𝑇𝑠4 (1.14) 
where 𝜖 is the emissivity of the material, 𝜎𝑅 is the Stefan-Boltzmann constant (5.67 × 10-8 
W/m2.K4) and Ts is the absolute temperature (K) of the surface. 
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1.5 Heat transfer in biological tissue 
The human body is a complex thermal system with heat generation and heat transfer 
occurring at multiple scales [73]. The vast heterogeneity in the vascular structure, variable 
blood flow in a complex arterial and venous network, varying tissue thermophysical 
properties and metabolic heat generation makes heat transfer analysis challenging. Heat 
generation occurs at cellular level due to various biochemical reactions while heat transfer 
occurs at multiple levels, cellular and molecular level, tissue and organ level, and 
interaction between the body and environment. The human body efficiently controls these 
processes to maintain its temperature in a narrow range. Any irregular thermal deviations 
from this state are often associated with abnormal physiological conditions. To identify 
these deviations, it is important to have a proper understanding of heat generation and heat 
transfer processes in the human body [73].  This is essential for multiple applications such 
as cancer diagnosis [74], hyperthermia [52,75], burn injury estimation [76] etc.  
Over the past 70 years, multiple efforts have been made to model the heat transfer 
processes occurring in tissue [73,77–79]. These models can broadly be classified as 
continuum and vascular heat transfer models [73,80]. Continuum models are models in 
which the effect of blood flow in individual vessels is ignored and instead is averaged 
across the control volume. Vascular models, on the other hand, account for effects of blood 
flow through individual blood vessels. This allows for the consideration of the effects of 
blood flow direction on the temperature distribution. Numerous applications have used 
these models to understand various heat transfer phenomena in the human body. 
Pennes was the first one to develop a bioheat transfer model based on his 
experimental analysis of resting human forearm [81]. He modified the transient heat 
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conduction equation by including two heat source terms – one due to perfusion and other 
due to metabolism. This model is one of the simplest and oldest forms of perfusion based 
heat transfer models. The primary assumption made by Pennes was that energy exchange 
between blood vessels and the surrounding tissue occurs across the capillary walls. This 
was based on the fact that exchange of nutrients and waste takes place between tissues and 
blood distributed by capillaries. Pennes also introduced a thermal equilibrium factor κ to 
correlate the arterial, venous and tissue temperatures. If thermal equilibrium is achieved 
between the blood and tissue (κ = 0), then the venous flow temperatures should be equal 
to the tissue temperature. Pennes also assumed that heat exchange due to blood flow can 





= 𝑘𝛻2𝑇 + 𝜌𝑏𝑐𝑏𝜔𝑏(1 − 𝜅) ( 𝑇𝑏 − 𝑇 ) + 𝑄𝑚 (1.15) 
 
here ρ is the tissue density, cp is the specific heat capacity of tissue, k is the tissue thermal 
conductivity, Qm is the metabolic heat generation rate, T is the tissue temperature and κ is 
the thermal equilibrium factor (0 ≤ κ ≤ 1). Density, specific heat, temperature and perfusion 
rate of blood are denoted by ρb, cb, Tb, and ωb respectively. Most studies that use the 
Pennes’ bioheat equation, including Pennes himself in his study, assume that complete 
thermal equilibrium is achieved (κ = 0). Equation 1.2 represents the energy balance in the 
tissue due to conduction, blood perfusion, and metabolic heat generation. The left hand 
side of the equation represents the change in internal energy of the tissue. On the right hand 
side, the first term represents the conductive diffusion of heat in the tissue, the second term 
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represents the heat source term due to blood perfusion, and the last term denotes a heat 
source due to tissue metabolism.  
Wulff [82] identified four fundamental shortcomings in the Pennes’ bioheat 
equation. He pointed out that combining local (tissue) and global (blood) control systems 
is not permissible. Pennes’ assumption of choosing three media with three temperatures at 
the same point in space, viz. tissue with temperature T, and two blood stream temperatures 
at the same point Tin and Tout, omits two additional equations. Pennes’ equation also 
neglects the convective contribution of other bio-fluids which are in motion and the heat 
transfer between tissue and blood flow is driven by the difference in tissue and blood 
temperatures rather than the temperature difference between blood flow temperatures. 
Wulff proposed a new model where in the blood flow contribution is modeled by a 




= 𝑘𝛻2𝑇 − 𝜌𝑏𝑐𝑏𝑼𝒉. ∇T + 𝜌𝑏𝑼𝒉∆𝐻𝑓∇ϵ  (1.16) 







here Uh local mean apparent blood velocity, hb is the specific enthalpy of blood, ∆𝐻𝑓  is the 
specific enthalpy of metabolic reaction, 𝜖 is the extent of reaction, u is the actual blood 
velocity in the capillary and 𝛺 is the spherical solid angle. Wulff suggested that thermal 
equilibrium between blood and tissue is achieved because of efficient heat transfer in 
porous media. Thus he considered the blood temperature to be equal to that of tissue. He 
also assumed that the metabolic reaction term as equivalent to metabolic heat generation. 
The most important feature of Wulff’s model is that he considered the directional nature of 
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heat transfer due to blood perfusion. The main limitation of this model is the assumption 
of thermal equilibrium between blood and tissue, which may not be necessarily true. 
In vascular models, the effect of blood perfusion on an individual vessel-by-vessel 
basis is taken into account to determine the temperature in and near individual blood 
vessels. Mitchell and Myers [83] were the first to develop a bioheat model which included 
the effects of countercurrent heat exchange between adjacent arteries and veins in addition 
to the heat exchange between each vessel and surrounding tissue. However, their model 
does not consider heat conduction in the tissue and their assumption of constant blood flow 
rate restricts the applicability to the main supply blood vessels [77,83]. Keller and Seiler 
[84] in their model, included both the countercurrent heat exchange between artery and 
vein, and also added an energy conservation equation for the surrounding tissue coupled to 
the artery and vein equations.  
Chen and Holmes [85] addressed the issue of thermal equilibrium between blood 
and tissue by proposing a blood-tissue continuum model based length scale analysis. They 
defined a thermal equilibrium length, the length at which the temperature difference 
between blood and tissue drops by 1/e its initial value. Based on this, they classified blood 
vessels into two categories, thermally significant and thermally insignificant blood vessels. 
They observed that thermal equilibrium was achieved mostly in medium size blood vessels 






= ∇. ((𝑘 + 𝑘𝑝)∇𝑇) + 𝜌𝑏𝑐𝑏𝜔𝑏
∗(𝑇𝑎
∗ − 𝑇 )




where 𝑘𝑝 is the thermal conductivity due to blood perfusion, 𝑇𝑎∗ is the blood temperature 
in the largest artery included in the continuum model, 𝜔𝑏∗  is the blood perfusion rate for 
blood vessels which are smaller in diameter than the largest artery in the model. The Chen 
and Holmes model is an extension of Pennes’ model with contributions of 
microvasculature both to the effective thermal conductivity and a contribution proportional 
to local blood perfusion velocity. It also includes the directionality effect of blood flow.  
Weinbaum et al. [86,87] conducted an in-depth evaluation of thermal equilibrium 
lengths for various geometrical configurations of vasculature in the peripheral tissue layer 
and developed three-layer models for tissue-vessel thermal interaction due to 
countercurrent flow. A deep tissue layer was modeled as an isolated countercurrent large 
vessel in a tapered cylinder. The intermediate layer was modeled as a pair of countercurrent 
terminal vessels. The outer cutaneous layer was modeled as a single or pair of vessels in 
the skin plexus. Their main observation from experiments and the results from their models 
was that temperature differences are due to incomplete countercurrent energy exchange in 
the thermally significant vessels. Weinbaum and Jiji recognized that their model required 
detailed information about the vascular structure and also that there is an uncertainty 
regarding the temperature of the blood entering the thermally significant blood vessels. 
Realizing this, they proposed a new simplified model [88] by approximating the mean 
tissue temperature with an average temperature of adjacent countercurrent pair of closely 
spaced and nearly equilibrated vessels. While this model included the effect of blood flow 
and vascular architecture on heat transfer, they removed the isotropic blood perfusion term 
as its contribution was negligible compared to heat transfer due to countercurrent blood 
flow. They also assumed that most of the heat conducted out through the wall of the 
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arteriole arrives through the wall of its paired vein. For a one dimensional case, where 
blood vessels and temperature gradient are in the same direction, the differential equation 


















here 𝑘𝑒𝑓𝑓 is the effective thermal conductivity, n is the vessel number density, 𝑟𝑏 is the 
vessel radius, V is the blood velocity within the vessel, 𝛾 is the relative angle between the 
direction of blood vessel and local tissue temperature gradient, 𝜎∆ is the shape factor of the 
vessels. Simulations conducted by Baish et al. [80,90], Wissler [91], and by Charny et al. 
[92], showed that the Weinbaum-Jiji model can only be applied to either tissues where ε < 
0.3 (ε – ratio of equilibrium length and actual vessel length) or muscle tissue (with low 
perfusion) that contains blood vessels with diameter < 0.2 mm. Wissler [91] also criticized 
the model for simplifying assumptions such as the tissue temperature is average of arterial 
and venous blood temperatures and tissue temperature has no influence on the heat transfer 
between the countercurrent vessels.  
Several other bioheat transfer models have been developed to address the 
limitations of the above and to give a more accurate prediction of temperatures in the tissue. 
Of these, the statistical steady state bioheat transfer model by Baish [93], dual-phase-lag 
bioheat model by Xu et al. [94], porous media based bioheat transfer models [78,95–97], 
discrete vasculature models [98–102], and recent models by Shrivastava et al. [103,104] 
improve and address the limitations of the models mentioned above.  
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Despite the drawbacks and criticism of Pennes’ equation, and being widely 
documented as incorrect with several shortcomings, it is still the most widely used equation 
for numerical studies in biological tissue [105]. This can be attributed to the linear 
microscopic thermal energy balance for perfused tissue in the Pennes’ model. Also, 
predicted temperatures using the Pennes’ model demonstrate good agreement with 
experimental measurements [106–108]. For tissues situated away from large blood vessels, 
the new terms added by the different models contribute minimally to the overall heat 
transfer [77]. We use the Pennes bioheat transfer model in all the numerical studies carried 
out in this dissertation. We assume complete thermal equilibrium has been achieved (𝜅 =
0, in equation 1.1). However, we modify the blood perfusion term to include the effects of 
thermal damage on the change in perfusion (explained in section 3.2.3).  
 
1.6 Computational modeling 
In the past two decades, a quantitative understanding of biological processes has 
developed to make computational modeling and simulation an important tool for 
biomedical applications [109]. Computational modeling has been widely used in multiple 
applications ranging from aerospace, automotive, biomedical, public policy, climate 
modeling etc. In biomedical applications, models allow for better and improved 
understanding of complex biological processes and to test and optimize new treatment 
procedures before translation to animal studies or patient trials. This can result in 
significant savings of both time and money, reduced ethical concerns associated with 
animal studies, in addition to improving the overall safety and performance of the new 
treatment procedure.  
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Building a computational model for a biomedical problem consists of the following 
four steps: 1. defining the biomedical problem/process, 2. Preparing/developing a 
mathematical formulation, 3. implementing the model in an algorithm and code, 4. 
interpreting the solution and optimization [109]. The first step in building a computational 
model involves defining the biomedical problem to be solved. In this thesis, we focus on 
building a computational model for magnetic nanoparticle hyperthermia to understand and 
devise strategies for its improvement.  
In the second step, an equivalent mathematical formulation of the problem defined 
in step 1 is created. This involves developing equations which accurately describe the 
physical process. The equations are based on fundamental laws of physics which govern 
the given process. In this thesis, the fundamental laws of physics that are used are – 
conservation of total mass (continuity equation) and conservation of energy (more 
specifically thermal energy, described in section 1.4). Setting up the mathematical 
formulation is the most critical step as the validity and relevance of the results obtained 
depend entirely on the formulation. The process of developing the mathematical 
formulation involves the following steps. The first step involves defining the goal of the 
simulation. In the current thesis, the main goal of the models used is to determine the 
temperature distribution in a given domain. The next step involves determining the 
geometry or the region on which we run the simulations. These geometries can be simple 
mathematical shapes (ellipse, ellipsoid, sphere, and cylinder – chapters 2 - 6) or can be 
complex shapes imported from images (rabbit liver model, chapter 5). Then, the governing 
equations and boundary conditions that describe the biomedical problem in step 1 are 
chosen. The governing equations used in this thesis are: heat conduction equation (chapter 
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5 & 6) and Pennes’ bioheat transfer equation (chapters 2 – 6). The implementation and 
limitations of Pennes’ bioheat equation have been explained in section 1.5. For the 
boundary conditions, Dirchlet and Neumann boundary conditions [72] were used 
depending on the problem. The equations were then solved by using the material properties 
and parameters relevant to the problem.  
The third step involves implementing or solving the mathematical formulation 
using an algorithm and a code. These can be developed in the lab or can be commercially 
available. In the studies reported in this thesis, COMSOL Multiphysics® 5.2a [110] was 
used to solve the computational models. COMSOL is a finite element method (FEM) based 
commercial software that solves partial differential equations across multiple physics such 
as heat transfer, fluid flow, mass transfer, electromagnetism, etc. Implementation of a 
mathematical formulation in COMSOL requires three main steps: preprocessing, 
processing, and post-processing [109]. Preprocessing involves setting up the problem in 
COMSOL by building a geometry, choosing the appropriate governing equations, 
boundary conditions, initial conditions, properties, and parameters, meshing the 
computational domain, choosing an appropriate solver, and setting the 
tolerances/convergence criteria. Processing involves solving the partial differential 
equations by transforming them into a set of algebraic equations and determining the 
unknown variables. Post-processing involves visualizing the obtained results, analyzing 
and interpreting them.  
As described previously, the geometry chosen in the mathematical formulation step 
is now implemented in COMSOL. This geometry can be simple mathematical shapes or 
complex realistic geometries imported from images using image processing software. The 
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necessary COMSOL physics modules are then chosen depending on the physics involved 
(bioheat transfer – chapters 2-4, 6; coupled electromagnetic and bioheat transfer physics, 
chapter 5). The initial and boundary conditions are then chosen based on the problem 
formulations. Properties and parameters are chosen to depict the real scenario as closely as 
possible. After this, the computational domain is then meshed. Meshing involves 
discretizing the computational domain into finite number of small, simple shapes. These 
small discretized shapes are known as elements and the points describing them are called 
nodes. Depending on the dimensionality of the problem (1-D, 2-D, or 3-D), the elements 
can be lines, triangles, quadrilateral, tetrahedrons, hexahedrons etc. The size and number 
of elements defines the fineness of the mesh. The more number of elements, the more finer 
the mesh is. Large number of elements however can lead to higher computational load and 
more solution time. Generally unstructured mesh is chosen, so as to have finer elements at 
boundaries and interfaces where the solution variables are expected to change rapidly, 
while coarse elements are chosen at nodes where there is little expected change in the 
solution variable.  
 Solution method in COMSOL involves finite element method (FEM), which is a 
numerical method for solving partial differential equations (PDE) by discretizing the 
domain into elements and approximating them with numerical model equations. For 
example, a dependent variable f in a PDE can be approximated by a linear combination of 
basis functions, given as 






here 𝜑𝑖 denotes the basis functions and 𝑓𝑖 denotes the coefficients of the functions which 
approximate the f with 𝑓ℎ . The set of linear algebraic functions are then solved by two 
classes of methods – direct and iterative. Direct methods are based on Gaussian elimination 
either by matrix operations or by LU decomposition. Iterative methods, generally used for 
large system of equations, involve starting with an initial approximation and iteratively 
changing this approximation to approach an exact solution [109]. Rate of convergence is 
improved by use of appropriate preconditioners. Examples of direct solvers used by 
COMSOL are PARDISO (parallel direct sparse solver), MUMPS (multifrontal massively 
parallel sparse direct solver) [110]. GMRES (generalized minimum residual), FGMRES 
(flexible generalized minimum residual), Conjugate Gradient, BiCGStab (Biconjugate 
gradient stabilized) are some of the iterative solvers used by COMSOL. FEM offers many 
advantages compared to other methods such as greater flexibility for modeling complex 
geometries, for modeling changing geometries (moving boundaries), and for choosing 
different basis functions across the domain.  
COMSOL generally uses FEM for spatial discretization while for time 
discretization in transient studies it uses finite difference method (FDM) to save 
computational memory and to improve computational speed. FDM methods are numerical 
methods for solving PDEs by approximating the differential operator using differential 
quotients to replace the derivatives. For example, a first order time derivative at a node can 










COMSOL uses implicit methods such as IDA, variable-order variable-step-size backward 
differentiation formulas (BDF) and Generalized-α, a second-order accurate method with a 
parameter α to control damping of high frequencies [110]. 
The fourth step in the building of computational model involves analyzing the 
numerical solution obtained and verifying and validating it with analytical solutions and 
experimental measurements. Once the model is verified and validated, it can then be 
optimized to understand the physics and also to develop new treatment strategies. 
 
1.7 Thesis overview 
In this thesis, we report the development of methods and tools to address the 
specific challenges that limit the clinical application of magnetic nanoparticle 
hyperthermia. The challenge of delivering a therapeutic thermal dose in the tumor with 
minimal healthy tissue damage despite variable nanoparticle distributions is addressed in 
Chapters 2 – 4. Different biological tissues have different electrical conductivities, making 
the monitoring of eddy current heating difficult in in vivo studies. To study this, we 
developed and validated a computational tool that can be used to predict temperature 
elevations due to eddy current heating in large tissue (Chapter 5). In the final chapter, we 
characterized and determined the heating potential of nanoparticle formulations that can be 
used for combination therapies.  
The content of the thesis is summarized below. 
Chapter 2 focuses on understanding the effect of nanoparticle distribution and heat 
output on temperature evolution in tumor using computational models. Two extreme cases 
of nanoparticle distributions, uniform and concentrated, were considered. We conducted 
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constant power simulations to highlight the differences in temperature distributions 
achieved for different nanoparticle distributions. We then showed that modulating the heat 
output of nanoparticles based on temperature measured at tumor-healthy tissue boundary 
can compensate for variable nanoparticle distributions in delivering a minimum effective 
thermal dose. 
In Chapter 3, an improved modulated power heating method is described and results 
from implementation in 2D and 3D computational models for a range of nanoparticle 
distributions including those derived from animal studies are reported. Temperature effects 
on perfusion were implemented by modeling perfusion as a function of thermal damage. A 
new method for modulating power using a PID controller with temperature feedback from 
tumor-healthy tissue boundary was presented. Comparisons between constant power and 
modulated power heating were carried out to highlight the advantages of modulated power 
heating over constant power heating. We show that modulated power heating can 
compensate for variable nanoparticle distributions and deliver effective tumor treatment 
with minimal healthy tissue damage. 
Chapter 4 presents the results of in vivo implementation of modulated power 
heating in mice models of liver cancer. We test the strategy on sub cutaneous xenograft 
tumors with two nanoparticle distributions generated by two intratumor nanoparticle 
injection methods using a syringe pump. The results from this study are then compared to 
results from computational models. 
In Chapter 5, we report the development of a new computational model to 
simultaneously solve the electromagnetic and heat transfer physics for magnetic 
nanoparticle hyperthermia. This model was built in COMSOL 5.2a using the AC/DC 
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module and Heat Transfer module. The model was verified using the existing analytical 
model and validated by comparing with results from gel phantom experiments. Results 
from the implementation of this model to rabbit liver models generated from computed 
tomography (CT) images and computed temperatures in the liver due to non-specific eddy 
current heating are presented.  
Chapter 6 presents the thermal and magnetic characterization of magnetic 
formulations used for image-guided magnetic nanoparticle hyperthermia. For the thermal 
characterization, the specific heat capacity and heating rates of the aqueous and lipiodol 
formulations was measured. Specific loss powers (SLPs) were then determined and 
compared for both the formulations. Bulk magnetization measurements were conducted to 
effect of lipiodol of the saturation magnetization of these nanoparticles. Additionally, 
simulations were carried out to further understand the change in thermal properties on the 
heat generated by these nanoparticle formulations. Also, simulations were conducted to 
predict the temperatures and thermal damage due to these nanoparticle formulations inside 
tumor tissue. 
The conclusions from this thesis are discussed in chapter 7. Challenges and future 






Chapter 2                     
Understanding the effect of 
nanoparticle distributions and heat 
output on temperature evolution in 
tumor 
This chapter focuses on developing computational models to understand the 
physics of heat distributions within the context of magnetic nanoparticle hyperthermia 
(mNPH) and to develop strategies that can be translated to the clinic to achieve reasonable 
therapeutic outcomes. In this chapter, two simple computational models are studied to 
understand the relationships between nanoparticle distributions, heat output, and the 
resulting temperature evolution in a two dimensional tumor-healthy tissue model. Two 
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extreme cases of nanoparticle distributions, uniform and concentrated, were considered. It 
is shown that varying the nanoparticle heat output can compensate for variable nanoparticle 
distributions to achieve a minimum effective thermal dose at the tumor-healthy tissue 
boundary. Modulating the nanoparticle heat output by controlling the temperature at the 
tumor-healthy tissue boundary can achieve therapeutic thermal dose at the tumor-healthy 
tissue boundary while simultaneously minimizing the healthy tissue damage.  
2.1 Introduction 
 Principal challenges encountered with all thermal therapies; arise from an inability 
to effectively deliver energy and control the delivered dose [10,111]. The main challenges 
for clinical implementation of mNPH are (1) the difficulty in effective targeting of tumors 
with magnetic nanoparticles, (2) the lack of precise control of nanoparticle distribution 
within tumors with percutaneous delivery, to enable precise energy deposition throughout 
the tumor volume [39,43–46]. The former results in too little material being deposited into 
the tumor while the latter leads to variable temperature distributions resulting in ineffective 
treatment. Nanoparticle distributions in the tumor after direct injection are dependent upon 
both injection parameters (e.g. injection rate, needle size, volume, viscosity, number of 
injection points) and also on tumor mechanical and physiological properties (e.g. interstitial 
pressure, density, vascularity). While studies [112] have been conducted to control the 
injection parameters, controlling the tumor mechanical and physiological properties is 
impossible. Thus, it is important to accept that variable nanoparticle distributions are a part 
of ‘clinical reality’ and robust treatment strategies should be developed to address these 
variable distributions to deliver sufficient tumor thermal damage.  
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 Thermal dose [25], defined as ‘time at temperature’, deposited to the tumor 
determines the effectiveness of hyperthermia. While achieving a uniform thermal dose in 
the tumor is ideal, effectiveness of thermal therapy is defined by/limited to the region of 
tumor receiving the lowest thermal dose [9]. The goal of hyperthermia is to achieve a 
minimum effective thermal dose in 90% of tumor volume while simultaneously 
minimizing the surrounding healthy tissue damage [9,113]. Thus, for mNPH the thermal 
dose deposited in the tumor depends on the concentration of the nanoparticles and the 
distribution of these nanoparticles. Given the small size of these nanoparticles, controlling 
the distribution inside the tumor is difficult. However, the variable heat output of these 
nanoparticles mainly depend on the applied AMF amplitude and frequency. This allows 
for non-invasive dynamic control of the heat output which results in controlled thermal 
dose deposition to the tumor. It is thus of interest to test whether these dynamic adjustments 
of the nanoparticle heat output can compensate for variable nanoparticle distributions in 
delivering an effective tumor thermal dose while simultaneously minimizing healthy tissue 
damage. 
Computational models enable easy and relatively inexpensive variation of model 
parameters (tumor and healthy tissue geometries and properties, nanoparticle distributions, 
temperature dependence of properties, etc.) as well as heating conditions, to improve 
understanding of the effects of intratumor nanoparticle distribution on tissue temperature 
distribution, thermal dose, and overall therapeutic effect and to devise new strategies to 
achieve effective treatment. They can be used to gain knowledge about temperature 
distributions which otherwise would be impossible considering the limitations in 
technology to accurately measure the temperature distributions throughout the tumor. 
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Considerable effort was devoted to developing mathematical models describing tissue 
heating with mNPH [114–121]. Andra et al. [114] were the first to analytically determine 
the temperature distributions achieved during mNPH. They modeled the tumor as a finite 
spherical region of homogeneous tissue containing magnetic nanoparticles, surrounded by 
an infinite spherical region of healthy tissue. The effects of blood perfusion were ignored. 
Bagaria and Johnson [115] considered two concentric spherical regions, with the inner 
spherical region having nanoparticles with distribution determined by a polynomial 
function. Variation of capillary blood perfusion was considered for both the healthy tissue 
and tumor. Durkee et al. [116] obtained exact analytical solutions in cylindrical coordinates 
with homogeneous, time-dependent heat sources and constant perfusion. Giordano et al. 
[117] derived fundamental solutions to the Pennes bioheat equation with constant perfusion 
in rectangular, cylindrical, and spherical coordinates, and applied them to magnetic fluid 
hyperthermia to determine the temperature distribution inside the tumor and surrounding 
healthy tissue. Fasla et al. [118] analytically solved the Pennes bioheat equation in spherical 
coordinates by considering point-like particle heat sources and the effects of metabolic heat 
generation and blood perfusion on temperature distribution. Xu et al. [119] developed a 
three-dimensional model based on experimental observations. Their model consisted of 
cuboidal tumor periphery loaded with nanoparticles and a necrotic spherical core with no 
nanoparticles. They considered an inhomogeneous distribution of nanoparticles, and blood 
perfusion was assumed to be constant. Attar et al. [120] assumed a partial dispersion of 
nanoparticles in the cancerous tissue and investigated the effect of this assumption on the 
temperature distribution. All the above studies focused on determining the temperature 
distributions achieved in the tumor and healthy tissue with constant power heating.   
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The aim of this study is to compare the temperature distributions obtained in the 
tumor and healthy tissue with constant power and modulated power heating. The 
relationships among nanoparticle distribution, heat output and the evolution of temperature 
distributions with time are explored in the context of whether dynamic non-invasive control 
of nanoparticle heat output can compensate for variable nanoparticle distributions to 
deliver an effective thermal dose at the tumor-healthy tissue boundary. It is shown that 
power modulation with probe placement at the tumor-healthy tissue boundary is sufficient 
to achieve a minimum effective thermal dose at the tumor margins, while simultaneously 
minimizing the healthy tissue damage. 
2.2 Model description 
Two computational thermal models were created to represent a tumor and surrounding 
healthy tissue (Figure 2.1). As nanoparticle distributions in tumors vary, we used the 
computational phantom to analyze two extreme cases of nanoparticle distributions, to 
better understand the effect of physical parameters of the system. The tumors contained 
either (a) uniform or (b) concentrated distribution of nanoparticles (Figure 2.1). Both 
models contained an identical total number of nanoparticles and differed by nanoparticle 
distribution. In the uniform distribution model, the nanoparticles are evenly distributed 
throughout the tumor area. In the concentrated model nanoparticles are concentrated in 
only 40% of the tumor area extending from its center (Figure 2.1). The healthy tissue and 
tumor were modeled as circles with radii, rtissue = 9.5 mm and rtumor = 4.5 mm respectively. 
The model dimensions were chosen to ensure that the temperature at the outer edge of 
(healthy) tissue can be assumed to be at constant body temperature T = 37oC [121]. Heat 
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transfer throughout either tumor or tissue, produced by the nanoparticles was modeled by 





2𝑇𝑛 + 𝜌𝑏𝑐𝑏𝜔𝑏,𝑛 ( 𝑇𝑏 − 𝑇𝑛 ) + 𝑄𝑚,𝑛 + 𝑄𝑝 (2.1) 
 
where n and b represent tissue (tumor, n=1; healthy n=2) and blood parameters, 
respectively. For either tumor or healthy tissue, ρn, cn, kn, Tn, Qm,n denote the density, 
specific heat, thermal conductivity, local temperature, and metabolic heat generation rate. 
Correspondingly, for the blood ρb, cb, ωb, Tb denote density, specific heat, perfusion rate, 
and temperature, respectively. Thermophysical properties for healthy tissue, tumor, and 
blood are summarized in Table 2.1 [74,122–126]. Qp denotes the total power generated by 
nanoparticles in each tumor. The nanoparticles are modeled as line heat sources with 
uniform heating strength. As a consequence, the total power generated within each of the 
model tumors is identical, in order to highlight differences in temperature distribution 




Figure 2.1 Schematic of the computational model of healthy tissue and tumor with uniform 
nanoparticle distribution, and concentrated nanoparticle distribution. 
At the interface between healthy tissue and tumor, conservation of heat flux and 













 𝑇𝑡𝑖𝑠𝑠𝑢𝑒(𝑟 = 𝑟𝑡𝑢𝑚𝑜𝑟 , 𝑡) = 𝑇𝑡𝑢𝑚𝑜𝑟(𝑟 = 𝑟𝑡𝑢𝑚𝑜𝑟 , 𝑡) (2.3) 
 𝑇(𝑟 = 𝑟𝑡𝑖𝑠𝑠𝑢𝑒) = 37 °C (2.4) 
The governing equations (Equation 1) with the boundary conditions (Equations 2.2 – 2.4) 
were solved numerically using COMSOL Multiphysics 4.4, a commercially available finite 
element solver. A grid size dependence study was carried out to ensure that calculated 
temperatures were sufficiently independent of a chosen model grid size. When the grid size 
was changed from coarse (14747 triangular elements) to fine (29804 triangular elements), 
the number of elements nearly doubled yet the calculated temperature along the radius of 
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the tumor changed by less than 0.01 %, indicating our chosen model parameters have 
negligible influence due to grid size. A similar comparative analysis was performed to 
determine whether calculated temperatures were affected by the chosen time step for the 
transient heating process. When the time step was increased from 0.2 s to 1 s, the change 
in calculated temperatures was negligible (<0.001%). The model results were validated by 
comparing the transient temperature profiles along the radius of tumor with the analytical 
solution given by Andra, et al. [114]. Satisfactory agreement between analytical and 
numerical solutions was observed, confirming the general validity of our model. 
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3760 [122] 0.51 [122] 0.003 [123] 6374.5 [74] 
Blood* 1060 
[125] 
3770 [125] N/A N/A N/A 
*Temperature of blood (Tb) was fixed at 37ºC [125]. (N/A – not applicable) 
Simulations in this study were conducted to approximate constant power and power 
modulated nanoparticle hyperthermia experiments for qualitative comparison. 
Thermophysical properties of tissues and blood were held constant for all simulations 
(Table 2.1). To approximate constant power heating, Qp (= 4.6 × 105 W/m2) was fixed for 
a simulated duration of 60 min. The total heating power was chosen to limit the maximum 
temperature in the tumor to <47 °C. 
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To simulate power modulated nanoparticle hyperthermia, the heating power of the 
nanoparticles (Qp(T)) was varied with computed temperature at a specific intratumor 
location (Tprobe) as the feedback control parameter. This was given by: 
 𝑄𝑝(𝑇) = {
9.2 × 105 W/m3,   𝑖𝑓 𝑇𝑝𝑟𝑜𝑏𝑒 ≤ 43.5 °C
0.92 ×  105 W/m3, 𝑖𝑓 𝑇𝑝𝑟𝑜𝑏𝑒 > 43.5 °C.
 (2.5) 
 
43.5 °C was the chosen temperature reference to control power input because it is the 
minimum (break-point) temperature considered clinically relevant for hyperthermia 
treatment of human cells from in vitro measurements [9,25,127]. To investigate the 
influence of temperature probe placement on the total thermal dose, three virtual 
temperature probe locations – (a) center of tumor, (b) halfway between tumor center and 
tumor-tissue boundary, (c) at the tumor-tissue boundary – were considered in the 
computational simulation as control points. Heating with modulated power was carried out 
for 60 min and the temperature distributions in both tumor and healthy tissues were 
obtained at the end of 60 min of heating. 
 
2.3 Results 
Temperature profiles obtained from simulations comparing idealized uniform (with 
nanoparticles uniformly distributed throughout ‘tumor’ area, Figure 2.1, top) with 
concentrated (nanoparticles at ‘tumor’ center extending to 40% of tumor volume, Figure 
2.1, bottom) magnetic iron oxide nanoparticles (MIONP) distributions for 60 min heating 
with constant power (Qp = 4.6 × 105 W/m3) are shown in Figure 2.2. In both cases, a 
temperature gradient within the tumor is predicted, which results from heat generated by 
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MIONPs that conducts throughout the tumor and dissipates into the surrounding tissue. 
Temperatures calculated at the tumor boundary with respect to time for the two models are 
shown in Figure 2.3. Steady-state is achieved rapidly, within about 300 seconds for both 
models, although the tumor-tissue interface temperature achieved by a uniform MIONP 
distribution is predicted to be slightly higher (T = 40.9 ºC) than that achieved by a 
concentrated MIONP distribution (T = 40.6 ºC). Heat flux (loss) at the tumor-tissue 
interface (heating of healthy surrounding tissue) is also predicted to be greater for the 
uniform distribution (656 W/m2) than for concentrated MIONP distribution (592 W/m2). 
Modulating power with computed temperature as the feedback control parameter 
(Qp(T)) produces different temperature profiles within the tumor depending upon both 
MIONP distribution and control temperature probe placement (Figures 2.3 (a) and (b)). 
Temperature gradients produced within a tumor bearing a uniform MIONP distribution are 
similar to those produced by constant power heating, although the steady-state temperature 
achieved at the tumor-tissue boundary is determined by placement of temperature sensor 
used in the control algorithm described by Equation 2.5. Similarly, power-modulated 
heating with a concentrated MIONP distribution produces similar temperature gradients 
within the tumor as with constant-power heating. Power-modulated heating with 
temperature monitoring at the tumor-tissue interface, however achieves identical steady-
state temperature at the tumor boundary for both concentrated and uniform MIONP 
distributions. By contrast, placement of temperature probes in either the tumor center or 
halfway between center and boundary for concentrated MIONP distribution limits heating 







Figure 2.2 Temperature distribution of uniform distribution model and concentrated 














Figure 2.3 Variation of tumor-healthy tissue boundary temperature with time for uniform 











Success of hyperthermia depends on the temperatures achieved inside the tumor 
and the treatment time (time at temperature). Temperature measurements in clinical trials 
for hyperthermia are often reported as index temperatures averaged over time. Index 
temperatures, denoted as Tx, are the temperatures which are exceeded by at least x% of the 
tumor volume [34]. Often T90, temperature achieved or exceeded in 90% of tumor volume, 
is used as a parameter to compare and correlate temperature measurements with treatment 
outcomes. Thermal dose, defined as time at temperature, is often measured as cumulative 
equivalent minutes normalized to 43 °C, denoted as CEM43. CEM43T90, defined as the 
thermal dose achieved or exceeded in at least 90% of tumor, is a superior indicator of 
treatment outcome over temperature alone [9,10,25,127]. Thus, rather than achieving a 
uniform temperature distribution (uniform thermal dose), the goal of hyperthermia therapy 
is to achieve a minimal effective thermal dose in >90% of tumor volume. In preclinical or 
clinical settings achieving this minimal thermal dose is often not realized due to technical 
challenges in energy deposition, inadequate temperature measurement, and lack of 
feedback control of energy deposition with temperature data. 
Magnetic iron oxide nanoparticles, due to their biocompatibility, small size, and 
ability to generate substantial heat, offer great potential for cancer hyperthermia [39]. As 
the nanoparticles are the main source of heat in mNPH, their concentration, and distribution 
inside the tumor, determine the treatment outcome. Current methods of delivery such as 
image guided percutaneous delivery [128,129] or direct intratumor injection can ensure 
consistent and sufficient delivery of nanoparticles into the tumor but fail to address the 
issue of nanoparticle distribution inside the tumor. The varied tumor biology and 
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physiology significantly influences the achievable nanoparticle distribution inside a tumor. 
Additionally, redistribution of nanoparticles during and after mNPH has been observed 
[44,130–134]. Thus, it is reasonable to expect that consistently achieving a controlled 
uniform nanoparticle distribution inside the tumor is not possible. Tumor regions with 
higher concentration of nanoparticles, predictably, will result in rapidly increasing 
temperatures, when compared to other tumor regions, when constant power heating begins 
(Figure 2.2). Temperatures and temperature gradients decrease rapidly in regions far away 
from the nanoparticles. The heat generated by these concentrated nanoparticle regions 
propagate through the tumor at a higher rate ( r3) rather than out of the tumor through the 
tumor-healthy tissue boundary (rate  r2) to the surrounding healthy tissue (r is the distance 
from the heating zone). Thus, local concentration of nanoparticles is favorable, provided 
the volume of heating zones and power meet minimum threshold values [118]. For constant 
perfusion, the heat flux at the tumor-healthy tissue boundary is thus higher for uniform 
distribution of nanoparticles (656 W/m2) compared to concentrated distribution (592 
W/m2), which potentially can lead to increased thermal damage to surrounding sensitive 
normal tissue and also result in under treatment regions within the tumor. Therefore, heat 
generation zones with volumes larger than a critical value, dependent on tumor volume, 
can lead to unfavorable heating of surrounding healthy tissue and tumor under treatment, 
as heat flux at the tumor-healthy tissue boundary will be higher than the rate of heat 
conduction within the tumor. Temperatures at the tumor-healthy tissue boundary reach a 
steady state (Figure 2.3), after an initial steep rise, depending on the nanoparticle 
distribution, the heating power applied and the heating duration.  
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Modulating power with single point thermometry can limit and control the thermal 
dose deposited in tumors with heterogeneous distribution of nanoparticles. In this case, 
placement of this single temperature sensor becomes crucial. If placed within a heating 
zone with nanoparticles, this temperature sensor will initiate an early reduction and control 
of applied power to limit the thermal dose within a prescribed value. This could lead to 
insufficient deposition of thermal dose to cover an adequate tumor volume (~ 90%) 
(Figures 2.4 & 2.5). When the temperature sensor is placed at or near the tumor-healthy 
tissue boundary, minimal thermal dose can be achieved in 90% of the tumor volume, for 
both the uniform and concentrated distributions. Power modulated mNPH with 
temperature feedback from the tumor-healthy tissue boundary can more likely achieve a 
minimal thermal dose of CEM43T90, compensating for variable nanoparticle distributions. 
However, for locally concentrated nanoparticle distributions, power modulated mNPH can 
likely produce higher intratumor temperatures to achieve the required tumor-healthy tissue 
boundary temperature. This could lead to ablation or necrosis in those local concentrated 
zones which can influence treatment outcomes for combination therapies. The simulations 
thus show that, with appropriate caveats, temperature monitoring at the tumor-tissue 
boundary is necessary to ensure a minimally effective thermal dose (CEM43T90).  
 
2.5 Conclusions 
This computational study focused on understanding the effect of nanoparticle 
distribution and heat output on the temperature evolution in a simple two dimensional 
model. Two nanoparticle distributions, uniform and concentrated, were considered. 
Pennes’ bioheat equation was solved to compute the temperature distributions inside the 
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tumor and the surrounding healthy tissue. Constant power heating simulations were carried 
out to highlight the differences in temperature distributions achieved for the different 
distributions. It was shown that modulation of heat output of the nanoparticles based on 
temperature feedback from the tumor-healthy tissue boundary can compensate for variable 
nanoparticle distributions to deliver a minimum effective thermal dose (CEM43T90). 
However, to be clinically relevant, further simulations with more realistic parameters (eg. 
temperature effects on perfusion), different tumor shapes, and three dimensional models, 
with better strategies to modulate power will be necessary. The above results allow us to 
speculate that, with knowledge of nanoparticle distribution, obtained through imaging, 
combined with computational modeling, we can guide effective temperature sensor 





Chapter 3                     
Temperature-control via power 
modulation to compensate for varied 
particle distributions – a 
computational study 
 
In this chapter, an improved modulated power heating method is described and 
results from implementation in 2D and 3D computational models for a range of 
nanoparticle distributions including those derived from animal studies are reported. For the 
2D models, six nanoparticle distributions – three obtained from previous animal studies 
and three idealized mathematical constructs, were considered. For the 3D models, three 
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mathematically constructed nanoparticle distributions were considered. Temperature 
effects on perfusion was implemented by modeling perfusion as a function of thermal 
damage. A new method of modulating heating power of nanoparticles using a proportional-
integral-derivative (PID) controller with temperature feedback from the tumor-healthy 
tissue boundary is presented. Comparisons between constant power heating and this new 
modulated power heating were carried out to highlight the advantages of modulated power 
heating. It is shown that modulated power heating with temperature feedback from the 
tumor-healthy tissue boundary can compensate for variable nanoparticle distributions and 
deliver effective tumor treatment with minimal healthy tissue damage. 
3.1 Introduction 
Among the challenges for clinical implementation of mNPH is the lack of precise 
control of nanoparticle distribution within tumors, to enable precise energy deposition 
throughout the tumour volume [43–46]. This could lead to under treatment of tumor and/or 
could result in significant thermal damage to the healthy tissue. Effectiveness of thermal 
therapy is defined by/limited to the region of tumor receiving the lowest thermal dose [9]. 
Given this, it has been generally accepted that achieving a minimum effective thermal dose 
(~ CEM43 ≥ 60 min) in a maximum volume (~ 90% or better) of tumor, to be the treatment 
objective or goal [9,25]. In addition, the treatment should also minimize the thermal dose 
deposition to the surrounding tissue to limit damage to the healthy tissue. Thermal dose, 
determined by time-at-temperature, is therefore dependent on the temperatures achieved. 
Thus, controlling the temperatures achieved inside the tumor would lead to control of the 
thermal dose deposited.  
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For mNPH, effective control of temperature requires controlled heat generation by 
nanoparticles and precise temperature measurement. Heat generated by nanoparticles, 
given by specific loss power (SLP, W/g of material), depends on the amount of magnetic 
material, its magnetic properties, magnitude of applied field and frequency. At fixed 
frequency, SLP increases non-linearly with increasing amplitude to a maximum value close 
to where magnetization saturation is achieved [51,56,57]. The heating output of the 
nanoparticles can therefore be controlled non-invasively and dynamically by modulating 
the amplitude of the applied alternating magnetic field (AMF). Real time temperature data 
can provide meaningful estimates of the heat that is being deposited into the tumor and 
healthy tissue, and can be used to modulate the AMF amplitude. However, measuring 
temperature continues to pose technical challenges in both clinical and preclinical settings 
[9,45]. Ideally, volumetric, in situ, real time and non-invasive temperature measurements 
are desired but lacking. In clinical settings, single point measurements are often used and 
are useful indicators of outcome [34].  While volumetric temperature information of the 
tumor and healthy tissue would be useful, single point temperature measurements, when 
the temperature probe is strategically placed, can offer valuable information for designing 
effective treatment strategies. 
Computational studies have been conducted to develop optimal strategies for 
mNPH considering nanoparticle heat deposition, distributions and tissue thermal properties 
[112,114–120,135–141]. While considerable progress has been made, most of these studies 
incorporate simplifications such as homogeneous nanoparticle distributions, zero or 
constant blood perfusion etc., for computational ease and efficiency. Of the previous 
optimization studies [112,115,136–141] for mNPH, most of them focused on determining 
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optimal constant magnetic field amplitude and magnetic nanoparticle parameters, for 
effective tumor treatment and minimal healthy tissue damage. Bagaria and Johnson [115] 
proposed an optimal nanoparticle distribution for effective treatment of tumors. Candeo et 
al. [136] optimized energy density with respect to particle concentration, diameter, and 
magnetic field intensity. Salloum et al. [112] developed an optimization algorithm to 
inversely determine the optimal heat source parameters for a multi-injection strategy for 
irregular tumor geometries. They proposed a model to determine the ferrofluid injection 
rate, volume, and concentration for a multi-point injection of nanoparticle for MNPH. Mital 
and Tafreshi [137] applied genetic algorithms to optimize parameters to maximize thermal 
damage to tumors and minimize healthy tissue damage based on a fitness function. Bellizzi 
et al. [138,139] proposed optimal criteria for choice magnetic field amplitude, frequency, 
and diameter of nanoparticles for effective treatment of tumor and minimizing healthy 
tissue damage and tested it on a human head model. Koch et al. [140] and Soetaert et al. 
[141] looked at the effects of time-dependent power heating on tumor temperatures and 
thermal damage in comparison to constant power heating. Koch and Winfrey [140] built 
models to optimize energy density in tumors using time-dependent magnetic nanoparticle 
power dissipation. The nanoparticle distribution was governed by a Gaussian probability 
function and blood perfusion was assumed constant. They showed that time-varying power 
depositions increased tumor temperatures and simultaneously decreased healthy tissue 
temperatures. Soetaert et al. [141] evaluated different modulations of a constant frequency 
sinusoidal waveform and showed that power modulation resulted in more tumor thermal 
damage compared to constant power heating. All of the above studies either focused on 
optimizing different magnetic nanoparticle parameters with constant power heating or 
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evaluated different preset amplitude modulations to optimize tumor heating. These studies 
did not consider dynamically modulating power based on computed temperatures either 
from the tumor or healthy tissue. 
Controlling the temperature at the tumor-healthy tissue boundary can ensure 
effective tumor treatment while simultaneously minimizing the healthy tissue damage. 
This temperature depends on the heat generated by the nanoparticles and controlling the 
nanoparticle heat output will enable control of the tumor-healthy tissue boundary 
temperature. Local temperature control using a proportional-integral-derivative (PID) 
controller is widely used in industry and in medicine [142–146]. Specifically in medicine, 
Salomir et al. [142] used a PID temperature control to regulate the temperature at a focal 
point during MR-guided focused ultrasound therapy. They obtained precise temperature 
control close to the precision of the temperature measurement both in vitro and in vivo. 
Mougenot et al. [143] further developed a three dimensional spatial and temporal control 
of temperature during MR thermometry guided focused ultrasound therapy. Haemmerich 
[144] implemented an automatic PI closed loop controller system and optimized the 
controller parameters for temperature controlled RF ablation.  
In the current study, we present a strategy to modulate the AMF amplitude, based 
on single-point temperature feedback, to achieve effective tumor treatment and minimize 
healthy tissue damage. We hypothesized that controlling the tumor-healthy tissue boundary 
at a target temperature for sufficient time can compensate for variable nanoparticle 
distributions to deliver effective therapy. To test this hypothesis, we considered six 
nanoparticle distributions – three derived from animal studies and three idealized 
distributions. Heat transfer in the tumor and healthy tissue was modeled using the Pennes’ 
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bioheat equation. Tumor and healthy tissue were modeled as ellipses and temperature 
effects on perfusion was considered. We implemented a proportional-integral-derivative 
(PID) controller to control the power output of nanoparticles in order to achieve a target 
temperature at the tumor-healthy tissue boundary and to minimize healthy tissue damage. 
The heating power of the nanoparticles was based on the experimental values for bionized 
nanoferrite (BNF) particles determined by Bordelon [56]. We compared the time-
dependent change in temperatures and thermal dose (CEM43) obtained in the tumor and 
healthy tissue, for both constant power and PID controlled modulated power heating. 
Modulated power resulted in effective tumor treatment with overall lower and 
homogeneous temperatures, compared to constant power. We then implemented the above 
strategy in 3D computational models where the tumor was modeled as an ellipsoid and 
three mathematical nanoparticle distributions were considered. A clinically relevant 
thermal dose of CEM43 ≥ 60 min was achieved for all nanoparticle distributions. This 
shows that taking advantage of variable heating power potential of nanoparticles and 
controlling the tumor-healthy tissue boundary temperature can compensate for variable 
nanoparticle distributions to deliver effective treatment. 
3.2 Model description 
Two concentric elliptical regions, shown in Figure 3.1, representing the tumor and 
a region of interest of the surrounding healthy tissue were chosen as the representative 
geometry for our study. The inner elliptical region (major axis lt = 9 mm, minor axis wt = 
6 mm) represents the tumor seeded with nanoparticles. The outer elliptical region (major 
axis l = 19 mm, minor axis w = 16 mm) corresponds to modelled healthy tissue. We assume 
that the outer boundary of the healthy tissue is in contact with the core body temperature 
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(infinite heat reservoir) maintained at 37oC. Heat transfer in the healthy tissue and tumor 







+ 𝜌𝑏𝑐𝑏𝜔𝑏,𝑛(𝑥, 𝑦, 𝑇𝑛) ( 𝑇𝑏 − 𝑇𝑛(𝑥, 𝑦, 𝑡) ) + 𝑄𝑚,𝑛
+𝑄𝑃(𝑥, 𝑦, 𝑡) 
(3.1) 
where the subscript n accounts for the tissue layer (n = 1 for the tumor and n = 2 for healthy 
tissue) and the subscript b the blood parameters, respectively. 𝜌𝑛 is the density, 𝑐𝑛 the 
specific heat, 𝑇𝑛(𝑥, 𝑦, 𝑡)  the local temperature, 𝑘𝑛 the thermal conductivity, 𝑄𝑚,𝑛 the 
metabolic heat generation rate in either the healthy tissue or tumor, and 𝑄𝑃 is the heat 
generated by the nanoparticles. The subscript m in Equation (3.1) refers to metabolic heat 
generation in tissue layer n. 𝜌𝑏 , 𝑐𝑏, 𝜔𝑏,𝑛(𝑥, 𝑦, 𝑇𝑛) and  𝑇𝑏 denote density, specific heat, 
perfusion rate, and temperature of blood, respectively. Table 3-1 summarizes the 
thermophysical properties for healthy tissue, tumor, and blood [74,122–126] used in this 
study. We assumed that there is no heat generation due to eddy currents by AMF in the 
tissue. At the interface between the tumor and healthy tissue, continuity in temperature and 












 𝑇𝑡𝑖𝑠𝑠𝑢𝑒|𝑖𝑛𝑡 = 𝑇𝑡𝑢𝑚𝑜𝑟|𝑖𝑛𝑡 (3.3) 
In Equation (3.2), the variable j denotes the surface normal to the elliptical boundary 
between tumor and healthy tissue. At the elliptical outer boundary of the healthy tissue, the 
temperature is constant, equal to the core body temperature 
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 𝑇𝑡𝑖𝑠𝑠𝑢𝑒 𝑏𝑜𝑢𝑛𝑑𝑎𝑟𝑦 = 37 °𝐶 (3.4) 
The initial temperature for both the tumor and healthy tissue was set at 37 °C in these 
simulations. 
Figure 3.1 Schematic of the computational geometry, tumor region surrounded by healthy 
tissue, with the thermal boundary conditions. (b) Sample digitized E1 binary model 
showing the tumor with nanoparticles. (c) Sample mesh for the model under (b). Note: 
Figures not to scale. 
 
3.2.1 Nanoparticle distributions 
The model magnetic nanoparticle distributed in the tumor region (Figures 3.2(a), 
(b)) are line heat sources [118]. If the individual heating power of the nanoparticles is QN, 
and the number of nanoparticles N (1460 in our study) distributed in the tumor is known, 




 𝑄𝑝 =  𝑁 × 𝑄𝑁 (3.5) 
In the present study, the heating power of nanoparticles was modeled based on 
experimentally determined SLP values for BNF nanoparticles at 150 kHz [56]. The 
corresponding alternating magnetic field amplitude at the chosen frequency can be 
estimated using the continuous polynomial approximation of SLP vs H given by Soetaert 
et al. [141]. The iron concentration in the tumor was assumed to be 5 mg Fe/cc of tumor 
[52]. The total heating power Qp can be obtained from SLP (specific loss power) 
experimental data, using the expression 




For example, when the total heating power delivered to the tumor is Qp = 5.18 × 105 W/m3 
and the iron concentration CFe = 5 mg Fe/cc, the SLP is 103.6 W/g Fe. At 150 kHz 
frequency, the SLP of 103.6 W/g Fe corresponds to a peak magnetic field amplitude of ~ 
13.5 kA/m. 
Six nanoparticle distributions were considered in this study. Three distributions 
were derived from tissue sections (E1, E2, E3) obtained from tumors injected with 
nanoparticles as described previously in [52,53] (Figure 3.2), and three were mathematical 
functions representing ‘idealized’ distributions (M1, M2, M3, Figure 3.2). 
Modeling nanoparticle distributions from tumor tissue sections  
Images of nanoparticle distributions taken from archived sections of human 
prostate tumor xenografts grown in mice were used to generate models E1-E3 (Figure 3.2). 
Experimental details have been previously described [52,53]. These methods are briefly 
reviewed here for clarity. Nanoparticles were comprised of aqueous BNF-Starch (catalog 
no. 10-00-102), obtained from Micromod Partikeltechnologie, GmbH (Rostock, 
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Germany), and were injected into tumors. Particles were used as received [52,53]. 
Formalin-fixed tumors were sectioned and stained with Perls’ reaction to visualize the 




Figure 3.2 Nanoparticle distributions used in the computational study (a) obtained from 
stained tissue sections from human tumor xenografts obtained from nude mouse tumor 
models [52,53], (E1- nanoparticles relatively uniformly distributed, E2- concentrated 
distribution along the major axis, E3- concentrated and offset along the minor axis) and (b) 
ideal nanoparticle distributions, (M1 - uniform, M2 – uniformly concentrated in 40% of 
tumor area, and M3 - Gaussian) used in the computational model. 
 
The stained tumor sections [52,53] were digitally imaged and these images were 
processed to display nanoparticle distributions in a format suitable for our computational 
model. The original high resolution (4752 × 3182 pixels) digital images of the stained 
sections were resized into smaller images (225 × 150 pixels), with no change in aspect 
ratio, to reduce the data volume and computational cost. The change in the ratio of stained 
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pixels to the total pixels in the resized image is minimal (~1.5 %). The images were then 
converted into binary form using MATLAB’s image processing toolbox. In these binary 
images, the dark pixels represent stained nanoparticle clusters, each of them acting as a line 
heat source 𝑄𝑁(𝑥, 𝑦, 𝑡), representative of the nanoparticle distribution in space in the tumor 
domain. Nanoparticle distributions obtained from the processed images of the three mouse 
models, E1, E2, and E3, are shown in Figure 3.2(a). 
Idealized nanoparticle distributions 
The three idealized distributions, were the uniform (M1) [114], concentrated (M2) 
[52], and Gaussian distributions (M3) [112,140,141] (Figure 3.2). In the M1 distribution, 
nanoparticles are evenly distributed throughout the tumor area. In the M2 distribution, the 
nanoparticles were arranged uniformly in an area occupying only the central 40% region 
of the tumor. For the M3 distribution, the nanoparticle distribution in the tumor was 
governed by a Gaussian probability function centered at the tumor center and extending to 


















In Equation (3.7), σx, σy are the standard deviations of x and y, respectively. In the 
current simulation, σx and σy were arbitrarily chosen to be 2 and 0.5, and the generated 
Gaussian distribution of points was truncated to fit inside the tumor. To compare heating 
effects among the six tumor models, the total number of nanoparticles N (dark pixels) in a 
tumor was fixed at N ~1460 ± 5 for each model. This means that the total heating power 
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delivered to each of the six tumor models is identical, allowing a quantitative comparison 
of temperatures and thermal doses. 
3.2.2 Perfusion models 
Effects of temperature on perfusion were accounted with three models, the (i) 
constant perfusion model (e.g. ‘classic’ Pennes equation) as described by Equation 3.1, the 
(ii) Arrhenius perfusion model; and, the (iii) modified Arrhenius perfusion model; as 
described previously [147,148]. In the first model, blood perfusion in both tumor and 
healthy tissue is constant (independent of temperature), 
 𝜔𝑏(𝑇) = 𝜔𝑏𝑖 (3.8) 
In the Arrhenius model, blood perfusion is described as a function of temperature 
and time, correlated to the degree of microvascular stasis (DS) expressed as 





 𝜔𝑏(𝑇) =  𝜔𝑏𝑖(1 − 𝐷𝑆) (3.10) 
In Equations (3.9) and (3.10), 𝐴 is the frequency or pre-exponential factor, 𝐸𝑎  the activation 
energy barrier, 𝑅 the universal gas constant, 𝑇(𝜏) is the absolute tissue temperature as a 
function of time and 𝜔𝑏𝑖 the initial blood perfusion rate. The degree of vascular stasis 𝐷𝑆 
varies between 0 (no vascular damage) and 1 (complete vascular shutdown). The values 
for 𝐴 and 𝐸𝑎  are shown in Table 3-1.  
The foundation for the modified Arrhenius perfusion model is the first-order kinetic 
Arrhenius model of vascular stasis (Equations 3.9 and 3.10), expanded by an additional 
term to increase the relative perfusion when vascular stasis is low. This latter model is 
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derived empirically from data determined experimentally by He et al. [147]. Schutt et al. 






ωbi(30.DS+1),  (DS≤0.02) 
ωbi(-13 DS+1.86),  (0.02<DS≤0.08)
ωbi(-0.79 DS+0.884), (0.08<DS≤0.97)
ωbi(-3.87 DS+3.87), (0.97<DS≤1.0) .
 (3.11) 
When the degree of stasis is low (𝐷𝑆 ≤ 0.02), there is an increase in perfusion. As the 
degree of stasis increases (0.02 < 𝐷𝑆 ≤ 0.08), perfusion first decreases moderately, and 
then more rapidly (0.08 < 𝐷𝑆 ≤ 0.97), before eventually becoming zero (0.97 < 𝐷𝑆 ≤
1.0). 
3.2.3 Constant power heating 
For the constant power simulations, the total heating power of nanoparticles Qp 
remained constant throughout the simulation. Temperature distribution 𝑇(𝑥, 𝑦, 𝑡) and 
thermal dose were evaluated as a function of time for each simulation. The total thermal 
dose achieved in the tumor was expressed as the cumulative equivalent minutes at 43 °C 
(CEM43) summed up during the course of heating [25]. Mathematically it is expressed as 






In Equation (3.12), R = 0.5 for T > 43 °C, and R = 0.25 for T ≤ 43 °C. CEM43 T90 
is defined as the total thermal dose expressed as cumulative equivalent minutes at 43 °C 
achieved or exceeded in 90% of the tumor area [9,32], with treatment considered effective 
when achieved for 60min or longer, CEM43 T90 ≥ 60 [9,32]. The power required to 
achieve a clinically effective thermal dose (CEM43 T90) within 20 minutes was computed 
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for the situations considered in this study. The heating power necessary to achieve such a 
treatment effect for a given treatment time is defined as the isoeffective heating power, 
Qiso. It was computed by iteratively carrying out a series of simulations with constant power 
settings until 90% of tumor area achieved thermal dose of CEM43 ≥ 60min. 
3.2.4 Modulated power heating 
For modulated-power heating, the heating power of nanoparticles was varied as a 
function of the temperature computed at the tumor-tissue boundary [19, 24]. As discussed 
in Attaluri et al [52], for a spherical tumor model with uniform distribution of 
nanoparticles, using the temperature at tumor-tissue boundary as feedback for power 
modulation results in effective thermal dose deposition in the tumor. In the current study, 
a 2D elliptical model was considered, which accounts for variability in two directions and 
different nanoparticle distributions, and thus required to precisely determine the location 
of temperature probe on the tumor-healthy tissue boundary. To determine this, eight probe 
locations (P1-P8, Figure 3.3) located on the tumor-tissue boundary, were considered. As 
in Chapter 2, for all the six nanoparticle distribution models, the heating power was 
alternated between two levels: the higher heating power was selected when the probe 
temperature was below 43.5 °C, and the lower heating power when Tprobe exceeded 43.5 
°C. The initial power and the heating algorithm are described mathematically as 
  𝑄𝑝(𝑇) = {
1.5 × 𝑄𝑖𝑠𝑜 ,   𝑖𝑓 𝑇𝑝𝑟𝑜𝑏𝑒 < 43.5 °𝐶
0.15 × 𝑄𝑖𝑠𝑜 , 𝑖𝑓 𝑇𝑝𝑟𝑜𝑏𝑒 ≥ 43.5 °𝐶  .
 (3.13) 
The higher heating power was chosen to be greater than Qiso to allow for the tumor to 
achieve the target temperature faster, which is clinically desired. The percentage area of 





target temperature faster at the target location and also minimizes temperature overshoot 
which would result in minimal healthy tissue damage. The PID controller is given by  







  𝑄𝑝(𝑇) =  𝑢𝑐𝑡𝑟𝑙(𝑇) 𝑄𝑚𝑎𝑥 (3.16) 
   
  
Figure 3.5 Specific loss power (W/g Fe) versus applied field (peak-to-peak, kA/m) for 
BNF-starch nanoparticles [56] 
 
In Equation 15, θ(x,y,t) is the difference between computed temperature at the probe 
location Tprobe (x,y,t) and the target temperature Tref. The gains Kp , Ki , Kd are the 
proportional, integral and derivative gains of the PID controller. uctrl adjusts the heat 
generation of nanoparticles by modulating the heating power applied based on the 
difference in measured temperature at the probe location and target temperature. Qmax is 
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the maximum power that can be generated by the nanoparticles at a given frequency. The 
maximum SLP of 537 W/g Fe (peak field strength of 47 kA/m at frequency 150 kHz) for 
BNF nanoparticles as reported by Bordelon [56] (Figure 3.5) was used for determining 
Qmax. 
The PID controller gains Kp , Ki , Kd were determined by using model-based control 
design methods based on Youla parametrization (Q-parametrization) [145,146,149,150]. 
By Q-parametrization theory, for a single-input single-output stable plant transfer function 





where Q(s) is any stable transfer function. We approximated our model system by a second 
order plant transfer function P(s) with three parameters, given in Laplace domain by, 
 𝑃(𝑠) =  
𝑔
(1 + 𝜏1𝑠)(1 + 𝜏2𝑠)
 (3.18) 
where g is the static gain for step input, τ1 and τ2 are time constants. The plant transfer 
function parameters were assessed by open loop step response. The power was stepped to 
30% of maximum power and the temperature response was recorded at the probe location. 
The static gain g, is given by the ratio of temperature gain achieved with the step in control 
input. 




The time constant τ1 was calculated as the delay between the maximum rate of change in 
temperature and the temperature response at the probe location. The time constant τ2 is the 
difference between the time taken for the temperature response to reach 63% of total 
temperature gain and the time constant τ1.   
74 
 
A second order transfer function Tr was chosen, given in the Laplace domain, 
 𝑇𝑟(𝑓, 𝜁) =  
𝑓2
𝑠2 + 2𝜁𝑓𝑠 + 𝑓2
 (3.20) 
where f is the closed loop frequency and ζ is the damping ratio. Using equations 14, 17 and 
20, the controller function C(s) was determined as, 
 𝐶(𝑠) =  




The individual gains can then be calculated as, 
 𝐾𝑝 = 
𝑓
2𝜁𝑔








 𝐾𝑑 =  
𝑓
2𝜁𝑔




After determining the PID controller gains, the power was modulated based on temperature 
feedback from the probe on the tumor-healthy tissue boundary determined previously. The 
computed temperature at the probe location Tprobe, was compared to a reference temperature 
signal Tref and the difference was fed into the PID controller. In the current simulations, the 
reference temperature signal Tref was chosen to be ramp signal, which begins at 37 °C, at t 
= 0 s, and reaches the target temperature at t = 30 s. This time point was chosen as it is 
clinically desirable to reach the target temperature as quickly as possible. The output from 
the PID controller uctrl modulates the nanoparticle heat output. 
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3.2.5 3D models 
Three 3D nanoparticle distribution models (Figure 3.6) were considered to further 
test the PID controlled modulated power heating described above. Tumors were 
represented by 3D ellipsoids of total volume of 150 mm3. The healthy tissue was a cube of 
length 5 cm. In the T1 (uniform) distribution model, the nanoparticles were evenly 
distributed inside the tumor. In the T2 (Gaussian-centered) distribution model, the 
nanoparticles were normally distributed at the tumor center. For the T3 (3pt-Gaussian), the 
nanoparticles were normally distributed at three centers (indicating points of injection). 
The same thermal model that was implemented for the 2D models was used for the 3D 
simulations. 
 
Figure 3.6 (a) Schematic of the 3D computational model with tumor and surrounding 
healthy tissue. (b) Sample mesh for the 3D model. (c) Three distributions, T1- Uniform, 
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T2 – Gaussian centered, T3 – 3pt-Gaussian distribution mimicking 3 point nanoparticle 
injection 
3.2.6 Solution method 
COMSOL Multiphysics 5.2a, a commercial finite element solver, was used to solve 
numerically the governing differential equations (Equation 3.1) subject to the boundary 
conditions described by Equations (3.2 – 3.4). A typical finite element grid for the E2 
nanoparticle distribution is displayed in Figure 3.1 (c). In all models, the distance between 
adjacent nodes was very small in the vicinity of the nanoparticles and increased with 
distance from the nanoparticles. For example, the mesh used to compute heating for the E2 
model consisted of 13932 triangular elements with a maximum element size of 2.47 mm 
and a minimum element size of 0.11 mm. To check the sensitivity of the solution to mesh 
size, the mesh size was refined by increasing the number of elements to 19060, which 
resulted in a change in maximum temperature of less than 0.01%. Similarly, for the 
transient solution, changing the time step from 1s to 0.5s had negligible (<0.01% change) 










Table 3-1 Thermophysical properties used in the simulation for tumor, healthy tissue and 
blood 
Properties Tumor Tissue Blood* 
Thermal Conductivity (k, W/m-
K) 0.51 [122] 0.51 [122] N/A 
Density (ρ,kg/m3) 1045 [122] 1045 [122] 1060 [125] 
Heat Capacity (Cp, J/kgK) 3760 [122] 3760 [122] 3770 [125] 
Initial Perfusion Rate (ωbi,1/s) 0.0095 [123] 0.003 [123] N/A 
Metabolic Heat Rate (Qm, W/m3) 31872.5 [74] 6374.5 [74] N/A 
Pre-factor (A, 1/s) 1.8e36 [151] 1.03e
38 
[151] N/A 
Activation Energy (Ea, J/mol) 2.38e5 [151] 2.49e5 [151] N/A 
*Temperature of blood (Tb) was fixed at 37ºC [125]. (N/A – not applicable) 
 
3.3 Results 
3.3.1 Temperature distributions 
In mNPH, the primary heat sources are the magnetic nanoparticles. Hence, the 
distribution of nanoparticles significantly influences the achieved temperature distribution 
in the tumor and healthy tissue. Figure 3.7 shows the temperatures achieved inside the 
tumor and healthy tissue after 20 minutes of constant-power heating (Qp = 10.6 × 105 
W/m3) and constant perfusion (Table 3-1). This power setting was chosen to yield a 
minimum thermal dose of CEM43 ≥ 60 min in 90% of tumor area in the uniform model. 
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Significant differences were observed in the temperature distributions among the six tumor 
models when nanoparticle heating was conducted using this constant power value for 20 
min. The E3 model was characterized by concentrated nanoparticle clusters (parallel to the 
minor axis) with corresponding high temperatures, whereas the uniform model exhibited 
small temperature differences and gradients, consistent with the nanoparticle distribution. 
The E2 model with broadly scattered nanoparticles in the tumor region demonstrated a 
temperature distribution approximating the uniform distribution. The temperature 
distribution for the E1 model resembled the idealized concentrated model. These results 
are consistent with those previously described by Attaluri et al. [52].   
 
Figure 3.7 Localized nanoparticle distributions lead to higher temperatures Computed 
temperature distributions in the tumor and surrounding healthy tissue for six nanoparticle 





A quantitative comparison of the characteristic temperature profiles for the six 
nanoparticle distributions and three perfusion models is displayed in Figure 3.8. The results 
demonstrate that the three idealized models (M1, M2, and M3) produced a symmetrical 
distribution about the tumor center along both major and minor axes, mirroring the 
nanoparticle distributions. On the other hand, the results derived from mouse tumor images 
displayed asymmetric temperature distributions. The asymmetry was most pronounced for 
E3, a distribution characterized by significant clustering of nanoparticles along a narrow 
vertical region parallel to the minor axis. As expected, the maxima for the temperatures 
were observed at the locations of the highest nanoparticle density along the respective cross 
sections. The E3 model also exhibited the highest range of temperature variations in the 
tumor (for constant perfusion), with a minimum of 40.0 °C and a maximum of 59.4 °C. 
The idealized uniform nanoparticle (M1) distribution exhibited the lowest range of 
temperature variations (~43 – 49 °C) among all models studied. The idealized Gaussian 
nanoparticle (M3) distribution exhibited the maximum temperature (for example 61.7 °C, 
constant perfusion) among all the nanoparticle models across all the perfusion models. 
When temperature-dependent perfusion was considered (Figure 3.8 (b), (c), (e), (f)), the 
range of tumor temperatures increased for all nanoparticle distributions, except for the 
idealized uniform distribution. The temperatures were similar for the two temperature-
dependent perfusion models. 
3.3.2  Constant power heating  
The isoeffective heating power Qiso for 20-min treatment was calculated for the six 
nanoparticle distributions and three perfusion models. The results are summarized in Table 
3-2. Conditions chosen for calculating the isoeffective power were based upon parameters 
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previously described by Attaluri et al. [52]. E3 required the highest heating power Qiso to 
achieve the isoeffective thermal dose for the three perfusion models, when compared with 
the other nanoparticle distributions. Differences in the isoeffective heating power were 
most pronounced for constant perfusion: the maximum power (19.6 × 105 W/m3) for E3 is 
contrasted to the minimum power (10.6 × 105 W/m3) for the M1 (uniform) distribution. 
Conversely, when temperature-dependent perfusion was taken into account, the various 
nanoparticle distributions, except E3, required similar isoeffective heating power (~ 8.4 ± 
0.4 × 105 W/m3). E3 nanoparticle distribution model required at least 20% more 
isoeffective heating power than the other nanoparticle distributions. This can be attributed 
to the asymmetry in the E3 nanoparticle distribution: regions of low nanoparticle 
concentration, away from the clusters, required more heating power than the high- or 
uniform-concentration regions to achieve the isoeffective dose and similar temperature 
levels. 
The thermal dose (CEM43  60 min) deposited into the healthy tissue after 20 
minutes of heating for the respective isoeffective power (Qiso) were compared for the six 
nanoparticle distributions (Table 3-2). E3, again, was found to be the least favorable 
distribution, depositing the highest thermal dose into the healthy tissue. The idealized 
uniform distribution (M1) deposited the lowest thermal dose into nearby normal tissue, 
independent of the perfusion model. The image-derived nanoparticle distributions (E1, E2, 
and E3) deposited more heat into adjacent normal tissues than any of the idealized models 
(M1, M2 and M3), regardless of perfusion model chosen for comparison. For temperature-
dependent perfusion, the thermal dose deposited into the healthy tissue was less than for 
constant perfusion for all nanoparticle distributions, except for the idealized uniform 
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model. The uniform distribution exhibited a slight increase for temperature dependent 
perfusion, when compared with the constant perfusion model. 
 
Table 3-2 Isoeffective heating powers for treatment time of 20 min for the six nanoparticle 
distributions with the three perfusion models. 
Nanoparticle 
Distribution 
Isoeffective heating power (× 105 
W/m3) 
Percent of healthy tissue with 













M1 10.6 8.0 8.1 0.2 0.5 0.4 
M2 11.8 8.0 8.1 2.0 2.0 1.9 
M3 12.5 8.2 8.2 2.7 2.6 2.6 
E1 13.6 8.8 8.9 6.6 5.1 5.2 
E2 12.2 8.3 8.4 3.5 3.2 3.2 







Figure 3.8 Choice of perfusion model influences model tumor and healthy tissue temperature distributions. Temperature distribution 
along the major and minor axes of computational model, for the six nanoparticle distributions after 20 min of heating at constant power 
Qp = 10.6 × 105 W/m3, major axis: (a) constant perfusion, (b) Arrhenius perfusion and (c) modified Arrhenius perfusion; and minor axis: 
(d) constant perfusion, (e) Arrhenius perfusion and (f) modified Arrhenius perfusion model. 
(a) 
(b) (c) 




3.3.3 Modulated power heating 
Eight probe locations (P1-P8, Figure 3.3), equidistant on the tumor-tissue 
boundary, were chosen to determine the best probe location for temperature feedback to 
modulate power for each of the nanoparticle distributions. The percent of tumor area and 
healthy tissue area with thermal dose of CEM43 ≥ 60 min was computed for the six 
nanoparticle distributions after 20 minutes of power modulated heating (Equation 3.13) 
with temperature feedback from each of the eight probe locations. The results were 
summarized in Table 3-3. For the ideal mathematical distributions M1 and M2, identical 
values were obtained due to symmetry. For each nanoparticle distribution, the probe 
location for which ~90% of tumor area having a thermal dose of CEM43 ≥ 60 min and 
~5% area of healthy tissue having thermal dose of CEM43 ≥ 60 min was chosen. E3 
distribution model had no probe location which satisfied both the criteria simultaneously, 
hence probe location P6 was chosen, which had a tumor thermal dose (CEM43 ≥ 60 min 
in 86.74% of tumor area)  and healthy tissue thermal dose (CEM43 ≥ 60 min in 12.77% of 
healthy tissue area) closest to our criteria. It can be observed that for both the idealized 
symmetric and image-derived asymmetric nanoparticle distributions, the ideal probe 
locations are the farthest from the nanoparticle distribution centers. 
The probe locations for each of the nanoparticle distributions determined above 
were used as temperature feedback locations for the PID controller. The gains for the PID 
controller were calculated by computing the open loop response for an input of 30% 
maximum power (uctrl = 0.3). The gain, g, and the time constants for each of the 
nanoparticle distributions were calculated from the open loop response. The gains Kp, Ki, 
Kd for the PID controller were then calculated (Table 3-4). Of the six nanoparticle 
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distributions, the uniform distribution (M1) has the highest open loop gain (23.8 K) while 
the off center concentrated nanoparticle distribution E3 had the least gain (17.63 K). This 
can be attributed the proximity of the probe (P1) to the nanoparticles in the uniform 
distribution, while for E3 distribution the feedback probe P6 is farther away from the 
nanoparticle distributions. For controlled open loop response, the probes located nearest to 
the nanoparticle distributions generated the highest open loop temperature gain. The 
proportional gain Kp was the highest (14.93 1/K) for off center nanoparticle distribution 
(E3) while the uniform distribution (M1) had the least (7.45 1/K). The integral gain Ki, 
which controls the temperature at the probe location to the reference temperature, was 
similar for all the distributions (0.042-0.047 1/s-K) except for E3 (0.057 1/s-K). The 
differential gain Kd , which allows for ramping up the proportional gain to achieve target 
temperature rapidly, was negligible for the uniform distribution (M1) while the E3 
distribution had the highest gain (145.54 s/K).  
Figure 3.9 shows the variation of power applied with time for each of the 
nanoparticle distributions when the temperature at the probe location (Table 3-3) was 
controlled using a PID controller with gains as in Table 3-4. Comparison of the variation 
in applied power for the six nanoparticle distributions show some significant differences. 
For distributions where nanoparticles were distributed uniformly in the tumor (M1 and E1), 
the applied power increased initially to the maximum and then gradually dampened and 
decreased to a lower value of ~30% maximum power. For distributions with concentrated 
regions of nanoparticles (E1, E3 and M2, M3), the applied power initially increased to 
maximum power available and after the probe temperature reached the target temperature 
of 43.5 °C, the input power oscillated between the maximum and a minimum power level. 
85 
 
The temperature profiles along the major and minor axis for each of the 
nanoparticle distributions after 20 minutes of modulated power heating with PID control 
are shown in Figure 3.10(a). All nanoparticle distributions except E3 attained a minimum 
temperature of 43.5 °C along both the major and minor axis inside the tumor. For E3 
distribution, the area near the tumor-tissue boundary away from the nanoparticles does not 
reach the target temperature. This can be attributed to the effect of offset and concentrated 
nanoparticle distribution away from the control probe. E3 distribution model attained the 
maximum temperature along the major axis (59.2 °C) while M3 (Gaussian) distribution 
achieved the maximum temperature along the minor axis (56.5 °C). Figure 3.10(b) shows 
the degree of survival α, for each of the nanoparticle distributions along the major and 
minor axis after modulated power heating with PID control. Significant damage can be 
observed for areas with or adjacent to nanoparticles inside the tumor (α = 0). Of all the 
models, E3 model has the highest damage in the surrounding healthy tissue (less α) along 
the major and minor axis. 
The thermal dose deposited in the tumor and healthy tissue for the six nanoparticle 
distributions, after 20 minutes of heating with power modulated heating using PID control, 
with modified Arrhenius perfusion model is shown in Figure 3.10(c). With power 
modulation using PID control, all nanoparticle distributions achieve a CEM43 ≥ 60 min in 
at least ~90% of tumor area. This shows that modulating power with temperature feedback 
from a probe on tumor-tissue boundary can deliver clinically relevant thermal doses to the 
tumor. The percent of healthy tissue area with CEM43 ≥ 60 min is less than 5% for all the 
nanoparticle distributions except for E1 (5.7%) and E3 (14.9%). 
86 
 
Comparison of the temperatures achieved inside the tumor subjected to constant power and 
modulated power heating, allows us to effectively assess the efficacy of one method over 
the other. Figure 3.11 and Figure 3.12, show the temperature distributions for each of the 
nanoparticle distribution models after heating using both the methods. It can be seen that 
for all the nanoparticle distribution models, the temperatures achieved by modulated power 
heating are lower than those achieved by constant power heating. The maximum and 
minimum temperatures Tmax, and Tmin, are lower for power modulated heating compared to 
constant power heating. For instance, for E1 model, Tmax, and Tmin, for modulated power 
heating were 53.1 °C, and 43.2 °C, compared to 55.3 °C, and 44.0 °C, for constant power 
heating. Similarly, even for an off centered distribution model E3, the maximum 
temperatures inside the tumor were 16.1% lower for modulated power heating when 
compared to constant power heating for the same model. Additionally, the homogeneity of 
the temperatures, achieved by both heating methods, can be assessed by comparing T10, 
and T90, (temperature achieved by at least 10% and 90% of tumor respectively) and the 
dimensionless heterogeneity coefficient HC defined as HC = (T10 – T90)/(T90 – Tcore) [70]. 
It can be seen that for all the models, T10, and T90, are lower for power modulated heating 
compared to constant power heating. The results for modulated power and constant power 
heating show that HC reduces for power modulated heating for all models except E2. The 
temperature distributions along the major and minor axis of the tumor and healthy tissue, 
obtained after 20 minutes of heating with modulated power and constant power, are shown 





Table 3-3 Percentage area of tumor and healthy tissue with thermal dose CEM43 ≥ 60 min 
after 20 min of heating with power modulation based on temperature feedback from 8 
probe location (P1 – P8, Figure 3.3) (Note: For models M1 & M2, symmetry was taken 
into account for the probe locations). 
Probe location 
Tumor area with CEM43 ≥ 60 min (%) 
E1 E2 E3 M1 M2 M3 
P1 89.29 93.96 95.56 90.82 93.54 92.96 
P2 67.35 90.06 57.89 90.82 93.54 93.08 
P3 85.89 31.01 58.89 53.47 55.54 53.79 
P4 45.63 73.49 50.78 53.47 55.54 53.75 
P5 92.73 68.10 88.07 72.49 79.21 78.51 
P6 47.08 78.72 86.74 72.49 79.21 78.67 
P7 77.44 54.84 37.75 72.49 79.21 78.77 
P8 35.10 84.92 41.60 72.49 79.21 78.67 
Probe location 
Healthy tissue area with CEM43 ≥ 60 min (%) 
E1 E2 E3 M1 M2 M3 
P1 5.10 4.07 20.26 0.54 3.14 3.49 
P2 0.82 3.23 0.84 0.54 3.14 3.57 
P3 4.24 0.00 1.00 0.00 0.00 0.00 
P4 0.00 1.40 0.20 0.00 0.00 0.00 
P5 6.11 0.95 13.34 0.00 0.21 0.35 
P6 0.00 1.87 12.77 0.00 0.21 0.35 
P7 2.54 0.15 0.00 0.00 0.21 0.39 







Table 3-4 Open loop response and PID control parameters for the nanoparticle distributions 
Model uctrl ΔT(K) g(K) τ1(s) τ2(s) f(rad/s) ζ 
Kp 
(1/K) 




E1 0.3 6.41 21.37 3.6 213.7 2 1.0 10.16 0.047 33.47 
E2 0.3 6.81 22.7 3.0 220.5 2 1.0 9.83 0.044 26.68 
E3 0.3 5.29 17.63 10.4 253.1 2 1.0 14.93 0.057 145.54 
M1 0.3 7.14 23.8 0.16 177.34 2 1.0 7.45 0.042 -0.67 
M2 0.3 6.76 22.53 4.3 234.2 2 1.0 10.57 0.044 42.05 
M3 0.3 6.71 22.37 6.6 227.9 2 1.0 10.47 0.045 64.63 
T1 0.3 5.02 21.03 0.03 152.97 2 1.0 7.26 0.048 -1.63 
T2 0.3 5.10 17.0 8.0 222.0 2 1.0 13.52 0.059 101.09 






obtained by modulated power heating in comparison to constant power heating along the 
major and minor axis of the tumor and healthy tissue for all the nanoparticle distribution 
models. Additionally, it can also be seen that more points in the tumor have similar 
temperatures in the case of modulated power heating when compared to constant power 
heating. Thermal dose, measured as CEM43, deposited in the tumor and healthy tissue, 
after 20 minutes of heating with constant power and modulated power is shown in Figure 
3.14(a). Significant thermal dose is deposited at tumor areas with or adjacent nanoparticles 
for both heating methods. Healthy tissue regions near the nanoparticles achieve high 
thermal doses (CEM43 > 60 min) whereas regions distal to the nanoparticles are 
unaffected. Comparison of time evolution of thermal dose deposition in the tumor (Figure 
3.14(b) and (c)), using both heating methods, revealed notable differences. With modulated 
power heating, more than 60% of tumor area achieved a therapeutic thermal dose of 
CEM43 ≥ 60 min in fewer than two minutes, for all the nanoparticle distribution models 
except M1 (uniform) model. Conversely, after two minutes of constant power heating, a 
maximum of ~ 30% (for E3 model) of tumor area achieved thermal dose of CEM43 ≥ 60 
min. Even for the case of M1 (uniform) distribution, with modulated power heating, 
therapeutic thermal dose was achieved in 60% of the tumor in six minutes compared to 
fourteen minutes with constant power heating. Until now, we implemented the modulated 
power heating with temperature feedback from tumor-tissue boundary, for different 
nanoparticle distributions in a 2D model. In order to test whether this heating method would 
compensate for variable nanoparticle distributions in a 3D model, we implemented this 
method for three nanoparticle distributions. Figure 3.15 shows the variation of applied 
power with time for the three 3D nanoparticle distribution models considered. For the T1 
92 
 
(uniform) model, the applied heating power peaks and then reduces to a lower power. In 
the case of T2 (Gaussian-centered) model, the applied power reaches a maximum and 
oscillates with damped amplitude before stabilizing at a lower power. The applied heating 
power oscillates continuously between a maximum and minimum heating power for the 





Figure 3.11 Controlled power heating results in increased temperature homogeneity and lower temperatures when compared to constant 
power heating Temperature distributions achieved in the tumor and healthy tissue after 20 min of heating by constant power and by 







Figure 3.12 Controlled power heating results in increased temperature homogeneity and lower temperatures when compared to constant 
power heating Temperature distributions achieved in the tumor and healthy tissue after 20 min of heating by constant power and by 







Figure 3.13 Power modulated heating using PID controller results in overall lower 
temperatures when compared to constant power heating Temperature distribution along the 
major and minor axis of computational model for (a) ideal mathematical distribution 
models, (b) image derived nanoparticle distributions, after 20 min of heating (i) by constant 
isoeffective power and (ii) by power modulation with PID control based on temperature 








Figure 3.14 Power modulated heating using PID controller leads to faster thermal dose 
deposition when compared to constant power heating (a) Thermal dose, measured as CEM, 
distribution for the six distributions, after 20 min of heating (i) by constant isoeffective 
power and (ii) by power modulation with PID control based on temperature feedback from 
probe at tumor-tissue boundary, with the modified Arrhenius perfusion model. Variation 
of percent of tumor area with thermal dose of CEM43 ≥ 60 min with time, by (b) constant 
isoeffective power heating, and (c) power modulated heating with PID control based on 












Figure 3.15 Variation of power with time for 3D models. Modulation of heating power 
with time using a PID control algorithm to achieve and maintain a target temperature of 
43.5 °C at the probe location for (a) T1 – Uniform distribution, (b) T2 - Gaussian centered; 
(c) T3 – 3pt Gaussian distribution mimicking 3 point nanoparticle injection; (d) percent of 
tumor area with CEM43 ≥ 60 min after 20 min of heating with PID controlled modulated 
power heating for the three 3D nanoparticle distribution models. 
 
Temperature distributions achieved in the tumor and healthy tissue along the XY, 
YZ, and ZX planes at the center of the tumor for the three 3D nanoparticle distribution 
models is shown in Figure 3.16. As expected regions with or adjacent to the nanoparticles 
achieve higher temperatures than distal regions. T2 (Gaussian-centered) distribution 
achieved the highest maximum temperature inside the tumor (91.29 °C) while the T1 
(uniform) model achieved the lowest maximum temperature of 51.6 °C. T2 model 




gradients across the tumor when compared to both the T1 (uniform) and T3 (3-point 
Gaussian) model. 
 
Figure 3.16 PID controlled power modulation achieves therapeutic temperatures inside the 
tumor. Temperature distributions achieved inside the tumor and healthy tissue, (a) XY 
plane, (b) YZ plane, (c) ZX plane, for the three 3D nanoparticle distribution models T1, T2 
and T3, after 20 min of heating by power modulation with PID control based on 
temperature feedback from probe at tumor-tissue boundary with the modified Arrhenius 
perfusion model 
Figure 3.17 shows the damage to healthy tissue, given by degree of stasis DS, for 
the three 3D nanoparticle distribution models, after 20 minutes of power modulated 
heating. It can be seen that the variation of damage in the healthy tissue clearly depends on 
the proximity of the nanoparticles to the tumor-healthy tissue boundary. In the XY plane, 
the region of highest damage (DS = 1) is symmetrically distributed close to the tumor-
healthy tissue boundary for both the T1 and T2 distributions, while it is asymmetrically 




nanoparticle concentrated areas. Similar distributions of damage were seen in the YZ and 
ZX planes. It can also be seen that the T1 (uniform) model displays the least damage 




Figure 3.17 Healthy tissue damage is higher for regions closer to nanoparticle distributions. 
Degree of thermal damage (DS) achieved inside the healthy tissue, (a) XY plane, (b) YZ 
plane, (c) ZX plane, for the three 3D nanoparticle distribution models T1, T2 and T3, after 
20 min of heating by power modulation with PID control based on temperature feedback 
from probe at tumor-tissue boundary with the modified Arrhenius perfusion model 
3.4 Discussion 
Temperature distributions achieved in the tumor and surrounding healthy tissue 




distributions achieved and the diffusion of heat (combining the effect of heat conduction 
and capillary blood perfusion). These determine the thermal dose deposited in the tumor 
and in turn the treatment efficacy. Previous experimental studies [52,53] have shown that 
variable nanoparticle distributions often result even with convection-enhanced delivery of 
nanoparticle suspensions that are directly injected into tumors. Diffusion of heat in the 
tissue is primarily influenced by perfusion. Blood perfusion acts as a heat sink that carries 
away and distributes the heat generated by the nanoparticles throughout the tissue. As the 
amount of heat deposited in the tissue increases, temperature induced damage reduces the 
blood perfusion in the affected region, ultimately decreasing it to zero. Thus, any potential 
strategy for mNPH, should consider the variability of nanoparticle distribution and the 
temperature effects on blood perfusion. At constant power, the nanoparticle distribution 
strongly affects temperature distributions inside the tumor (Figure 3.7). Tumor regions 
having high concentration of nanoparticles exhibit higher temperatures in contrast to 
regions with few or no nanoparticles. Temperatures and temperature gradients decrease 
rapidly in regions farther away from the nanoparticle clusters. The high concentration of 
nanoparticles in the tumor center causes the M2 (Gaussian) model to achieve the highest 
maximum temperature inside the tumor. The M1 (uniform) model attains the lowest local 
maximum tumor temperature because the nanoparticles are distributed throughout the 
tumor and heat generated by isolated nanoparticles rapidly diffuses through the tissue 
yielding much smaller gradients. When temperature-dependent perfusion was considered 
(Figure 3.8), temperatures attained in the tumor and healthy tissue were much higher than 
with the constant perfusion model. Locally high temperatures produced decreased 




increased local temperature, because blood perfusion is the dominant heat diffusing 
mechanism from regions containing nanoparticles. Thus, it is important to consider 
temperature-dependent perfusion when developing treatment strategies to improve 
efficacy.  
Response to hyperthermia was computed by calculating the thermal dose deposited 
in the tumor. A uniform temperature distribution in the tumor is often considered desirable, 
but achieving a minimum effective temperature in 90% of tumor area is more clinically 
realistic, relevant, and is demonstrably effective [9,113]. Previous nanoparticle 
hyperthermia studies focused on temperature distribution alone, however achieving a 
minimum clinically relevant thermal dose (CEM43 ≥ 60 min) in a larger volume of the 
tumor [9,32,43] is considered a better measure of treatment outcome. The isoeffective 
heating power, Qiso, was chosen as the minimum heating power required to achieve a 
thermal dose equivalent of CEM43 ≥ 60 min in at least 90% of tumor area (T90) during a 
simulated 20-min treatment duration. With constant perfusion, significant differences of 
isoeffective heating power were determined for the six nanoparticle distributions (Table 
3-2). The E3 model required the highest isoeffective power of 19.6 × 105 W/m3 and the 
uniform model required the lowest, 10.6 × 105 W/m3. When temperature-dependent 
perfusion was considered, all models required at least 20% less heating power than for 
constant perfusion. This can be attributed to the fact that as perfusion (and the associated 
heat removal) decreases with increasing thermal damage, more of the heat produced by the 
nanoparticles is retained in the tumor, leading to higher thermal dose. Moreover, the 
difference in isoeffective power required was significantly reduced for all distributions 




between M1 & E2) except for the E3 model. Thermal damage, induced by increased heat 
deposition and reduced heat loss due to perfusion, minimized the effect of differences in 
nanoparticle distributions, leading to similar isoeffective heating powers for a variety of 
distributions. Therefore, our results demonstrate that the commonly used constant 
perfusion model underestimates tumor temperatures and overestimates the required heating 
needed to achieve a clinically effective thermal dose. 
While estimating the isoeffective heating power Qiso is computationally feasible, 
determining it experimentally is challenging. Isoeffective heating power Qiso, allows us to 
determine the power required to deposit an ideal thermal dose in the tumor. But it does not 
take into consideration the resulting damage/ thermal dose deposited in the surrounding 
healthy tissue. A better heating method should aim to deposit therapeutic heat in the tumor 
while simultaneously minimizing the damage to the surrounding healthy tissue.  
  Invasive thermometry during hyperthermia treatment is often practiced clinically 
to measure the thermal dose and compare among treatments [34,113,152]. While multiple 
thermal measurements would ensure better estimation of thermal dose, its invasiveness 
often makes possible only single-point temperature measurements during treatment.. A 
treatment strategy which takes advantage of single point thermometry measurements, using 
real time temperature feedback from this sensor, is realistic for clinical applications. 
In the previous chapter, we showed that modulating power using temperature 
feedback from a sensor at the tumor-tissue boundary can ensure a minimal effective 
thermal dose deposition (CEM43 T90), for uniform and concentrated nanoparticle 
distributions, in a spherical model. However, asymmetry in tumor shape and nanoparticle 




tissue boundary. Choosing a probe location too close to the nanoparticles will result in 
under treatment of tumor while choosing it far away can result in increased healthy tissue 
damage. Thus, eight locations equidistant on the tumor-tissue boundary were chosen to 
determine the best probe location for temperature feedback. The criteria for choosing a 
probe location was to ensure that thermal dose of  CEM43 ≥ 60 min was achieved in 90% 
of tumor area and in less than 5% of healthy tissue. Except for E3, all other nanoparticle 
distribution models had probe locations that satisfied the above criteria (Table 3-3). This 
highlights the fact that concentration of nanoparticles closer to the tumor-tissue boundary 
is unwanted and can lead to ineffective treatment and undesirable healthy tissue damage.  
A proportional-integral-derivative (PID) controller is often used in industry and 
medicine to control temperature at a given location. Its robustness and ease of 
implementation has made it the most widely used controller in many industries for sensitive 
control. In the current study, we implemented a PID temperature controller (Figure 3.4) to 
regulate temperature at the probe location on the tumor-tissue boundary determined 
previously for each nanoparticle distribution. To implement the PID controller, we 
computed the open loop gains for each of the nanoparticle distribution models (Table 3-4). 
Of the six nanoparticle distributions, uniform model (M1) had the highest open loop gain 
g (23.8 K) while the E3 model had the least gain (17.63 K). Location of nanoparticles closer 
to the probe would result in higher open loop gains, while the distributions with probes 
away from the nanoparticles would have lower open loop gains. Distributions with higher 
open loop gains required lower proportional gains, with M1(uniform) model having the 




(14.93 1/K). Since the derivative controller allows for higher proportional gains, models 
with higher proportional gain have higher derivative gains (for E3, Kd = 145.54 s/K).  
Significant differences were seen in the variation of power with time for the six 
nanoparticle distributions (Figure 3.9). For distributions M1 and E1, the applied power 
reached a maximum and plateaus out at a lower power for the remainder of the treatment 
duration. This implies that the probe reached the target temperature faster and the controller 
was able to control the probe temperature effectively. For distributions M2, M3 and E2, E3 
the applied power reached a plateau, after which it oscillated between a set of maximum 
and minimum powers. For the three distributions M3, E2, and E3, the peak of this 
oscillations was the maximum power possible Qmax, while for M2 it was around 75% of 
Qmax. For M1 and E1 models, which were characterized by a uniform and diffused 
nanoparticle distribution in the tumor, the probe attained the target temperature relatively 
faster and at lower powers. The tumor models that were characterized by concentrated and 
clustered nanoparticle distributions (M2, M3 and E2, E3) required the controller to operate 
at maximum and minimum power. The distance of the probe location from the nanoparticle 
heat sources for these distributions results in a delay between the control action and the 
temperature output. This required the controller to actively control the temperature output 
which resulted in the observed oscillatory input. Arora et al. [153] reported similar 
oscillating control inputs in their thermal dose control system developed for ultrasound 
treatments. Further tuning of the PID controller can improve its performance and lead to a 
smoother power input.  
By controlling and achieving the target temperature of 43.5 °C at the tumor-healthy 




and minor axes inside the tumor, for all the six nanoparticle distributions except E3 (Figure 
3.10(a)). Similarly, the degree of survival α is the lowest in the tumor region for all the 
nanoparticle distributions (Figure 3.10(b)). However, for E3 model, the location of 
nanoparticles are off set from the tumor center and closer to the tumor-tissue boundary, 
results in low degree of survival α both along the major and minor axes in the surrounding 
healthy tissue. PID controlled power modulation delivers clinically relevant thermal dose 
of CEM43 ≥ 60 min in ~ 90% of tumor area in all the nanoparticle distribution models 
(Figure 3.10(c)), while minimizing the healthy tissue damage (Figure 3.10 (d)). This is true 
for all the nanoparticle distributions except E3. For E3 distribution, increased healthy tissue 
damage occurs (~ 14.9%), clearly showing that off center concentrated nanoparticle 
distribution close to the tumor-tissue boundary is highly undesirable. 
Comparison of the temperatures achieved for each of the distribution models with 
constant power heating and PID controlled modulated power heating highlights the 
advantages of the modulated power heating. Overall, lower temperatures were achieved 
for all the models, with power-modulated heating compared to constant power heating 
(Figure 3.11Figure 3.12). The maximum and minimum temperatures attained in the tumor 
were lower with modulated power heating compared to constant power heating, for all the 
models except E2 (Figure 3.12). E2 model, characterized by concentrated nanoparticle 
distribution along the tumor major axis, has a slight increase in Tmax with modulated power 
heating (Tmax = 57.91 °C) compared to constant power heating (Tmax = 57.52 °C). 
Comparison of heterogeneity coefficient HC [155], obtained from both heating methods 
for all the models, allow us to comment on the homogeneity of the temperature 




distribution models except E2, with modulated power heating compared to constant power 
heating. The improvement in homogeneity is more striking with the E3 model where HC 
decreases from 2.02 (constant power) to 1.76 (modulated power). The time evolution of 
thermal dose deposition in the tumor with modulated power heating significantly differ to 
that with constant power heating (Figure 3.14 (b), (c)). Higher thermal doses were 
deposited faster with modulated power heating compared to constant power heating. For 
the models M2, M3, E1, E2, and E3, at least 60% of the tumor achieved a thermal dose of 
CEM43 ≥ 60 min in ~65 s with modulated power heating. With constant power, the same 
models require ~560 s, to achieve a similar thermal dose. Even for M1 (uniform) model, 
constant power heating took more time (468 s) compared to modulated power (63 s) to 
achieve a CEM43 ≥ 60 min in at least 20% of tumor area. Thus, modulated power heating 
would allow for faster deposition of higher thermal doses, allowing for optimizing and 
reduction of total treatment time. Additionally, pulsing of magnetic field amplitude 
implemented in animal experiments show that pulsed high amplitude AMF are well 
tolerated by mice [49,154]. 
We further implemented the PID controlled modulated power heating in 3D models 
with three distributions – T1 (uniform), T2 (Gaussian-centered), and T3 (3-pt Gaussian) 
distributions. For all the three models, clinically relevant thermal dose of CEM43 ≥ 60 min 
was deposited in more than 90% of tumor area, after 20 minutes of heating with modulated 
power heating (Figure 3.15(d)). The variation of applied power with time for T1 (uniform) 
distribution (Figure 3.15 (a)) followed a similar trend to that observed for the 
corresponding 2D model (Figure 3.9). For T2 (Gaussian-centered) model, the applied 




plateauing to a constant value (Figure 3.15 (b)). This is in contrast to the trend that we 
observed for the corresponding 2D model (M3, Figure 3.9). In the 2D model, it is assumed 
that there is no heat transfer occurring in the third dimension and all the heat generated is 
diffused in the remaining two dimensions. But in the case of 3D model, heat transfer occurs 
in all the three dimensions resulting in the different applied power profile. This difference 
is not apparent in the 3D model of uniform distribution since the heat sources are 
distributed everywhere in the tumor replicating the assumption in 2D model. For T3 (3-pt 
Gaussian) model, the applied power reaches a maximum power and oscillates between a 
maximum and minimum power condition. Temperatures achieved in the tumor and healthy 
tissue were dependent on the nanoparticle distributions, with regions adjacent or with 
nanoparticles exhibiting higher temperatures compared to regions away from the 
nanoparticles (Figure 3.16). The degree of healthy tissue damage (DS) for the three 3D 
nanoparticle distribution models after 20 min of modulated power heating (Figure 3.17), 
shows that healthy tissue regions proximal to the nanoparticle concentrations incur more 
damage compared to regions away from them. Of the three models, T1 (uniform) model 
has the least healthy tissue damage and T3 (3pt-Gaussian) has the highest healthy tissue 
damage (~ 2x that of uniform model). The above results show that PID controlled 
modulated power heating enables us to deliver a therapeutic thermal dose into the tumor 
with overall lower temperatures and better temperature homogeneity, compared to constant 
power heating, for various nanoparticle distributions. 
One of the limitations of our current computational study is that the effect of onset 
of eddy current heating in the healthy tissue when exposed to high amplitude alternating 




to the square of the product of applied magnetic field amplitude (H), frequency (f) and 
diameter (D) of the induced current loop. For large volumes of tissue (a patient torso of ~ 
30 cm diameter), the product of frequency and amplitude limits for applied magnetic field 
should be H.f ≤ 4.85 × 108 A/(m-s) [156,157]. This onset of eddy current heating at high 
amplitudes could lead to unwanted heating of healthy tissue leading to possible thermal 
damage. This could also potentially lead to increased blood flow in the healthy tissue due 
to marginal increase in temperature as the body activates its thermoregulation. This could 
result in increased thermal gradients at the tumor-healthy tissue boundary, cooling of the 
tumor and increased heat flux at the tumor tissue boundary. Including the eddy current 
heating could further improve the above proposed PID controlled power modulation with 
temperature feedback at tumor-tissue boundary making it translatable to the clinic. Another 
limitation of the current study is that effect of temperature on the thermal properties of the 
tissue such as thermal conductivity, specific heat capacity has not been considered. Change 
in thermal properties due to thermal damage can affect the heat transfer in the tumor and 
tissue which can then influence the temperature distributions achieved. As next steps, 
experimental investigation should be performed to validate the model.  
3.5 Conclusions 
In this study, we proposed a new heating method of modulating the heating power 
of nanoparticles based on temperature feedback from the tumor-healthy tissue boundary. 
We hypothesized that attaining a target temperature of 43.5 °C at a specific location on the 
tumor-tissue boundary allows us to achieve effective treatment of tumor with minimal 
healthy tissue damage and can compensate for variable nanoparticle distributions. First, we 




obtained from animal models and three idealized mathematical models. We considered 
three perfusion models available in literature to demonstrate the importance of considering 
the temperature effects on perfusion and the resulting temperature distributions. We then 
implemented a PID controller to control the power output of nanoparticles based on 
temperature feedback. The thermal dose deposited into the tumor and healthy tissue was 
computed to assess the effectiveness of this method. Modulated power heating allowed for 
effective tumor treatment with overall lower temperatures compared to constant power 
heating. We then showed that our proposed modulated power heating method successfully 
deposits clinically significant thermal dose in three 3D nanoparticle distribution models. 
The presented method is clinically significant as it addresses one of the principal challenges 
of mNPH of variable intra-tumor nanoparticle distributions. Experimental and clinical 
investigations are further needed to validate the above method. Also, the effect of non-
specific heating due to eddy currents should be considered as this can lead to unwanted 
healthy tissue heating at higher applied fields. Overall, our method shows that with single-
point thermometry and power modulation, effective tumor treatment is consistently 







Chapter 4  
Temperature-control power 
modulated hyperthermia in mouse 
models of liver cancer 
 
In this chapter, we report the results of a pilot study where we implemented the 
temperature control power modulated magnetic nanoparticle hyperthermia in mice with 
subcutaneous xenograft liver cancer tumors. Two nanoparticle distributions were generated 
by employing two injection methods – 2-pt and 3-pt injection using a syringe pump. 




modulated to attain and maintain a target maximum temperature at the tumor-healthy tissue 
interface of 43.5 °C. The outcome of the treatment for 2-pt and 3-pt injected mice was 
determined. Additionally, 2-pt and 3-pt injected tumors were harvested, fixed, sectioned, 
and stained with Perl’s reagent to characterize the nanoparticle distribution inside the 
tumors. 3D computational models were built and analyzed to correlate and understand the 
findings from the animal experiments.  
4.1 Introduction 
Pre-clinical animal studies are used to test new treatment strategies and can provide 
useful information for further refinement and improvement before testing them in humans. 
Mice share many physiological and pathological features with humans [158] and have been 
used for pre-clinical  testing for more than 100 years. Extensive analysis of mice and human 
genomes have led to genomic manipulations in the mouse to generate models of human 
pathologies  [159] such as heart disease, different cancers, hypertension, diabetes, obesity, 
glaucoma, blindness, anxiety, depression etc. Mice are relatively inexpensive, easy to 
maintain and can be bred in captivity. This makes mice an ideal model for preclinical 
studies with more than 25 million mice used in research laboratories every year [158].  
Multiple optimization studies [112,115,136–141]  have been proposed for improving the 
efficacy of magnetic nanoparticle hyperthermia, by delivering a therapeutic dose in the 
tumor and minimizing healthy tissue damage. While some of the models were based on 
realistic organ geometries developed from CT images [139], none of the above were tested 
or implemented in either pre-clinical animal models or clinical studies. As discussed 
previously, computational models are usually based on simplified geometry and physics 




tissue response. While computational models are an excellent tool for gaining a better 
understanding of the physiological processes and developing new strategies, the developed 
strategies should be tested in animal models, in order to understand the complexities of 
implementing the assumptions in the model, to gather feedback for further improving the 
method and to validate it.  
In the recent years, LeBrun et al. [160] and Pearce et al. [105] compare their 
numerical simulation models with in vivo mouse studies. LeBrun et al. [160] validated the 
treatment efficacy of their MicroCT-based theoretical simulation approach in prostate 
cancer PC3 xenografts. Their theoretical approach [161] was based on using MicroCT 
images to generate volumetric heat generation rate distributions and control the treatment 
time either for partial or complete ablation. The experimental end points in their animal 
study were tumor growth delay and histology. Results showed complete ablation 
confirming their simulations. However, they did not measure/report any temperature data 
and they assume repeatable nanoparticle distributions for every tumor based on their 
previous experiments [69]. Pearce et al. [105] coupled their numerical models to 
experimental measurements to study the effectiveness of current thermal damage 
prediction models [29]. However, they did not present or test any optimization methods for 
effective tumor treatment or minimal healthy tissue damage.  
The goal of this study was to implement and evaluate a temperature control 
modulated power heating protocol similar to the one described in chapter 3 in mouse tumor 
models. We sought to test this protocol for two nanoparticle distributions generated using 
two injection methods – 2-pt and 3-pt injections. Applied power was manually modulated 




controller presented in chapter 3. Temperatures were measured at multiple locations and 
temperature at the tumor-healthy tissue interface was controlled. Thermal dose and total 
applied power were calculated and compared. 3D nanoparticle distributions were generated 
from slides stained with Prussian blue to compare the distributions obtained from 2-pt and 
3-pt distributions. Ablation of tumors after treatment prevented us from evaluating the 
therapeutic efficacy of the heating protocol using tumor growth delay studies. We 
successfully showed that the temperature at the tumor-healthy tissue boundary can be 
controlled for both the distributions. Simulations were then carried out to compare and 
understand the results from experiments. Overall, the challenges for in vivo implementation 
of our modulated power heating protocol have been identified and future steps for further 
testing of this protocol have been presented. 
 
4.2 Material and Methods 
4.2.1 Experimental design 
The goal of this pilot study was to evaluate whether temperature-controlled power 
modulated magnetic nanoparticle hyperthermia can compensate for variable nanoparticle 
distribution in animal tumor models. To do so, we generated two nanoparticle distributions 
in subcutaneous tumors using two injection methods – 2-pt and 3-pt injections. The 
experiment consisted of culturing HepG2 liver cells under recommended conditions and 
injecting them into male nude mice for growing subcutaneous xenograft tumors. Once the 
tumors reached the target volume, mice were divided into two groups based on injection 




AMF treatment cohort, and nanoparticle distribution cohort. The number of mice in each 
group and cohorts are shown in Table 4-1. For animals in the modulated AMF treatment 
cohort, temperature probes were inserted at four locations in the tumor- intra-tumor, tumor 
surface, and on either side of tumor-healthy tissue interface after injection. Mice were then 
treated with temperature control power modulated magnetic nanoparticle hyperthermia for 
20 min. The power was modulated so as to rapidly achieve and maintain a target 
temperature of 43.5 °C at the tumor-healthy tissue interface. After treatment, the outcome 
of the experiment was coded – no ablation (0), partial ablation (1) and ablation (2). The 
temperature and applied power data were analyzed to calculate the thermal dose deposited 
and total energy applied. The schematic for the experimental design of modulated power 
nanoparticle hyperthermia is shown in Figure 4.1. 
For animals in the nanoparticle distribution cohort, tumors were harvested and fixed 
in formalin immediately after injection. They were paraffin embedded and ten slices were 
obtained at 0.2 mm distance apart and stained with Perl’s reagent to obtain the nanoparticle 
distribution. The stained slides were then scanned and digitally stored. The images were 
processed in ImageJ and MATLAB to obtain the 3D nanoparticle distribution. 
4.2.2 Magnetic iron oxide nanoparticles 
Two batches of commercially available Bionised nanoferrite (BNF) magnetic iron 
oxide nanoparticles obtained from micromod Partikeltechnologie (Rostock, Germany) 
were used in this study. BNF nanoparticles are a mixture of magnetite (Fe3O4) with 
maghemite (γ-Fe2O3) and their magnetic, heating and imaging properties have been 
extensively characterized [55–57]. The iron concentration of the received BNF 




that uses a chromogenic compound ferene-s for quantification of iron in samples containing 
iron oxide nanoparticles [162]. It consists of digesting a known volume of iron oxide 
nanoparticle in acid and compared with iron standards. The color of the sample depends 
on the amount of iron present in the samples. The absorbance for both the nanoparticle 
sample and iron standards are measured using a spectrometer and then compared to 
determine the iron quantity in the nanoparticle sample. The iron concentration for the two 
batches of BNF nanoparticles used in this study is shown in Table 4-4. 
 
Table 4-1 Treatment groups and cohorts considered in this study with the number of mice 
in each cohort 
 2-pt 3-pt 
Treatment 6 6 
NP distribution 3 3 
 
Nanoparticle distribution within a tumor after direct intratumor injection is 
determined by tumor physiological and mechanical properties such as interstitial pressure, 
tissue density, stromal content, and vascularity, and injection parameters such as injection 
rate, volume, and solution viscosity. Using a low injection volume and injection rate allows 
for a controlled and concentrated nanoparticle distribution in the tumors [132]. High 
concentration of nanoparticles would allow lower injection volumes thereby reducing the 
injection times. Hence, the stock BNF nanoparticle samples were further concentrated by 
magnetic-assisted settling using a strong rare earth permanent magnet for 24 hrs. The 
nanoparticle rich fraction was collected by removing the supernatant. The iron content of 
these concentrated nanoparticles was determined again by ferene-s assay [162] and are 




The specific loss power (SLP) of these nanoparticles was determined by methods 
described in chapter 6. Briefly, 1 mL volume samples of the nanoparticles with 5 mg Fe/mL 
concentration were prepared in Type I 51 glass tubes (LaMotte, Chestertown, MD) and 
weighed before they were inserted into a cylindrical Styrofoam holder. The holder was 
then inserted into four-turn modified vertical solenoid coil which generates a magnetic field 
(± 10% peak amplitude) at fixed frequency of 155 ± 10 kHz. Magnetic field amplitude of 
8 – 44 kA/m (peak) were applied for a duration of 100 s and the temperature rise in the 
nanoparticle samples was measured using a fiber optic temperature probe. The SLP was 
then estimated from the heating rate data that satisfy the (quasi)-adiabatic criteria [60].   
 
4.2.3 Animal tumor models 
Human hepatocellular carcinoma cells (HepG2) were used in this study. HepG2 
cells were purchased from ATCC® (VA, USA) and cultured under sterile conditions. Cells 
were cultured in Minimum Essential Medium (MEM, Sigma Aldrich) with L-glutamine, 
Earle’s salts and sodium bicarbonate, containing 10% fetal bovine serum (FBS), at 37 °C 
and 5% CO2. Cells were grown in T-175 cm2 flasks and were harvested when 80 - 90% 
confluence was reached. Harvesting of cells included trypsinizing followed by 5 minutes 
of incubation. The cells were then resuspended in the media and were spun down for 5 min 
at 1000 rpm. The supernatant was removed and cells resuspended in PBS for counting. 
After counting, cells were again spun down for 5 min at 1000 rpm and were resuspended 
in PBS to yield a concentration of 30 million cells per mL. They were then transported to 




Eighteen male nude mice (Athymic Nude – Foxn1nu, Charles River Labs, 
Germantown, MD) aged 4-6 weeks (weight 20 – 30 g) were used in this study. All animals 
were housed in an Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) accredited facility in compliance with the guide for care and use of 
laboratory animals. All animals received food and water ad libitum. They were housed in 
temperature and humidity controlled rooms with 12/12 light/dark cycles. All the animals 
were monitored on a daily basis to ensure their health and any distress associated with 
treatment. The animals were euthanized immediately when they showed any signs of 
distress that prohibited them from eating, drinking, or moving. The Johns Hopkins 
Institutional Animal Care and Use Committee approved all procedures. 3 × 106 HepG2 
cells suspended in 0.1mL of PBS were injected into the right flank of the mouse. Animals 
were monitored on a regular basis for overall health and tumor growth. Once the tumors 
became palpable (usually in 2-3 weeks), tumor volumes were measured regularly (once 
every 2-3 days) using a calipers. Tumor volumes were calculated by measuring tumor 
dimensions in three orthogonal directions and were calculated using the formula [163], 
 𝑉𝑜𝑙𝑢𝑚𝑒 =  
𝜋
6
 𝑎 𝑏 𝑐 (4.1) 
Here a, b, and c, are the caliper measurements of tumor in orthogonal directions. 
Once the tumor reached 0.3 cm3 ± 0.05 cm3, the mice were injected with nanoparticles and 





4.2.4 Nanoparticle injections 
Mice were anaesthetized with ketamine-xylazine, with a dose 0.01 mL per gram of 
mouse weight, for nanoparticle injections. BNF nanoparticles were injected using a syringe 
pump (Harvard Apparatus, South Natick, MA) with a Hamilton syringe and 26 gauge 
needles. The total iron dose was fixed at 8mg of Fe per gram of tumor for each of the 
injection methods. A slow injection rate of 5 µL/min was chosen [132]. Slow injection 
rates and lower injection volumes (achieved by using concentrated BNF nanoparticles) and 
use of syringe pump for injections allow for controlled and repeatable injection of 
nanoparticles with minimal leakage of nanoparticles [132]. Two injection methods were 
used to generate different nanoparticle distributions. Three point injection method (3-pt) 
consisted of injecting the nanoparticles into three sites in the tumor, which are in a 
triangular formation, with equal volume (1/3rd of total injection volume) in each injection 
site (Figure 4.1). Two point injections (2-pt) consisted of injecting the nanoparticles into 
two injection sites, located in diagonally opposite directions in the tumor, with equal 
volume (1/2 of total injection volume). After the nanoparticle injection, mice were 
immediately treated with alternating magnetic field (AMF) using the horizontal mouse coil 
configuration and water jacket described below.  
4.2.5 Alternating magnetic field system and water jacket 
The AMF system and the water jacket used for nanoparticle heating system has 
been previously described [52,164,165]. The AMF equipment mainly consists of three 
components: power supply, an external matching capacitance network, and a horizontal 




which provides an alternating current to a resonant circuit with variable frequencies (135-
445 kHz). The external capacitance network was adjusted for stable oscillations at 155 ± 
10 kHz. The horizontal modified solenoid coil has a diameter of 10 cm and generates a 
uniform (±10 % of peak amplitude) magnetic field. The power supply, capacitance network 
and the coil are all cooled using a closed-loop circulating water system connected to a 200-
L reservoir of distilled water.  
A concentric polyacrylic water jacket filled with distilled water was placed inside 
the horizontal coil [164]. The water jacket was connected to a closed-loop bench-top 
circulating bath (Hoefer Scientific Instruments, San Francisco, CA) capable of circulating 
water at 4L/min. The water jacket provides thermal regulation of anaesthetized mice which 
lose thermoregulatory control and become hypothermic. It also allows for minimizing the 
thermal interaction between the mouse and the coil, which can either be a heat source or 
heat sink depending on the power setting used [52,164,165]. 
4.2.6 Thermometry 
Mouse and water jacket temperatures were measured with RF-resistant fiber-optic 
temperature probes (FISO, Quebec, Canada). All probes were calibrated using a NIST 
certified standard thermometer before use. Temperatures were recorded at 0.45 s intervals, 
and for at least 30s after the rectal temperature reached at least 35 °C, before AMF field 
was switched on. For each mouse, five temperature probes were used, inserted in the 
rectum, inside the tumor, on the tumor surface, and two (one on each side) at the tumor-
healthy tissue interface (Figure 4.1). Another probe was used to measure the water jacket 
temperature before and during the experiment. Temperatures measured at the tumor-




a target temperature of 43.5 ± 0.5 °C, at the tumor-healthy tissue interface rapidly and 
control it for the remainder of the treatment duration. The maximum temperature achieved 
between the two tumor-healthy tissue interface probes was used to control the AMF power 
applied in the experiment. This results in minimizing the temperatures achieved in the 
healthy tissue and thereby the thermal damage. 
4.2.7 Modulated power thermal therapy  
The aim of the current study was to evaluate the temperature controlled power 
modulated AMF heating for two nanoparticle distributions in mice. The applied power was 
modulated based on temperatures measured at the tumor-healthy tissue interface. For each 
cohort, 3-pt, and 2-pt, six mice were considered (Table 4-1). Mice were randomly assigned 
into the two experimental cohorts. Total AMF exposure was 20 min. Heating for all the 
mice was started by applying a magnetic field amplitude of 44 kA/m (peak) and monitoring 
the temperatures at the two locations on the tumor-healthy tissue interface. AMF amplitude 
was then manually modulated to achieve a target temperature of 43.5 ± 0.5 °C at the tumor-
healthy tissue interface. The water jacket temperature was dynamically adjusted to ensure 
the rectal temperature was always below 41 °C. Applied AMF field amplitudes were noted 
with time to calculate the total energy applied for each mouse, based on the total iron 
injected and the measured SLP of the nanoparticles. After treatment, mice were euthanized 
after 48-72 hours based on the treatment outcome. Treatment outcome was arbitrarily 
coded based on degree of ablation observed, 0 (no ablation), 1 (partial ablation, <50% of 





4.2.8 Total energy applied and thermal dosimetry 
The total energy deposited in the tumor can be calculated by using the mass of iron 
injected into the tumor (mFe), the applied field (H), duration applied (Δt) and SLP of the 
nanoparticles. The total applied energy is given by, 




The temperature measured at the tumor-healthy tissue interface was normalized to 
convert time-temperature curve to an equivalent time at 43 °C (CEM43) to calculate the 
thermal dose [25]. The thermal dose is given by the expression, 𝐶𝐸𝑀43 =  ∫ 𝑅43−𝑇(𝜏)𝑑𝜏𝑡
0
, 
where R = 0.5 for T > 43 °C and R = 0.25 for T < 43 °C.  
4.2.9 Intratumor nanoparticle characterization – Prussian blue staining 
Mice selected for intratumor nanoparticle distribution were euthanized immediately 
after nanoparticle injection and the tumors were harvested. Tumors were fixed in 10 % 
formalin for 48-hrs for histopathology. To accurately assess the nanoparticle distribution 
in the tumors with 2-pt and 3-pt injections, ten sections of each tumor were taken and 
stained by the following method. Formalin fixed tumors were paraffin embedded and ten 
slices of 0.5 micron thickness each were taken at 0.2 mm distance separation beginning 
with the top. All these sections were stained with Perl’s reagent (Prussian blue) [52,166] 
to qualitatively assess distribution of BNF nanoparticles (positive stain for ferric, Fe3+). 
The stained slides were scanned at 40x magnification using Aperio ScanscopeTM slide 




MATLAB to obtain the distribution of nanoparticles in the tumors. Briefly, the scanned 
images were first imported into ImageJ as low resolution images using the Bioformats 
plugin. They were then converted into RGB format and the stained blue pixels were then 
segmented by color thresholding. The segmented image was then converted into a binary 
image with dark pixels showing the nanoparticle distribution. This binary image was 
exported as a text image and read into MATLAB as a matrix. The matrices obtained from 
the ten slices of each tumor were then reconstructed into a 3D distribution in MATLAB 
(Figure 4.3).  
4.2.10 Computational model 
Simulations were conducted to compare with the in vivo experiments. Three 
dimensional FEM computational models were constructed and implemented in COMSOL 
5.2a (COMSOL Inc., Burlington, MA). Tumors were modeled as ellipsoids with the 
dimensions similar to the measured animal tumor dimensions (volume ~ 0.3 cm3 ± 0.05 
cm3). The healthy tissue computational domain was modeled as a cuboid of dimensions 2.5 
cm (x-direction), 3.5 cm (y-direction), and 1.5 cm (z-direction). The healthy tissue domain 
was further divided into two layers: skin layer (0.75 mm thickness) and muscle layer 
(Figure 4.4). The tumor was centered in the top layer of the healthy domain with a skin 
layer to mimic the in vivo mouse experiments. 
Heat transfer in the tumor and healthy tissue was modeled using the Pennes’ bioheat 









here n and b represent tissue (tumor, n = 1; muscle tissue, n = 2; skin tissue, n = 3) and 
blood; respectively. The density, specific heat capacity, thermal conductivity, local 
temperature, and metabolic heat generation rate are denoted by ρn, cn, kn, Tn, Qm,n and t is 
the treatment time. The thermophysical properties considered in the study were shown in 
Table 4-2.  
Constant core body temperature of 37 °C was assumed at the bottom surface. All 
the four sides were assumed to be thermally insulating and the adiabatic boundary 
condition was considered. Continuity of temperature and conservation of heat flux 
conditions were considered at the different tissue interfaces. For the skin surface, both on 
the tumor and muscle, convective boundary condition with free convection heat transfer 




|𝑠𝑘𝑖𝑛𝑠𝑢𝑟𝑓𝑎𝑐𝑒 = ℎ (𝑇 − 𝑇𝑤𝑗(𝑡))  (4.4) 
Twj is the water jacket temperature and z is the normal to the skin surface. The initial 
temperature was considered to be 35 °C to match with the experiments. The variation of 







distributions at the injection point were considered to be a Gaussian distribution [112]. The 
Gaussian distributions were generated similar to those described in section 3.2.1. The 
heating protocol used in simulations mimicked experimental conditions used in AMF 
treatment of mice. The corresponding water jacket temperatures for each of the heating 
protocol were also taken. For blood perfusion, modified Arrhenius model (as described 
previously in section 3.2.2) was considered. The initial perfusion values for each of the 
three tissues was shown in Table 4-2. The activation energy Ea, and the frequency factor 
A, required for computing the thermal damage to vasculature for each of the tissues was 
shown in Table 4-3.  
Table 4-2 Thermophysical properties of tissues considered in this study 
 Density, ρ (kg/m3) 
Specific 
heat, 
c (J/kg K) 
Thermal 
conductivity, 










Tumor 900 [105] 3700 [105] 0.4 [105] 0.018 [167] 1500 [168] 
Muscle 1050 [105] 
3700 
[105] 0.5 [105] 
0.00175 
[105] 1000 [105] 
Skin 700 [105] 3700 [105] 0.3 [105] 
0.00088 
[105] 250 [105] 
Blood* 1060 [125] 
3770 
[125] N/A N/A N/A 
*Temperature of blood (Tb) was fixed at 37ºC [125]. (N/A – not applicable) 
 
Table 4-3 Values of activation energy Ea and frequency factor A considered in this study 
 Activation Energy, Ea (J/mol) 
Frequency factor 
A (1/s) 
Tumor 5.064 × 105 [141,148] 2.984 × 1080  [141,148] 
Muscle 1.38 × 105   [169] 6.36 × 1019   [169] 




COMSOL Multiphysics 5.2a was used to solve for the temperature distributions. 
Grid sensitivity and time step sensitivity studies were carried out to ensure that the chosen 
grid size and time step size had negligible effect on the computed temperatures.  
4.3 Results 
4.3.1 Characterization of BNF nanoparticles 
For the two batches of BNF nanoparticles used in the animal experiments, iron 
concentrations of the stock and concentrated versions were determined by the ferene-s 
assay and summarized in Table 4-4. The high concentration of nanoparticles allow us to 
minimize the injection volume which in turn minimizes the injection time. The SLP of both 
batches of nanoparticles was measured for magnetic fields of 8 – 44 kA/m (peak) at fixed 
frequency of 155±10 kHz and shown in Figure 4.5. Both batches exhibited a similar S-
shaped heating curve with change in amplitude which is characteristic of BNF 
nanoparticles [56,57]. Also, this non-linear variation of SLP with amplitude allows us to 
generate more heat by minimal change in the applied field amplitude.  
 
Table 4-4 Measured concentration of nanoparticles used in the study 
Batch 
Iron concentration,  Stock 
solution (mg Fe/mL) 
Iron concentration, Concentrated 













Figure 4.5 Specific loss power of two batches of nanoparticle BNF-0651710 and BNF-
1231710 used in this study. The box represents the inter-quartile range of the measured 
SLPs at that field and the whiskers show the range of the estimated SLPs which are outside 





4.3.2 Modulated power AMF thermal therapy 
For mice subjected to modulated power AMF therapy, a summary of tumor 
volumes, quantity of iron injected, total energy deposited for unit tumor volume, thermal 
dose measured at the tumor-tissue interface and the outcome of the therapy (0 – no ablation, 
1 – partial ablation, 2 – ablation) are provided in Table 4-4. Power modulated AMF 
treatments were well tolerated by all mice. Tumor volumes of 2-pt injected mice were 
0.281 ± 0.029 cm3, while for 3-pt injected mice were 0.292 ± 0.026 cm3 (mean ± SD). 
Statistical analysis using Mann-Whitney non-parametric tests showed there is no difference 
(p-value = 0.5887 > 0.05) between the tumor volumes considered for 2-pt and 3-pt 
injection. After injection, five temperature probes were inserted, four inside the tumor and 
one in the rectum. AMF treatment was well tolerated by mice with rectal temperatures for 
all the mice were controlled and maintained well below 41 °C. Temperatures were 
measured at the tumor – healthy tissue interface using two probes on either side of the 
tumor (right and left). The aim of the experiment was to attain and maintain the maximum 
temperature measured at the interface (either left or right) to 43.5 ± 0.5 °C. Representative 
temperatures measured during the experiment for mice injected with 2-pt and 3-pt 
nanoparticle injections is shown in Figure 4.6. All the mice were initially exposed to a field 
of 44 kA/m (peak) and this applied field was later modulated based on the maximum 
temperature measured at the tumor-healthy tissue interface. It can be seen that temperature 
at the interface can be controlled robustly for both the nanoparticle distribution models by 
modulating the AMF amplitude appropriately. The temperatures initially increased steeply 




attain the target temperature as fast as possible so as to generate a higher thermal dose in 
the tumor in less treatment time.  
Figure 4.7 shows the applied power-time curve for each of the mice in the 
modulated power hyperthermia groups. While the initial applied field (44 kA/m, peak) is 
same for all the mice, the applied power differs slightly because of the slight difference in 
tumor volumes which in turn resulted in different iron content in the tumors. As mentioned 
previously, nanoparticles were injected based on tumor volume to yield a fixed 
concentration of 8 mg/mL. Thus, the injected iron content was different for different mice 
resulting in different initial heat input. The median duration of high field (44 kA/m) was 
higher for 2-pt nanoparticle injected mice (91 s) compared to 3-pt nanoparticle injected 
mice (70 s). The measured thermal dose at the tumor-tissue interface for each of the mice 
with 2-pt and 3-pt injection is plotted in Figure 4.8(a). The median thermal doses measured 
for mice with 2-pt injection was 28.45 min (CEM43) compared to 32.14 min (CEM43) for 
mice with 3-pt injection. However, statistical analysis using the Mann-Whitney test showed 
no statistically significant difference between the thermal doses deposited at the tumor-
healthy tissue boundary for the two groups of mice (p-value 0.1320 > 0.05). The total input 
heat energy normalized to tumor volume (J/cc of tumor) deposited in the tumors with 2-pt 
and 3-pt injection was computed and compared in Figure 4.8(b). It can be seen that 2-pt 
injected tumors required higher median heat energy (1267 J/cc) compared to 3-pt injected 
tumors (1102 J/cc). But it can be observed that there is a significant overlap in the 
interquartile ranges of the total energy plots for 2-pt and 3-pt injected tumors. This shows 




Table 4-5 Summary of the tumor data, measured thermal dose and outcome for mice exposed to modulated power AMF. Codes for 













M1 0.259 2.07 1295 30.04 2 (A) 
M2 0.279 2.23 1436 23.64 2 (A) 
M3 0.332 2.66 946 30.77 2 (A) 
M4 0.252 2.02 948 26.22 1 (PA) 
M5 0.290 2.32 1238 29.30 1 (PA) 
M6 0.271 2.17 2227 27.60 1 (PA) 
3-PT 
M7 0.322 2.58 1599 35.32 0 (NA) 
M8 0.256 2.05 1042 30.28 1 (PA) 
M9 0.268 2.14 1130 35.07 2 (A) 
M10 0.317 2.53 1074 29.11 1 (PA) 
M11 0.289 2.31 657 33.99 0 (NA) 







and 3-pt injected tumors, overall the difference is not significant. This was further 
confirmed by conducting non-parametric Mann-Whitney test which yielded a p-value of 
0.4848 (> 0.05). 
Nanoparticle distributions in tumors for mice injected with 2-pt (n = 3) and 3-pt (n 
= 3) injections were assessed by Prussian blue staining. Representative sample slides for 
each of the six tumors along with reconstructed distributions is shown in Figure 4.9. 
Analysis of the Prussian blue slides for the six tumors show particles in the external plasma 
membrane and extracellular space. This is consistent with previous observations by 
Giustini et al. [48] where they observed more than 95% of the nanoparticles in the 
extracellular space within the first hour post-injection. It can also be observed that more 
nanoparticles are present in the injection path. 3D distributions generated from the stained 
individual slices show a clear difference in nanoparticle distributions. For mice injected 
with nanoparticles using the 2-pt injection method, two concentrated regions of 
nanoparticles can be seen in the generated distributions showing possibly the injection 
locations. A similar observation can be made for two of the mice injected with 
nanoparticles using the 3-pt injection method. For the third case, Prussian blue images 
show all particles clustered in a single extracellular space thereby clearly not showing the 
three sites of injection. It can be inferred from the 3D projections that the distributions 
achieved with 2-pt and 3-pt injections are different and no two tumors have the same 
nanoparticle distribution. This also highlights the fact that controlling the nanoparticle 
distribution by controlling the injection methods alone is insufficient and depends heavily  




The outcome of temperature-control modulated power hyperthermia on all the mice 
with two different distributions was summarized in Table 4-5. The outcomes were 
categorized using the following codes – 0 (no ablation), 1 (partial ablation, <50% of tumor 
volume ablated) and 2 (ablation, more than 50% of tumor volume ablated). Maximum 
ablation was observed for 2-pt injected tumors (code-2, n = 3) compared to 3-pt injected 
tumors (code-2, n =1). All 2-pt injected tumors were either ablated or partially ablated. For 
the 3-pt injected tumors, only one of the tumors was ablated and two were partially ablated. 
Simulations were carried out to further understand the results obtained through 
experiments. For this, two nanoparticle distributions mimicking the 2-pt and 3-pt injections 
were considered. The heating power of the nanoparticles was varied based on the applied 
power measurements from mouse experiments. Temperature distributions achieved for 2-
pt and 3-pt distributions at the center of the tumor across the XY, YZ, and ZX planes was 
plotted in figure 4.10. The green contour line plotted is the 43.5 °C isotherm in each of the 
plots. As expected, higher temperatures were observed at the nanoparticle concentrated 
regions compared to regions away from nanoparticles. Ablative temperatures of greater of 
45 °C can be observed for the skin layer above the tumor with temperatures going higher 
than 50 °C in some areas. On the other hand, temperatures at the tumor-healthy tissue layer 
were lower than those compared to the skin layer above the tumor. Thermal damage given 
by Ω,   






is plotted for the tumor, muscle and skin layer at the center along the YZ plane. Ω > 1 is 
generally associated with irreversible thermal damage and burn injury for skin [169]. In 




pt distribution model, extensive damage occurs in the skin layer above the tumor while for 
the 3-pt model no damage is seen. This is consistent with our experimental observations. 
Variation of temperature with time at one location below the tumor-healthy tissue 
boundary is plotted for the two nanoparticle distribution models to compare with 
experiments and is shown in Figure 4.12. It can be seen that initially the temperature rises 
steeply reaching a maximum and then reduces and settles down and oscillates close to 43.5 
°C. This trend is similar to the trend observed in experiments (Figure 4.6). For the 2-pt 
distribution, the temperature reached a maximum of 48.31 °C and then settled down to 43.5 
± 0.5 °C, while for the 3-pt distribution model the temperature rise is not so steep and has 












The potential of magnetic nanoparticle hyperthermia to achieve targeted, tumor-
specific heating while minimizing damage to surrounding healthy tissues has been shown 
in multiple preclinical and clinical studies [39,41,42,45,46,49,50,52,133,170]. However, 
challenges remain for magnetic nanoparticle hyperthermia to become a clinical modality. 
The main challenges have been, 1) the ability to generate sufficient therapeutic heating at 
lower magnetic field amplitudes and frequencies to minimize non-specific eddy current 
heating; 2) to deliver sufficient quantity of nanoparticles into the tumor to achieve 
sufficient thermal damage, and 3) to achieve a nanoparticle distribution which can lead to 
desirable temperature elevations across the entire tumor volume. Considerable efforts have 
been made to develop optimization methods to address these challenges [112,115,136–
141]. However, none of these models/methods have been tested in preclinical or clinical 
models.  
The aim of this pilot study was to implement the temperature control power 
modulated magnetic nanoparticle hyperthermia (similar to methods developed in chapters 
2 and 3) in an animal model of liver cancer. In doing so, we wanted to understand the 
challenges associated in implementing a computationally developed strategy and to 
improve the proposed method based on our findings. One of the main advantages of our 
proposed modulated power heating method was that necessary tumor damage can be 
achieved for a range of nanoparticle distributions with minimal surrounding healthy tissue 
damage. Hence, to test this we chose to generate two nanoparticle distributions by 
considering two injection methods – 2-pt and 3-pt. The nanoparticle injections were carried 




the range of operating fields (8 - 44 kA/m, peak) at fixed frequency of 155 ± 10 kHz (Figure 
4.5). This enabled us to inject lower volumes of nanoparticles (< 15 µL) at a low injection 
rate of 5 µL/min, thereby attaining controlled nanoparticle release. Despite this, a slight 
backflow of nanoparticles along the needle track was observed. With the two injection 
methods, we were able to generate two different nanoparticle distributions consistently as 
evidenced by the analysis of Prussian blue images (Figure 4.9). A high concentration of 
particles can be observed at the injected locations (two for 2-pt and three for 3-pt). Most of 
the nanoparticles were observed within the extracellular space, which is consistent with 
observations done by Giustini et al. [48].   However, it is important to note that despite 
using the same controlled injection method, the distributions were vastly different even in 
the same injection method cohort. This highlights the fact that controlling the nanoparticle 
distribution inside the tumors needs further optimization and tumor physiology has an 
important role to play.  
Temperature feedback controlled power modulated hyperthermia was implemented 
successfully for both the nanoparticle distributions. We were able to achieve a good control 
of the temperature at the tumor-healthy tissue boundary by modulating the power based on 
temperature feedback at the same location. The target temperature of 43.5 °C was achieved 
for all the mice independent of the nanoparticle distribution (Figure 4.6). There was no 
difference (statistically insignificant) among the two groups for the thermal dose deposited 
or the total energy applied (Figure 4.8). However, the treatment outcome was different for 
the two groups. 3 mice in the 2-pt injection group experienced complete ablation (code -2) 
compared to only 1 mouse with 3-pt injection. Tumor regions with high concentration of 




ablation. As mentioned previously, the backflow of nanoparticles along the needle path 
could result in the concentration of nanoparticles close to the skin surface which could have 
led to skin injury. We then performed simulations on subcutaneous ellipsoidal tumor model 
to compare and understand our experimental observations. We implemented the same 
heating protocol that was used in our experiments and also included the variation in water 
jacket temperature as the surface boundary condition. This is important for subcutaneous 
tumors because the heat transfer between the mouse and water jacket takes place through 
the skin. Performed simulations show a similar trend, predicting skin burn and ablative 
temperatures for 2-pt nanoparticle distribution tumor compared to 3-pt model (Figure 
4.10). For the 2-pt tumor model, high degree of thermal damage, Ω >> 4, can be observed, 
comparable to our experiments [169]. Additionally, it can be seen that the temperature at 
the tumor-healthy tissue boundary for both the simulated 2-pt and 3-pt tumor models 
exhibits a temperature-time curve similar to that of our experiments (Figure 4.12). Thus, it 
can be inferred that our simulations qualitatively predict the experimental outcomes.  
The therapeutic efficacy of temperature-controlled modulated power hyperthermia 
could not be tested in this study. Tumor ablation combined with skin burns precluded tumor 
growth delay studies, as this violates our IACUC protocol. However, some significant 
conclusions and lessons can be made from our in vivo testing of temperature-controlled 
modulated power nanoparticle hyperthermia. We were able to show that the temperature 
at the tumor-healthy tissue boundary can be controlled consistently for both the distribution 
models. This shows that temperature-controlled modulated power hyperthermia can be 
implemented in in vivo mouse tumor models for different nanoparticle distributions. 




parameters cannot lead to repeatable nanoparticle distributions inside the tumor, as 
evidenced from the analysis of Prussian blue images. Our method of generating of 3D 
nanoparticle distributions using Prussian blue images provides an alternative method to 
visualize and understand the nanoparticle distributions for labs which do not have access 
to imaging technologies.  
One limitation of the study is the use of subcutaneous tumors. While subcutaneous 
tumors allow for easier delivery of nanoparticles by direct intratumor injection and tumor 
size measurements, the proximity of the tumor to the skin surface causes significant 
limitations. Simulations from our deep tissue tumor models in Chapter 2 and Chapter 3, 
and our subcutaneous tumor models in this chapter do show limited thermal damage in the 
healthy tissue, however the change in thermal boundary conditions for the subcutaneous 
models especially on the skin surface results in enhanced heat transfer at the skin surface 
causing higher temperatures and thermal damage at the skin surface. Future studies should 
be focused on orthotopic tumors so as to overcome this limitation. Additionally deep seated 
tumors have more clinical relevance compared to subcutaneous tumors. It should also be 
noted that for critical organs, the margins for healthy tissue damage are minimal 
highlighting the need for more careful planning before implementing this method.  
Another limitation of the study is the uncertainty associated with temperature probe 
placement at the tumor-healthy tissue interface. We have shown in our simulations that the 
location of the temperature probe placement (Table 3.3) is indeed critical for the success 
of the method and this location depends on the nanoparticle distribution inside the tumor. 
Hence, future studies should use imaging methods such as CT imaging, to determine the 




better results. This approach can be used to determine the individualized heating protocol 
and probe placement before the treatment. In addition, the use of PID controlled power 
modulation method presented in simulations could give a more controlled heating 
compared to step heating method implemented in this study.  
While the method to generate 3D nanoparticle distributions using Prussian blue 
images presents a cost-effective method, it has some limitations. It should be noted that the 
method produces an approximate 3D nanoparticle distribution as it is generated from a 
discrete number of tumor slices separated by a distance. Also, the processing of tumors 
from harvesting to embedding in paraffin can have an effect on the distribution of particles 
and tumor volume. In addition, the difficulty of image registration among the different 
slices can have an effect on the generated 3D distributions. This method can be improved 
by ensuring registration of images which would give a more aligned and realistic 
nanoparticle distribution. 
As mentioned above, future experiments should be aimed to work with orthotopic 
tumor models compared to subcutaneous models for a better understanding of the efficacy 
of power modulated hyperthermia. Also, to test the therapeutic efficacy of the modulated 
power hyperthermia, tumor growth delay results should be compared to both untreated 
controls and constant power hyperthermia treated mice. 
4.5 Conclusions 
In summary, in vivo experiments were conducted in subcutaneous HepG2 tumors 
implanted in male nude mice. Temperature-control modulated power heating method 
similar to the methods proposed in the previous chapters (chapters 2 and 3) was 




methods, 2-pt, and 3-pt. Using Prussian blue staining, it has been shown that the generated 
nanoparticle distributions for the 2-pt and 3-pt models are qualitatively different. 
Additionally, it was also shown that the generated distributions are qualitatively different 
for each tumors in the same group. Temperature data from the experiments show that the 
tumor-healthy tissue boundary temperature can be consistently controlled with modulated 
power heating method for both the distribution models. However, tumor ablation and skin 
burns on the tumor surface prevented us to pursue tumor growth delay studies to test the 
efficacy of this method. Results from our numerical simulations using a subcutaneous 
models do predict the response observed in our experiments. In conclusion, while 
temperature at the tumor-healthy tissue boundary can be controlled using our heating 
method, studies in large animals using orthotropic tumors models should be conducted to 






Chapter 5  
Thermal and electromagnetic 
modeling of magnetic nanoparticle 
hyperthermia 
 
This chapter focuses on developing a coupled thermal and electromagnetic model 
for simulation of magnetic nanoparticle hyperthermia. The model will help us estimate the 
non-specific eddy current heating in large volumes during magnetic nanoparticle 
hyperthermia and can equip us to develop effective treatment strategies for clinical 
translation of magnetic nanoparticle hyperthermia. The coupled electromagnetic and 




cylindrical model was first developed and the temperatures achieved due to 
electromagnetic heating were computed. This model was verified with analytical 
expression for power absorbed by a cylinder exposed to an alternating magnetic field at a 
fixed frequency. Uncertainty analysis was conducted to determine the effect of uncertainty 
in input parameters on the computed temperature distribution. We then identified the 
important parameters that have a significant effect on the computed temperature 
distribution. The computational model was then validated with experimental data obtained 
from agar gel phantoms exposed to an alternating magnetic field. After this, a three 
dimensional model of rabbit liver was built from computed tomography images. The 
resulting temperature distributions achieved due to non-specific heating of exposed tissues 
after 20 min of treatment at given AMF field and frequency conditions was computed. Our 
results show significant temperature elevations due to non-specific eddy current heating in 
the exposed tissues. 
5.1 Introduction 
The quantity of heat generated by magnetic nanoparticles increases with increasing 
applied magnetic field amplitude and frequency. However, at higher fields and frequencies, 
exposed tissues can generate significant non-specific heating due to generation of eddy 
currents. Larger treatment volumes or large volumes of tissue exposed to an alternating 
magnetic field generate more heat resulting in more off-target tissue heating [61,156,171]. 
Also, time-varying magnetic field can induce other effects on the exposed tissue [172]. The 
heat generated due to these eddy currents can propagate throughout the body and can 
stimulate a complex thermoregulatory response in the body. This thermoregulatory 




and the exposed healthy tissue. Thus, the limits due to off-target eddy current heating 
should be considered when optimizing the applied field and frequency for magnetic 
nanoparticle hyperthermia.  
In in vivo experiments, monitoring eddy currents and eddy current heating is 
difficult. Hence, to develop methods for mitigating the effects of eddy currents, modeling 
of eddy current generation and heating is important. Efforts have been made to model eddy 
current heating by developing coupled electromagnetic and thermal models [173,174]. 
Both of these models were based on specific coil designs and were not extensively 
validated with experimental data. Stigliano et al. [174] conducted a partial validation of 
their model by comparing their simulated temperature with measured temperatures in a 
agar gel phantom only at one time point. Additionally, the effect of input parameter 
uncertainties on the simulated eddy current heating and temperatures was not considered.  
During the past fifty years, there has been a significant increase in the use of 
computational simulations to model physical and biological processes in research, analysis, 
and design of engineering processes. The impact of modeling and simulation can be seen 
across different areas encompassing both the physical and biological world. For example, 
modeling has been used to understand cardiovascular flows, designing new equipment, 
modeling environmental phenomena, designing engines, etc. Considering the impact of 
computational modeling and simulations, the credibility of these models is of paramount 
importance. Often, one of the main concerns cited by field engineers, doctors, fund 
managers, and lay people is whether the predictions made by these simulations are credible. 
Thus, it is very important to assess the accuracy of a given model so that decisions can be 




computational model is by verification and validation [175]. Assessment of the accuracy 
of a solution to a computational model with known solutions (often analytical) is known 
as verification. Validation, on the other hand, is the assessment of the accuracy of a 
computational solution by comparison with experimental data [175]. It is therefore 
important to verify and validate a computational model before using it for devising 
treatment strategies or understanding of complex phenomena.  
In this study, a coupled thermal and electromagnetic model was developed using 
COMSOL. The model was then verified with the analytical model and validated with 
temperature measurements obtained from gel phantoms. Uncertainty analysis was carried 
out to estimate the uncertainties in the computed temperature distributions and to determine 
the parameters that have the most influence on the computed temperature distributions. A 
realistic rabbit liver model was then built by importing the liver geometry from X-ray 
computed tomography (CT) imaging data. The temperature distributions achieved due to 
eddy current heating were computed. Significant rise in temperatures was observed at the 
edges of the liver. Our model is the first step towards building a robust and validated 
clinical treatment planning model for magnetic nanoparticle hyperthermia. 
5.2 Materials and Methods 
5.2.1 Coupled electromagnetic and heat transfer model 
Electromagnetic and heat transfer analysis was carried out in COMSOL 5.2a, a 
multi-physics finite element solver, on a cylindrical geometry of diameter Dgel and height 
Hgel representing a gel phantom, as shown in Figure 5.1. Three concentric cylinders were 




dimensions of the gel phantom were chosen to be close to the size of a human liver [176]. 
Electromagnetic and heat transfer simulations were simultaneously carried out by coupling 
Maxwell’s equations and transient heat conduction equation. The effect of alternating 
magnetic field on the cylindrical gel phantom with conductivity σ can be described by 
Maxwell’s equations: 
 𝛻 × 𝐻 = 𝐽 (5.1) 
 𝐵 = ∇ × 𝐴 (5.2) 
 𝐸 = −𝑗𝑓𝐴 (5.3) 
 𝐵 =  σE + jfD, (5.4) 
where J is the current density, A is the magnetic vector potential, E is the electric field 
intensity, B is the magnetic flux density, and D is electric flux density. Heat transfer in the 




= 𝑘∇2𝑇 + 𝑄𝑒𝑑𝑑𝑦  (5.5) 
 
where ρ is the density, Cp is the specific heat, T is the temperature, k is the thermal 
conductivity and Qeddy is the heat produced due to eddy currents. The boundary conditions 
for the electromagnetic modeling,  given by a uniform alternating magnetic field of 
amplitude H and frequency f, was imposed on the outer surface of the coil. For heat transfer 
modeling, the outer surfaces of the water jacket were subjected to an external forced 
convection boundary condition with plate averaged heat transfer coefficient, given by 
 𝑞𝑜 = ℎ𝑐𝑜𝑛𝑣  (𝑇 − 𝑇𝑒𝑥𝑡) (5.6) 





where L is the length of the water jacket, U is the water flow velocity, and Text is the water 
temperature. The open faces of the water jacket were modeled by free convection boundary 
condition given by, 
  𝑞 = ℎ𝑓𝑟𝑒𝑒(𝑇 − 𝑇∞) (5.8) 
 
where T∞ is the ambient temperature and hfree is the free convection heat transfer 
coefficient. The thermal and electrical properties used in the simulations are summarized 
in Table 5.1. 
Equations (5.1) – (5.8) were coupled and simultaneously solved using finite 
element analysis.  Sensitivity of the solution to grid size and time step size were carried out 
to ensure choice of mesh size and time step has negligible effect on the computed 
temperature. For example, when the number of domain element were changed from 9523 
to 17244 elements, the resulting temperature at three locations (gel center, at rgel/3 from 
center, and 2rgel/3 from center) changed by less than 0.01%.  
5.2.2 Verification with analytical model 
The analytical expression for the power absorbed by a cylindrical tissue of radius r 
exposed to an alternating magnetic field of constant amplitude H and frequency f is given 
by, 






Where µo is the permeability of free space, σ is the electrical conductivity [156,157,177]. 





5.2.3 Validation with experimental model – Gel phantom model 
Cylindrical gel phantoms were prepared by heating a solution of 1% agarose (Type 
I-A, low EEO, Sigma Aldrich, Lot #SLBC0292V), with Sodium Chloride, crystal (J. T. 
Baker, Lot K17586) in 750 ml of distilled deionized water. The solution was heated using 
a heating plate and a magnetic stirrer until all agar was dissolved in the solution. The 
solution was then allowed to solidify and cool to room temperature for more than 12 hours 
to ensure uniform temperature inside the gel. The dimensions of the gel were then measured 





] = 215 ×
(𝑔𝑟𝑎𝑚𝑠 𝑜𝑓 𝑁𝑎𝐶𝑙)
(𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒,  𝑚𝐿)
+ 0.0529 (5.10) 
 
5.2.4 Alternating magnetic field system 
The AMF system consists of three main components: a power supply, an external 
capacitance-impedance matching network, and a modified Maxwell coil. The AMF system 
has been well described by Attaluri et al [179]. Briefly, it consists of three-piece induction 
coil set connected to a power supply. The power supply is a 120-kW induction heating 
system (PPECO, Watsonville, CA) that provides alternating current to a resonant circuit 
with variable frequencies (135 – 440 kHz). The external impedance matching network 
(AMF Life Systems, Auburn Hills, MI) was adjusted for stable oscillations at 155 ± 10 
kHz. The uniformity of the field generated was measured and it was shown that the 
variation in the generated field was < 10 % at ± 5 cm along the length of the coil and in the 




transfer between the gel and the coil. It was connected to a chiller (ThermoFlex, Thermo 
Fisher Scientific, Newington, NH) which was maintained at 20 °C. 
 
 
Figure 5.2 Experimental setup for the gel phantom experiments. Agar gel phantoms were 
inserted in the center of a 20 cm horizontal modified Maxwell coil inside a water jacket 
with temperature controlled at 25 °C. Temperatures were measured at the center of the gel, 
r/3, and 2r/3 distance along the radius of the gel, where r is the gel radius. 
 
The gel phantom was allowed to equilibrate to room temperature for more than 12 
hours before inserting it into the coil. The gel was then inserted into the coil and exposed 
to a constant alternating magnetic field of amplitude 6.96 kA/m (peak) and at fixed 
frequency 160 kHz (observed) for 15 minutes. Temperatures were measured radially at 
three locations (r = 0, rgel/3, 2rgel/3) at the center of the gel (H/2) using optical fiber 
temperature probes (FISO, Quebec, Canada). These measurements were then used to 




5.2.5 Uncertainty analysis 
Uncertainty exists with any measurements conducted and are often reported for 
experimental data. It is therefore important to consider uncertainties associated with the 
parameters when they are applied to mathematical models. Often, average values are 
considered for mathematical models which might lead to difficulty validating mathematical 
models using experimental data. Sensitivity analysis is required to evaluate the propagation 
of measurement uncertainties into mathematical models. It becomes more critical when 
experimental data are used to validate the results of a computational model, because the 
uncertainties can become highly significant. Rabin [180] proposed a general model for the 
propagation of uncertainty in measurements into heat transfer simulations and applied it to 
a cryosurgery model. We apply the same model to compute the uncertainty associated with 
the computed temperatures due to the uncertainties associated with the input parameters. 
In our current model, the temperature T generated in the gel due to eddy current 
heating depends on the gel dimensions, like diameter (Dgel) and height (Hgel), thermal 
properties like density (ρ), thermal conductivity (k), and specific heat capacity (Cp), 
electrical conductivity (σ), applied magnetic field conditions like magnetic field strength 
(H), frequency (f), the gel position inside the coil determined with respect to the coil center 
given by radial distance of the center of the gel from coil center (x_pos), and along the axis 
of the coil (y_pos), and the location of the probe. To compute the uncertainty in the 
temperature attained in the gel we must consider the uncertainty associated with each of 
the above input parameters. The mean values of the parameters were based on recorded 
data and/or applied conditions. The mean values of the parameters and their uncertainty 




uncertainty range was determined from the coil specifications. For the electrical 
conductivity of the agar gel phantom with salt, the uncertainty was assumed to be 5% based 
on data from Bennett [178]. The density of the gel was determined by weight and volume 
measurements and the uncertainty was based on the measured variations. The specific heat 
capacity of the gel was taken from [181]. The thermal conductivity of the gel and the 
uncertainty values were based on data from Zhang et al. [182]. The diameter and height of 
the gel were measured using a ruler and the uncertainty was taken to be half of the lowest 
distance marker (1 mm). The position of the gel with respect to the coil was measured using 
a ruler and the uncertainty of 5 mm was chosen based on experience. The location of probes 
was measured using a ruler placed on the top of the gel and the corresponding uncertainty 
was chosen based on the diameter of the fiber-optic probe [183], the least count of the ruler 
and the gel structure. The ambient temperature was measured using a standard room 
thermometer and the water jacket temperature was measured using a fiber-optic 
temperature probe.   
The temperature at any time can be represented as a function of all input model 
parameters: 
 𝑇 = 𝑓(𝑝1, 𝑝2, 𝑝3, …… , 𝑝𝑛) (5.11) 
here 𝑝1, 𝑝2, 𝑝3, …… , 𝑝𝑛 are the individual parameters. 
Assuming the value of each parameter is independently associated with an 
uncertainty δ, the uncertainty in the temperature distribution can be calculated as, 
 𝑇 ± 𝛿𝑇 =  𝑓(𝑝1 ± 𝛿𝑝1, 𝑝2 ± 𝛿𝑝2, 𝑝3 ± 𝛿𝑝3, …… , 𝑝𝑛 ± 𝛿𝑝𝑛) (5.12) 

















𝛿𝑝𝑖 = [𝑇𝑖 − 𝑇0]∆𝑝𝑖=𝛿𝑝𝑖 ≡ ∆𝑇𝑖 (5.14) 
The overall uncertainty can then be calculated as [180,184]: 








The effect of uncertainty in each individual parameter on the temperature 
distribution was calculated individually by varying each parameter individually using 
values shown in Table 5-1. The uncertainty at each of the probe locations was computed. 
After this, the top two parameter uncertainties that produce the highest uncertainty in the 
computed temperatures were identified. Based on this, the maximum uncertainty in those 
parameters was considered while the remaining parameters were fixed at nominal values. 
The temperature distributions were then computed at each of the probe locations and the 
uncertainty in probe location (±3 mm) was also considered. The initial temperatures were 
adjusted to match with the measured values. If the difference between any of the three 
computed temperatures at each probe location (T (probe), T (probe+3mm), and T (probe-
3 mm)) and the measured temperature was < 5%, then the computational model is said to 






Table 5-1 Mean parameter values and their uncertainties considered in the simulation 
Parameter Mean value Uncertainty 
Magnetic field amplitude, H (kA/m) 6.96 kA/m ±10% [179] 
Frequency (kHz) 160 ±10% [179] 
Electrical Conductivity (S/m) 0.3325 [178] ±10%  [178] 
Density (kg/m3) 960 ±5% 
Specific heat capacity (J/kg-K) 3900 [181] ±10% [181] 
Thermal conductivity (W/m-K) 0.566 [182] ±5% [182] 
Diameter of gel (m) 0.103 ±0.5 mm 
Height of gel (m) 0.093 ±0.5 mm 
Position along radius of gel (cm) 0 ±5 mm 
Position along axis of gel (cm) 7.0 ±5 mm 
Probe location (cm) 0.05, 1.85, 3.45 ±3 mm 
Water Jacket Temperature (°C) 20 ±0.5 °C 
Ambient Temperature (°C) 20 ±1 °C 
 
5.2.6 3D models of rabbit liver from CT images 
X-ray computed tomography (CT) images of a rabbit liver, which is part of our 
ongoing liver cancer study, was used to build a 3D model in this study. The CT scan 
experiments were conducted by Dr. Eleni Liapi and Dr. Sahar Mirpour. Briefly, adult white 
New Zealand rabbits were housed in an Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) - accredited facility in compliance with the Guide for 
the Care and Use of Laboratory Animals and procedures were approved by the Johns 
Hopkins Institutional Animal Care and Use Committee (IACUC). White New Zealand 




imaging. At specific time points, each animal was selected for VX2 tumor implantation in 
the liver and subsequently underwent CT imaging. 
The CT images of rabbit were first imported into 3DSlicer [185], an open source 
software for visualization and medical image computing. 3DSlicer allows simultaneous tri-
axial display of the sagittal, coronal, and transverse medical images, as well as a 3D view 
of the segmented structure. Manual segmentation was done to extract the liver from the 
other organs. The gray level value for each of the tissues was determined by pointing the 
crosshairs on the input image in the region of interest. Then, manual segmentation was 
done by inputting the lower and higher threshold gray level value in the processing window 
and the smoothness parameter was set to maximum. Since the gray level values of the soft 
tissue organs are very close to each other, automatic segmentation does not yield a desirable 
result. 
After segmentation, the files were converted into .stl format and then imported into 
MeshLab® [186], for meshing. Surface treatment was necessary to smooth sharp edges and 
artifacts obtained in reconstructed geometries to ensure convergence in finite element 
simulations. The imported liver geometry was first meshed and then it was smoothed by 
using a Laplacian mesh smoothing method. Several iterations of mesh smoothing were 
carried out to ensure a well smoothened geometry and convergence in finite element 
simulations. The meshed geometry was exported and saved as a .stl file. It was then 
imported into COMSOL Multiphysics 5.2a, a commercially available finite element solver, 
using the mesh import functionality. The imported mesh was then converted into a 




was again meshed to conduct finite element heat transfer and electromagnetic simulations. 
The workflow of building 3D models from CT scan images is shown in Figure 5.3.  
Coupled electromagnetic and heat transfer simulations were then carried out on the 
liver model and the geometry considered is shown in Figure 5.4. The computational 
geometry mainly consists of three domains: 1. the extracted liver domain, 2. spherical 
tumor inside the liver, and 3. muscle tissue surrounding the liver. The complete geometry 
was exposed to a constant field of amplitude of 19.89 kA/m at fixed frequency of 160 kHz.  
Heat transfer in the tissues were modeled using the Pennes bioheat equation [81], 





2𝑇𝑛 + 𝜌𝑏𝑐𝑏𝜔𝑏,𝑛 ( 𝑇𝑏 − 𝑇𝑛 ) + 𝑄𝑚,𝑛 +𝑄𝑝 (5.16) 
Where n and b represent tissue (liver, n =1; tumor, n =2; muscle, n=3) and blood; 
respectively. ρn, cn, kn, Tn, Qm,n denote the density, specific heat, thermal conductivity, local 
temperature, and metabolic heat generation rate, for either tumor or healthy tissue and t is 
the heating time. ρb, cb, ωb,n, Tb denote density, specific heat, perfusion rate, and 
temperature, of blood respectively. Constant perfusion was considered in the current study 
for ease of computation and to gain preliminary insights into the temperature distributions. 
The thermal and electrical properties of the tissues considered in the model were given in 












c (J/kg K) 
Thermal 
conductivity, 










Liver 1079 [122] 3540 [122] 0.52 [122] 0.018 [167] 14414 [168] 
Tumor 1079 [122] 3540 [122] 0.52 [122] 0.018 [167] 72070 [74] 
Muscle 1090 [122] 3421[122] 0.49 [122] 0.0027 [74] 684.2 [74] 
Blood* 1060 [125] 3770 [125] N/A N/A N/A 
*Temperature of blood (Tb) was fixed at 37ºC [125]. (N/A – not applicable) 
Thermal boundary conditions considered for this model are: constant core body 
temperature of 37 °C at all the outside boundaries of the muscle domain and the continuity 
of temperature and heat flux at the domain interfaces. For the electromagnetic boundary 
conditions, a constant magnetic field of 19.89 kA/m (peak) at a fixed frequency of 160 kHz 
is applied on the outer boundaries of the muscle layer. Simulations were carried out for a 
treatment duration of 20 min at constant amplitude and the resulting temperature 
distributions were computed. 
 
Table 5-3 Tissue electrical properties used in the simulations 
 Electrical conductivity, σ 
(S/m) 
Permittivity (1) 
Liver 0.0954 [122] 6090 [122] 
Tumor 0.0954 [122] 6090 [122] 







5.3 Results and Discussion 
For clinical implementation of magnetic nanoparticle hyperthermia, it is important 
that the nanoparticles generate substantial heat for tumor thermal damage. The heat 
generated by nanoparticles increases with increasing applied magnetic field amplitude and 
frequency as stated previously. Thus, it can be thought of that increasing the applied field 
and frequency can help in attaining therapeutic temperatures. However, the interaction of 
surrounding healthy tissue with the applied magnetic field results in unwanted non-specific 
eddy current heating which can effect body thermoregulation leading to perfusion changes 
which in turn can effect tumor heating. This places limits on the range of applied magnetic 
field amplitudes and frequencies that can be used [61,62]. Additionally, monitoring and 
measurement of eddy currents and eddy current heating in in vivo studies is challenging 
[187].  Coupled thermal and electromagnetic model can help us estimate the temperatures 
due to eddy current and can help develop treatment strategies to reduce it. 
Accuracy of computer simulation models and confidence in their results needs to 
be critically assessed before they can be used for prediction or research. Validation and 
verification are the primary methods in gaining confidence in the results and quantifying it 
[175]. In this study, we verify our computational model with the available analytical 
solution for temperature distribution in a cylinder exposed to an alternating magnetic field. 
We then validate our computational model with experimental data obtained from gel 




5.3.1 Verification with analytical model 
The temperature distribution in the computational cylindrical phantom after 15 min 
exposure to a constant alternating magnetic field of 13.94 kA/m at a fixed frequency of 160 
kHz is shown in Figure 5.5. It can be observed that temperature increases away from the 
center of the phantom, with the lowest temperatures at the center and highest temperatures 
at the periphery. This shows that more heat is being generated in regions away from the 
phantom center compared to center of the phantom. This trend is indeed consistent with 
that predicted by the analytical solution given by equation 5.9, where the heat generated is 
proportional to the square of the distance from the center of the field.  
Equation 5.9 gives the analytical expression for the heat generated by a body 
exposed to an alternating magnetic field. Equation 5.9 is valid for cylindrical domains 
exposed to a constant magnetic field and if√𝑓𝜎𝜇𝑜𝑟𝑚𝑎𝑥 ≪ 1 [156,157,177]. In our case, the 
value of √𝑓𝜎𝜇𝑜𝑟𝑚𝑎𝑥 is 0.04 << 1. Hence, the analytical solution can be used to verify our 
computational model. The computed temperatures at three locations in the phantom, center, 
r/3 and 2r/3 were compared to temperatures calculated using the analytical expression and 
plotted in Figure 5.6. Excellent agreement can be seen between the computed temperatures 
and the temperatures calculated using the analytical expression, thus verifying the 






Figure 5.6 Verification of computational model with analytical expression Comparison of 
computed temperatures with the coupled electromagnetic and heat transfer model with 
temperatures calculated using the analytical expression for power absorption at center of 
gel shows excellent agreement therefore verifying the model. 
 
5.3.2 Uncertainty analysis and validation with experimental model 
Validation of computational model is done by comparing the data from simulations 
with experimental data. However, one of the main challenges is the uncertainty present in 
the input parameters used in simulation. Neglecting the uncertainties associated with the 
measured data, can yield incorrect results of either invalidating a correct model or 
validating an incorrect model [188]. Also, uncertainty propagation from parameters is often 
neglected in bioheat transfer simulations as only the average values are used [180]. 
However, estimation of uncertainties for all the parameters would be impractical and would 




or that can influence the outcome significantly. Using uncertainty analysis the parameters 
to which the predicted temperature distribution is most sensitive to can be determined.  
Uncertainty analysis was carried out for all the relevant parameters in the 
simulation as shown in Table 5-1. The corresponding uncertainties were calculated based 
on the procedure as explained in section 5.2.5. The uncertainty in computed temperatures 
due to individual parameter uncertainties and the overall uncertainty was plotted in figure 
5.7. Temperature uncertainty was plotted at three locations, center of the phantom, r/3 
distance from the phantom center and 2r/3 distance from phantom center. It can be seen 
that the uncertainty in the temperature is most sensitive to the parameters that influence the 
heat generation term followed by parameters that influence heat transfer. The parameters 
that result in heat generation are applied magnetic field H, frequency f, probe location, and 
electrical conductivity σ. The parameters that influence heat transfer are density ρ, specific 
heat capacity Cp, thermal conductivity k, and temperatures of water jacket and ambient. As 
predicted the uncertainties in the parameters that influence generation have the most effect 
on the computed temperatures. The rate of heat generation, given by equation 5.9, is 
proportional to the square of the product Hf. Hence, variability in either of them has a 
strong effect on the computed temperatures. Of the other parameters, the next sensitive 
parameter is the uncertainty in probe placement. This can also be predicted as the heat 
generation term is also directly proportional to the square of the distance (r) from the center. 
The variability in electrical conductivity has the next important effect on the computed 
temperatures. Of the parameters that influence the heat transfer in the gel, the variability in 




overall uncertainty is compared for each of the three locations, the uncertainty increases 
significantly as we move away from the phantom center.  
After this we compared the computed temperatures with the experimental values 
for validation of the computational model. If the measured temperatures fall within the 
range of computed temperatures (± 5%) with corresponding uncertainties at a given 
location, then the model is said to be validated. This was satisfied for all the three probe 
locations. However, we wanted to test the model more rigorously to compare with 
experimental data. To do this, we chose to find the parameter values which fit the computed 
temperatures at the center to the measured values (difference of < 5%) and for the same 
parameter values we compared the computed and measured at the other two locations. The 
parameter values were the mean values reported in Table 5-1 for all the parameters, except 
for H, Cp, and, ρ. The uncertainty in probe placement was still shown as this was 
independent of the gel properties and coil properties. The computed and measured 
temperatures were then plotted for each of the locations along with probe placement 
uncertainties and shown in Figure 5.8. Excellent agreement can be observed between the 
computed and measured values with the maximum absolute error <2 % at each of the probe 
location. This validates our computational model. 
5.3.3 3D models of rabbit liver 
The verified and validated coupled thermal and electromagnetic model was then 
implemented on a 3D liver model generated from CT scan images as shown in Figure 5.4. 
Simulations were performed for a constant magnetic field of 19.89 kA/m (peak) at a fixed 
frequency of 160 kHz leads for 20 min. The resulting temperature distributions after 100s 




with the temperatures lower closer to the liver center and increasing radially away with the 
maximum temperatures achieved on the liver edges. Even after 100s of exposure, 
considerable heating occurs at the liver edges with a temperature increase of ~ 1.5 °C. After 
20 min of exposure, the temperatures further increase with a maximum of 40.81 °C 
observed at the liver edges. Thus, mild hyperthermic temperatures (39 – 41 °C) are 
obtained in the liver due to eddy current heating. Our model successfully simulates the 
eddy current heating in large organs such as liver and highlights the importance of 
considering heating due to eddy currents when optimizing magnetic nanoparticle 













Figure 5.7 Variation of uncertainty in temperatures measured at the center, r/3, and 2r/3, with time, due to uncertainty in individual 
parameters identified in Table 5-1. The variation in overall uncertainty of temperature with time was plotted for each probe location. It 
can be seen that the computed temperatures are most sensitive to the uncertainties in applied field (H), frequency (f), probe placement 









Figure 5.8 Validation of computational model with experimental data Comparison of 
measured temperatures and computed temperatures at (a) center of the gel, (b) r/3 along 
the radius of the gel, (c) 2r/3 along the radius of the gel, where r is the gel radius. Excellent 
agreement between the computational and measured temperature is observed confirming 
the validity of the computational model. The effect of uncertainty in probe placement 
(given by ±3 mm) on the computed temperatures is also shown. The maximum absolute 











temperature distribution. This model was then verified using the analytical solution 
(equation 5.8) by implementing it on simple cylindrical model. Temperatures were 
computed at three locations (center, r/3, and 2r/3) and compared to the calculated 
temperatures using the analytical solution. Excellent agreement was obtained between the 
computational model and analytical model verifying our computational model.  
Uncertainty analysis was conducted to determine the variation in computed 
temperatures with uncertainty in input parameters. We identified that the variability in 
parameters in the heat generation term has the most influence on the computed 
temperatures followed by the parameters in heat transfer terms. Overall uncertainty 
increases with increase in distance from the gel center. The computed temperatures were 
then compared with the measured temperatures in gel phantom. The difference in the 
computed and measured temperatures was < 2% validating our computational model. 
The model was then implemented on a realistic rabbit liver model developed from 
CT images. Pennes bioheat transfer equation was used to model the macroscopic heat 
transfer in liver tissue. Simulations were performed for a constant field with amplitude of 
19.89 kA/m (peak) and fixed frequency of 160 kHz. Simulation show a significant heating 
at the edges of liver with temperatures reaching up to mild hyperthermia range of ~ 40.81 
°C.  
Our verified and validated model lays the foundation for developing effective 
treatment strategies optimizing tumor therapeutic thermal dose and minimizing the of-
target eddy current heating. This model can also help in designing new magnetic coils so 
as to minimize off-target tissue heating. The model can further be improved by 




Temperature dependent perfusion can take into account the thermoregulation function of 
the human body which can further help in designing better treatment strategies. This model 
can be further used to the test limitations of the modulated power heating method proposed 
























Chapter 6  
Thermal and magnetic 
characterization of nanoparticle 
formulations for image guided 
hyperthermia 
 
In this chapter, thermal and magnetic properties of dual contrast magnetic iron 
oxide nanoparticle formulations were characterized. The dual contrast magnetic iron oxide 
nanoparticle formulations considered in this chapter were magnetic iron oxide 
nanoparticles combined with lipiodol®, an ethiodized oil. These formulations have both CT 




an alternating magnetic field. These can be used in intra-arterial therapies such as 
transarterial chemoembolization (TACE) to administer chemotherapy and hyperthermia 
simultaneously for primary liver cancer. The heating potential of these new lipiodol 
nanoparticle formulations was extensively characterized by measuring their thermal 
properties at fixed frequency with different magnetic field amplitudes. These were then 
compared to the original aqueous formulations (as-synthesized) for assessing the 
differences between both the formulations. Bulk magnetic properties of both aqueous and 
lipiodol formulations were measured and compared. Lipiodol formulations of magnetic 
iron oxide nanoparticles showed higher temperatures compared to aqueous formulations at 
different applied magnetic field amplitudes at fixed frequency. Comparison of thermal 
properties show that lipiodol formulations have lower volumetric heat capacities compared 
to aqueous formulations resulting in higher rise in temperatures despite reduction in SLP. 
Magnetization of lipiodol formulations was significantly lower compared to aqueous 
formulations at all temperatures showing that lipiodol has a shielding effect on the 
magnetic nanoparticles. These results highlight the importance of evaluating the heating 
performance of any new nanoparticle formulations by measuring the change in both the 
thermal and magnetic properties. 
6.1 Introduction 
Magnetic nanoparticles have gained significant importance in the recent past for 
their use in biomedical applications [38]. The ability to control their size, responsiveness 
to magnetic fields and biocompatibility have led to their use in many medical applications 
such as imaging [189,190], therapy [43,49,50], and drug delivery [191]. Magnetic 




which generate heat when exposed to an alternating magnetic field [51]. The ability to 
selectively heat tumor tissue compared to other hyperthermia modalities such as 
microwave, whole body hyperthermia etc., makes mNPH a very attractive treatment 
modality [37]. The biological rationale, that thermal damage to cells is complementary to 
DNA damage, plus the effects of elevated temperature on tumor blood perfusion and 
oxygenation, support the use of hyperthermia as a combined therapy modality along with 
radio- or chemo-therapies [9,10,13,192–196].  
Primary liver cancer is the second leading cause of cancer-related death in the world 
and fifth most frequently diagnosed in men in the US [1,197]. Patients are often diagnosed 
at advanced stages of cancer resulting in limited non-surgical palliative treatment options. 
Image guided therapies for primary liver cancer, such as TACE, are minimally invasive 
treatment options that offer selective tumor targeting by delivering drugs through the 
hepatic artery [198–201]. Combining magnetic nanoparticles with chemotherapeutic drugs 
and delivering them through TACE allows for combination treatment using hyperthermia 
and chemotherapy. Several efforts were carried out to implement magnetic nanoparticle 
hyperthermia with TACE [66,128,129,202–205]. The principal challenges identified were 
the lack of sufficient heating from the nanoparticles and the MRI artefacts created by 
nanoparticles [129]. Recent studies show significant increase in heat generation by 
nanoparticles [53,55,66]. Attaluri et al. [66] developed new nanoparticle formulations and 
conducted a feasibility study to show that these nanoparticle formulations generate 
significantly higher temperatures. These nanoparticle formulations were made combining 
the BNF nanoparticles with ethiodized oil (Lipiodol®) [206]. It was shown that these 




temperatures when compared to BNF nanoparticles without lipiodol. However an 
extensive characterization of thermal and magnetic properties was not done. The success 
of any nanoparticle formulation would depend on efficient synthesis, complete 
characterization, and performance under operating conditions [59]. Thus it is important to 
characterize the thermal properties and magnetic properties of these formulations and 
compare them with their original samples to understand the effect of lipiodol on the 
nanoparticles.  
The aim of the current work was to determine the thermal and magnetic properties 
of lipiodol formulations of nanoparticles which can offer both CT and MRI imaging 
capabilities. Two magnetic iron oxide nanoparticles and their lipiodol formulations were 
considered. The heating rates of these four nanoparticle formulations were determined by 
measuring the change in temperature at different amplitudes. The higher rise in 
temperatures observed for BNF-lip in comparison to BNF-water is mainly attributed to the 
change in thermal properties of solvent. SLP of lipiodol formulations of both BNF and 
JHU nanoparticles was lower than the corresponding aqueous formulations. Bulk 
magnetization measurements show a significant reduction in magnetization and changes in 
approach to saturation magnetization for both BNF-lip and JHU-lip compared to their 
respective aqueous formulations. These results show that the changes in magnetic and 
thermal properties of the formulations need to be considered for estimating the heating 






6.2 Materials and Methods 
6.2.1 Magnetic iron oxide nanoparticles 
The magnetic iron oxide nanoparticles used in this study are: Bionised nanoferrite 
(BNF) nanoparticles and Johns Hopkins University (JHU) nanoparticles. BNF 
nanoparticles (micromod Partikeltechnologie, Rostock, Germany) are starch-coated iron 
oxide solid core nanoparticles synthesized by a high temperature and high pressure 
homogenization process [55,57]. They have a mean hydrodynamic diameter of 80 nm and 
iron concentration of 19.2 mg/mL (lot 0601610-02). JHU nanoparticles (NanoMaterials 
Technology, Singapore) are citric acid coated iron oxide core-shell particles which are 
synthesized by a high gravity controlled precipitation process [53,57]. They have a mean 
hydrodynamic diameter of 56.8 nm and iron concentration of 85 mg/mL (lot 
Fe000H1503225). Both the nanoparticles are a mixture of magnetite (Fe3O4) with 
maghemite (γ Fe2O3) have been extensively characterized previously and their heating 
potential measured [57]. 
6.2.2 Preparation of lipiodol formulations of BNF and JHU nanoparticles 
Lipiodol®, an ethiodized oil, is a commonly used carrier fluid for image guided 
procedures such as TACE, mainly due to its radio-opacity, drug delivery and transient and 
plastic embolization of tumors [206]. It is a pale yellow to amber color clear liquid with an 
iodine concentration of 480 mg/mL (37% w/w). Lipiodol formulations of BNF and JHU 
nanoparticles, BNF-lip and JHU-lip, were prepared as follows. 1% of polysorbate-20 
(Tween®-20, Sigma Aldrich, St Louis, MO) was added to aqueous suspensions of BNF 




Bloomington, IN) was then added to this mixture by 1:1 v/v ratio, followed by vortexing 
for 5 minutes, giving the BNF-lip emulsion, as previously described [66]. JHU-lip, 
emulsion of JHU nanoparticles and lipiodol, was prepared by mixing the aqueous 
suspension of JHU nanoparticles and lipiodol with a 1:1 v/v ratio and sonicating for 15 
minutes. Fresh batches of lipiodol formulations of both the particles were prepared using 
the same starting materials for each of the experiments described in this chapter. 
 
6.2.3 Physical characterization by transmission electron microscopy (TEM) 
The sizes and arrangement of nanoparticles in the aqueous and lipiodol 
formulations of both BNF and JHU nanoparticles were characterized using TEM 
(Philips/FEI BioTwin CM120) working at 80 keV. The samples were diluted to 200 
µL/mL, and 5 µL of sample was placed onto a 400 mesh carbon coated copper grid and 
dried overnight before imaging. The lipiodol formulations were intractable for imaging 
since the non-volatile lipiodol prevented drying on sample grids for TEM [66]. Hence 
surrogate suspensions for both BNF-lip and JHU-lip, were prepared as follows [66]. The 
nanoparticle rich fractions for BNF-lip and JHU-lip formulations were collected by 
magnetic-assisted settling using strong rare earth permanent magnets for 60 min and the 
supernatant was removed. The nanoparticle rich fractions were then re-suspended in 
lipiodol and sonicated for 15 min. The suspensions were then filtered through a MILLEX®-
HV (0.45 µm) filter unit to yield a concentrated paste of BNF-lip and JHU-lip emulsions 




6.2.4 Temperature measurements  
The change in temperatures of aqueous and lipiodol formulations of BNF and JHU 
nanoparticles were measured by using alternating magnetic field (AMF) equipment and 
methods previously described [56,165,207]. The AMF equipment mainly consists of three 
components: power supply, a matching external impedance network (matchbox in Figure 
6.1), and a vertical solenoid configuration (coil in Figure 6.1). The power supply is a 120-
kW induction heating system (PPECO, Watsonville, CA) that supplies an alternating 
current to an external impedance match network (AMF Life Systems, Auburn, MI) which 
was adjusted to oscillate at a stable frequency of 155 ± 10 kHz. The vertical four turn 
modified solenoid coil generates a magnetic field (± 10% peak amplitude) and is cooled 
using a closed-loop circulating water cooling system. The generated magnetic field was 
measured using magnetic field probes (AMF Life Systems, Auburn Hills, MI) and mapped 
to the applied voltage of the power supply. The solenoid coil was calibrated for SLP 
measurements with a copper wire [207].  
The experimental setup for measuring the rate of temperature changes of BNF, 
BNF-lip, JHU and JHU-lip, is shown in Figure 6.1. An insulating cylindrical Styrofoam 
holder was used to minimize the thermal interactions between the sample and the 
surroundings, especially to limit the heat transfer from the vertical solenoid coil during the 
experiment. 1 mL volume samples of all the four nanoparticle formulations were prepared 
in Type I 51 glass tubes (LaMotte, Chestertown, MD) and weighed before inserting them 
into the cylindrical Styrofoam holder. The iron concentration in all the nanoparticle 
formulations was fixed at 5 mg/mL. Temperatures of the samples were measured using a 




Canada). Care was taken to ensure that the probe was immersed inside the solution and the 
probe was sealed using parafilm. The samples were allowed to equilibrate with the 
surroundings before heating. This was ensured by monitoring the temperature and letting 
it to stabilize to a constant temperature (maximum deviation of ± 0.05 °C) for 30 s. After 
this, alternating magnetic field was applied for a duration of 100 s and the temperatures 
were recorded at 0.45 s intervals. The samples were then removed from the chamber and 
allowed to cool down before subjecting them to heating at another amplitude. The process 
was repeated for all the samples at different magnetic field amplitudes. 
The change in temperatures of the four nanoparticle formulations, BNF-water, 
BNF-lip, JHU-water, and JHU-lip, were measured at a range of magnetic field amplitudes, 
beginning at 8 kA/m to 32 kA/m at 4 kA/m intervals, at a constant frequency of 155 ± 10 
kHz. Samples of water, lipiodol-polysorbate20-water (BNF-lip background) and lipiodol-
water (JHU-lip background), were prepared and temperatures measured at each power 
setting to account for heating contributions from solvent(s) and the calorimeter. The rise in 
temperatures for the nanoparticle formulations was determined by subtracting the initial 
temperature of the sample from the measured temperatures at each time point. The rise in 
temperatures due to nanoparticle heating, given by the net increase in temperatures with 
time, of the nanoparticle formulations were then determined by subtracting the 
temperatures of their respective background samples from these temperatures. 
6.2.5 Specific heat capacity measurements 
Lipiodol, BNF, BNF-lipiodol, JHU, and JHU-lipiodol, samples were sent to 
Intertek laboratories (Allentown, PA) for specific heat measurements. The heat capacity of 




Q2000) DSC, calibrated at 10°C/min with an Indium standard. Approximately 10 mg 
samples were encapsulated in T-zero hermetic DSC pans. All pans were matched within 
0.050 mg. The samples were then analyzed from 22 to 115°C using a sapphire heat flow 
standard. ASTM E-1269-05 was followed with the exception that a heating rate of 
10°C/min. was used. The purge gas was nitrogen with a flow rate of 50 cc/min. 
 
Figure 6.1 Experimental setup for measuring the heating rates of nanoparticle formulations 
  
6.2.6 Specific loss power determination 
The heat generated by the nanoparticles (SLP) exposed to AMFs is defined as the 
thermal power generated per unit mass of magnetic material. Heat generated by the 
nanoparticles can be estimated by measuring the temperature evolution with time of a 




temperature can be used to estimate the SLP of the nanoparticles based on the principle of 
conservation of energy, which is described in section 1.4. Based on first law of 
thermodynamics, if there is no mass or energy exchange between the nanoparticle sample 
and surroundings (adiabatic conditions), and if the heat generated is solely due to the 
nanoparticles, then the heating rate (SLP) of the nanoparticles can be estimated by , 







Here C is the heat capacity of the sample, mFe is the mass of iron in the sample, ΔT 
is the temperature increase, Δt is the change in time and ∆𝑇
∆𝑡
 is the rate of change of 
temperature with time [56,60].  The SLP for the aqueous and lipiodol formulations of BNF 
and JHU nanoparticles were determined from the temperature measurements and measured 
specific heat capacities using Equation 6.1., which is valid only under (quasi-) adiabatic 
conditions [60]. It was estimated by using methods and MATLAB code developed by 
Soetaert et al. [60]. Briefly, the method consists of identifying the (quasi)-adiabatic regions, 
where the ratio of net temperature rise and the time difference is within 5% of the net 
temperature increase slope. This net temperature rise slope was then used to estimate SLP 
using equation 6.1, where heat capacity C was determined by the product of specific heat 
capacity of the sample and the mass of the sample. This procedure was repeated for 
multiple time intervals (minimum of 6 s and maximum 100 s) and every time range that 
resulted in (quasi)-adiabatic conditions was considered to yield a new SLP-value. The 
average of all obtained SLP values was defined the measured SLP value and the standard 




6.2.7 Computational model – in vitro heating 
Heat transfer simulations were carried out to understand the role of heat transfer in 
the higher temperature changes observed for lipiodol formulations of nanoparticles. The 
heat generated by the nanoparticles is mainly stored in the formulation and is transferred 
to the surroundings by conduction, convection, and radiation. Computational simulations 
were carried out to compute the temperature rise in the sample for a heating rate (given by 
SLP) at a given magnetic field amplitude and frequency. For the lipiodol formulations of 
both BNF and JHU nanoparticles, two different SLP values were considered. In the first 
case, it was assumed that there was no difference in SLPs between the aqueous and lipiodol 
formulations. This was done to clearly understand the role of change in thermal properties 
of lipiodol formulations compared to aqueous formulations. In the second case, measured 
SLPs of lipiodol formulations were chosen. This allows us to understand the combined 
effect of change in thermal properties and SLPs on the rate of change in temperatures for 





values measured. The density of the samples were taken that of water (1000 kg/m3) for 
aqueous formulations and for lipiodol formulations it was taken to be 1140 kg/m3 which 
was determined by using the lipiodol density (1280 kg/m3) [206]. The thermal properties 
of styrofoam were chosen as follows, density (50 kg/m3) [210], thermal conductivity (0.033 
W/m-K) [213], and specific heat capacity (1215 J/kg-K) [214]. The temperature for the 
surroundings was assumed to be 23 °C (296.15 K) based on the experimental 
measurements. The outside of the styrofoam holder was exposed to the coil inside, hence 
a temperature boundary condition of Tcoil (t) was considered. For all other surfaces exposed 
to the surroundings, free convection heat transfer coefficient of 10 W/m2 K was considered. 
Heat loss due to radiation was neglected. Simulations were carried out for a time step of 
0.45s similar to that of our experimental conditions. SLPs were considered at two magnetic 
field amplitudes in the simulation, 12 kA/m, and 20 kA/m. The temperature changes for 
the aqueous and lipiodol formulations of both BNF and JHU nanoparticles were computed 
to compare with the observed experimental results. 
6.2.8 Magnetic characterization by magnetometry 
 Any magnetic material is well defined by its saturation magnetization (Ms) which 
is defined as the maximum magnetization observed when all the magnetic moments of the 
material are aligned parallel to the applied external magnetic field [51]. Saturation 
magnetization for the four nanoparticle formulations can be determined from the hysteresis 
loops measured at different temperatures. In this work, hysteresis loops were measured at 
temperatures from 5 K to 300 K at an applied field of ± 5570 kA/m using a superconducting 
quantum interference device vibrating sample magnetometer (SQUID VSM, Quantum 




(LakeShore Cryogenics) and sealed with epoxy to prevent evaporation of the water solvent 
during measurement under vacuum. Contributions from sample holder, water, polysorbate-
20, and lipiodol, were subtracted from the respective sample data. These experiments were 
conducted by Dr. Cindi Dennis at the Material Measurement Laboratory, National Institute 
of Standards and Technology, Gaithersburg, MD, USA. 
6.2.9 Computational model – in vivo heating 
Computational simulations were carried out to estimate the temperatures achieved 
in tissues with aqueous and lipiodol nanoparticle formulations of nanoparticles. Two 
concentric spheres (Figure 6.3) were considered to represent the tumor and healthy tissue 
model in this study. The inner sphere of volume 1 cm3 (d = 1.24 cm) represents the tumor 
while the outer sphere of diameter 12 cm represents the healthy tissue. The healthy tissue 
was chosen to be sufficiently large so as to impose a constant core body temperature 
boundary condition of 37 °C [141]. Heat transfer in the tumor and healthy tissue was 





2𝑇𝑛 + 𝜌𝑏𝑐𝑏𝜔𝑏,𝑛 ( 𝑇𝑏 − 𝑇𝑛 ) + 𝑄𝑚,𝑛 + 𝑄𝑝 (6.2) 
here n and b represent tissue (tumor, n = 1; healthy tissue, n = 2) and blood; respectively. 
ρn, cn, kn, Tn, Qm,n denote the density, specific heat, thermal conductivity, local temperature, 
and metabolic heat generation rate, for either tumor or healthy tissue and t is the heating 
time. ρb, cb, ωb,n, Tb denote density, specific heat, perfusion rate, and temperature, of blood 
respectively. For the current simulations, thermophysical properties of liver [122] were 
taken for healthy tissue which are summarized in Table 6-1. The metabolic heat generation 




power generated by nanoparticles in the tumor. In the current simulations, homogeneous 
uniform distribution of nanoparticle formulations were assumed inside the tumor. The 
volume of nanoparticle solution injected in the tumor was taken to be half  the tumor 
volume [66]. The mean values of specific heat c1, density ρ1, and thermal conductivity k1, 
for the tumor with the two nanoparticle formulations, BNF-water and BNF-lip, was 
approximated by,  
 𝑐1 = (1 −  𝜂)𝑐2 +  𝜂𝑐𝑛𝑝 (6.3) 











Here ρnp, cnp, knp, are the density, specific heat capacity, and thermal conductivity, 
of the nanoparticle formulations [215] and η is the volume fraction. The specific heat 
capacities of the nanoparticle formulations were taken from the values determined from 
measurements described in section 6.2.5. For the BNF-water formulation, the density and 
thermal conductivity were taken that of water, (1000 kg/m3, and 0.609 W/m-K) [210]. 
Since BNF-lip formulations consist of 1:1 v/v of water and lipiodol, the density was 
determined by using equation 6.4 with density of lipiodol taken as 1280 kg/m3 [206] and 
density of water to be 1000 kg/m3. Similarly thermal conductivity was determined using 
equation 6.5, with thermal conductivity of lipiodol taken as that of oil, given by 0.15 W/m-
K [211,212]. The SLP of BNF nanoparticles estimated at 20 kA/m in section 6.2.6 was 
used for Qp, the heat generated by the nanoparticles in this simulation. 
Thermal damage in tissue depends on the temperature achieved and time at 
temperature. Previous in vitro studies [26,29,30,32] have shown that thermal damage to 









where Ω is the Arrhenius damage index, A is the frequency factor, ΔEa is the activation 
energy barrier, and R is the universal gas constant. The survival fraction α is then given by: 
 𝛼(𝒓, 𝑇, 𝑡) =  𝑒−Ω(𝐫,T,t) (6.7) 
The values for A and ΔEa were taken to be 2.984 × 1080 1/s, and 5.064 × 105 J/mol 
respectively [141,148].  
Perfusion in tumor and healthy tissue was modeled as a function of thermal damage, 
which is based on modified Arrhenius model of thermal damage which was described in 
section 3.2.2. The initial perfusion ωbi for both tumor and healthy tissue was taken to be 
0.018 1/s [141,167].  
Continuity of temperature and conservation of heat flux boundary conditions were 
applied at the tumor-healthy tissue interface and the constant core body temperature 
boundary condition was assumed at the healthy tissue boundary. Summarized, the 












 𝑇𝑡𝑖𝑠𝑠𝑢𝑒(𝑟 = 𝑟𝑡𝑢𝑚𝑜𝑟 , 𝑡) = 𝑇𝑡𝑢𝑚𝑜𝑟(𝑟 = 𝑟𝑡𝑢𝑚𝑜𝑟 , 𝑡) (6.9) 
 𝑇(𝑟 = 𝑟𝑡𝑖𝑠𝑠𝑢𝑒) = 37 °C (6.10) 
The equations (6.2, 6.8 – 6.10) were solved numerically using finite element 
methods. Grid dependency tests were carried out to ensure that the chosen grid size had 
negligible effect on the computed temperatures. Changing the grid size from normal (10181 
tetrahedral elements) to fine (18889 tetrahedral elements) resulted in less than 0.04% 






6.3.1 Physical characterization by TEM 
TEM images of aqueous and lipiodol formulations of BNF and JHU nanoparticles 
is shown in Figure 6.4. Aqueous formulation of BNF nanoparticles show individual particle 
cores comprising iron oxide crystals forming small aggregates. The particles form 
elongated arms and the crystallites are in parallelepiped shapes consistent with previous 
observations [57,66]. When suspended in lipiodol (BNF-lip), the particles form large dark 
spherical clusters surrounded by lighter oil coating. In the case of JHU nanoparticles, a 
dense core of multiple spherical crystallites can be seen for the aqueous formulations. For 
the lipiodol formulations of JHU nanoparticles, dense particle aggregates are formed 
similar to the ones observed with BNF-lipiodol. The alteration of lipiodol formulations of 
BNF and JHU nanoparticles to make them tractable for TEM imaging limits the 





Figure 6.4 Aggregation of nanoparticles is observed in lipiodol formulations of both BNF 
and JHU nanoparticles. TEM images of aqueous and lipiodol formulations of BNF and 
JHU nanoparticles (clockwise) BNF nanoparticles in water; BNF-Lip – BNF nanoparticles 
suspended in lipiodol; JHU-Lip – JHU nanoparticles suspended in lipiodol; and JHU 






Figure 6.5 Measured change in temperatures with time for aqueous and lipiodol 
formulations of (a) BNF and (b) JHU nanoparticles with varying magnetic field amplitude 
(8 – 32 kA/m) at constant frequency of 155 ± 5 kHz. Contributions from water, lipiodol-






6.3.2 Heating rates of aqueous and lipiodol formulations 
The net change in temperature with time for the aqueous and lipiodol formulations 
of BNF and JHU nanoparticles measured at a range of magnetic field amplitudes beginning 
with 8 kA/m to 32 kA/m at 4 kA/m intervals at 155 ± 10 kHz frequency is shown in Figure 
6.5. As explained earlier, in the time-temperature data shown here the contributions from 
the respective backgrounds has been subtracted. Higher temperature changes were 
consistently observed for lipiodol formulation of BNF nanoparticles, compared to 
corresponding aqueous formulations across all measured amplitudes. This was not the case 
for JHU nanoparticles. While JHU-lip had higher temperature changes at lower amplitudes 
(8-16 kA/m), at higher amplitudes (20 – 32 kA/m) the difference in the change in 
temperature gradually decreased and were lower than that of aqueous formulations. These 
trends can be seen clearly when the difference in temperature changes between lipiodol 
and aqueous formulations is plotted in Figure 6.6. For BNF nanoparticles, lipiodol 
formulations consistently exhibited higher temperature changes across all amplitudes when 
compared to aqueous formulations. The difference in temperature change with time for the 
BNF nanoparticles increased consistently with increasing amplitude from 8 – 24 kA/m, 






Figure 6.6 Higher temperature rise was observed in lipiodol formulations of BNF 
nanoparticles at higher applied fields, while for JHU nanoparticles this is not true. 
Difference of temperature changes between lipiodol and aqueous formulations of (a) BNF 
and (b) JHU nanoparticles with varying applied magnetic field amplitude (8 – 32 kA/m) at 






Figure 6.7 No deterioration was observed in nanoparticle formulations due to repeated 
exposure to alternating magnetic field. Rate of change in temperature with time for lipiodol 
formulations of BNF and JHU nanoparticles when exposed to magnetic field amplitude of 
20 and 32 kA/m at constant frequency of 155 ± 5 kHz 
 
Replicate measurements of a given sample for the lipiodol formulations of BNF 
and JHU nanoparticles were carried out at 20 kA/m and 32 kA/m to estimate the 
reproducibility of the observed heating and the effect of repeated heating. The first 
derivative, approximated as the net temperature rise for each time step, was plotted with 
time (Figure 6.7), to determine if there were any changes. The plots show a similar change 
in the rate of change in temperature for both the lipiodol formulations suggesting that 
repeated exposure to alternating magnetic fields and heating have negligible effect on the 





Figure 6.8 Lipiodol formulations of nanoparticles have lower specific heat capacities than 
the corresponding aqueous formulations. Specific heat capacities of lipiodol, aqueous and 
lipiodol formulations of BNF and JHU nanoparticles measured using a differential 
scanning calorimeter between the temperatures 30 – 80 °C. (Specific heat capacity values 
for water were taken from [210]) 
 
Table 6-2 Specific heat capacity of lipiodol and nanoparticle formulations at 35 °C 







The rate of change in temperature is primarily influenced by the quantity of heat 
generated by the nanoparticles and the degree of heat transfer occurring which depends on 
the thermal properties of the formulation. Heat transfer in the formulation is mainly 




solvent and inversely proportional to the sample density and specific heat capacity. 
Measured values of specific heat capacities of lipiodol, BNF-water, BNF-lipiodol, JHU-
water and JHU-lipiodol were plotted in Figure 6.8. It can be seen that lipiodol has ~ 3 times 
lower specific heat capacity than that of water (1.394 J/g/°C at 35 °C). This resulted in 
lower (< ~2 x) specific heat capacities for BNF-lip and JHU-lip when compared to their 
aqueous formulations. It can also be observed that specific heat capacities remain relatively 
constant with change in temperature in the temperature range of 30-80 °C (Figure 6.8). 
Heat generated by nanoparticles, denoted by specific loss power (SLP), of the four 
nanoparticle formulations were reported in Figure 6.9. The temperature change rates and 
specific heat capacities of the nanoparticle formulations determined previously were used 
to determine the SLP for all the formulations. SLP estimated for the aqueous formulations 
of BNF and JHU nanoparticles were consistent with previously measured values 
[56,57,60]. They exhibit a non-linear amplitude dependent response (S-shaped curve) with 
both the aqueous and lipiodol formulations of BNF and JHU nanoparticles following a 
similar trend [56,57,216]. Both JHU-water and JHU-lip nanoparticles generate higher 
heating when compared to BNF-water and BNF-lip nanoparticles at lower amplitudes and 
this difference reduces at higher fields. This is consistent with previously reported values 
of SLP for BNF and JHU nanoparticles. However it is interesting to note that, while JHU-
lip exhibits higher SLP than BNF-lip, the difference reduces further from 82% at 8 kA/m 
to ~0 % at 32 kA/m. 
Interestingly, SLP values for lipiodol formulations of both BNF and JHU 
nanoparticles were consistently lower than that of their corresponding aqueous 




SLPs between the aqueous and lipiodol formulations is lower (average 26%) when 
compared with JHU nanoparticles (average 32%). Additionally, JHU-lip appears to be 
reaching saturation at lower fields (~ 20 kA/m) when compared to other nanoparticle 
formulations which were not close to saturation at the highest measured field amplitude of 
~ 32 kA/m. Further statistical analysis was carried out to compare the SLPs of the aqueous 
and lipiodol formulations of nanoparticles. To do this, all obtained values of SLPs for all 
formulations at each field were plotted using the box-whisker plots (Figure 6.10 and Figure 
6.11). In this plot, the boxes show the interquartile range (first (25%) and third (75%) 
quartiles, with the inside solid line showing the median SLP value. The whiskers show the 
maximum and minimum SLP values obtained for the formulations at each field. Mann-
Whitney analysis was conducted to compare the medians of both the formulations for BNF 
and JHU nanoparticles. Statistically significant difference (p-value <0.0001) was observed 
between the median SLPs of the aqueous and lipiodol formulations of both BNF and JHU 
nanoparticles. Both the reduced SLP and saturation of SLPs at lower amplitudes for 
lipiodol formulations, compared to aqueous formulations, suggests changes in the magnetic 








Figure 6.9 Specific loss power (SLP) of lipiodol formulations of BNF and JHU 
nanoparticles is lower than that of their aqueous formulations SLP of aqueous and lipiodol 
s formulations of (a) BNF and (b) JHU nanoparticles with varying magnetic field amplitude 






Figure 6.10 Statistical analysis of SLP for aqueous and lipiodol BNF nanoparticle formulations show significant difference. Box and 
whisker plots for the measured SLPs for BNF_Water and BNF_Lipiodol at fields of 8 – 32 kA/m at fixed frequency of 155 ± 10 kHz. 
Boxes denote the interquartile range while the center line shows the median SLP measured for each formulation at a given field. The 
whiskers denote the maximum and minimum values measured. Statistically significant reduction in SLP is observed (p<0.0001, ****) 






Figure 6.11 Statistical analysis of SLP for aqueous and lipiodol JHU nanoparticle formulations show significant difference Box and 
whisker plots for the measured SLPs for JHU_Water and JHU_Lipiodol at fields of 8 – 32 kA/m at fixed frequency of 155 ± 10 kHz. 
Boxes denote the interquartile range while the center line shows the median SLP measured for each formulation at a given field. The 
whiskers denote the maximum and minimum values measured. Statistically significant reduction in SLP is observed (p<0.0001, ****) 







6.3.3 In vitro heating simulation results 
Computed temperature changes with time for aqueous and lipiodol formulations of 
both BNF and JHU nanoparticles using measured SLPs are shown in Figure 6.12 and 
Figure 6.13. Temperature change was computed for SLP values at two field amplitudes of 
12 kA/m and 20 kA/m. For BNF nanoparticles, temperatures were consistently higher for 
lipiodol formulations at both amplitudes as observed in experiments (Figure 6.12). For 
same SLP, BNF-lip formulation exhibited higher temperatures than BNF-water and this 
was even higher at 20 kA/m when compared to 12 kA/m. When SLPs measured for BNF-
lip was used, the temperature of lipiodol formulation was lower than that with same SLP 
as that of aqueous formulation. However, the temperature was still higher than that of BNF-
water. For JHU nanoparticles, at both fields, for same SLPs, JHU-lip exhibited a higher 
temperature rise compared to JHU-water. However, when the measured SLP values for 
JHU-lip were used, the temperature change for JHU-lip was higher than JHU-water at 12 
kA/m and it was lower at 20 kA/m. This was similar to the trend observed in experiments 
(Figure 6.5 and Figure 6.6). These results show that lipiodol significantly influences both 
the thermal properties and the heat generation rates for the lipiodol formulations. 
6.3.4 Magnetic characterization 
 Hysteresis loops for the aqueous and lipiodol formulations of BNF and JHU 
nanoparticles at temperatures between 2 K and 300 K were shown in Figure 6.14 and Figure 
6.15. It can be seen that both the aqueous and lipiodol formulations of BNF and JHU 
nanoparticles have similar S-shaped curves at all temperatures. But the lipiodol 




compared to their aqueous formulations. Magnified view of hysteresis loops with virgin 
curves in the range of applied field of ± 36 kA/m for all the four nanoparticle formulations 
is shown in Figure 6.16 and Figure 6.17. It can be observed that the area enclosed by the 
hysteresis loops for all the nanoparticle formulations decreases with increase in 
temperature from 2 K – 300 K. Also, area enclosed by the hysteresis loops for lipiodol 
formulations of both BNF and JHU nanoparticles was lower than the corresponding 
aqueous formulations across all temperatures.  
 The variation in maximum magnetization for the four nanoparticle formulations is 
shown in Figure 6.18. For BNF nanoparticles, the lipiodol formulations have an average 
~36% lower maximum magnetization than BNF-water. In the case of JHU nanoparticles, 
this difference was slightly lower with lipiodol formulations having a mean ~ 24% lower 
maximum magnetization than JHU-water (Figure 6.18). Of all the four nanoparticle 
formulations, BNF-water has the highest maximum magnetization across all temperatures, 
with a maximum of 23.26 ± 0.67 kA m2 g-1 at 2 K. Interestingly, while BNF-water had 
higher maximum magnetization when compared to JHU-Water, for lipiodol formulations 
JHU-lipiodol had higher maximum magnetization compared to BNF-lipiodol. There was 
little difference in coercivity between lipiodol and aqueous formulations for both BNF and 
JHU nanoparticles (Figure 6.19). Overall, as expected coercivity of both the formulations 
of JHU nanoparticles was lower than that of BNF nanoparticles [51,53]. The approach to 
saturation for each of the nanoparticle formulations is shown in Figure 6.20. If it is assumed 
that the easy axis of nanoparticles for all the four formulations is aligned along the direction 








where M(H) is the total magnetic moment, N is the number of particles, m is the magnetic 
moment per particle, kB is the Boltzmann constant and T is the temperature. The measured 
M-H data were fitted to the above equation and the difference in the measured and fitted 
data were plotted for all the nanoparticle formulations as shown in Figure 6.21and Figure 
6.22. The second peak position in the field shows the effective anisotropy field which is 
proportional to the area enclosed by the loops. At 250K, the estimated effective anisotropy 
field for BNF-water and BNF-lipiodol was found to be 342.6 kA/m and 412.1 kA/m 
respectively. Similarly, the estimated effective anisotropy field for JHU-water and JHU-
lipiodol at 250K was 129 kA/m and 173 kA/m respectively. The area enclosed by the 
hysteresis loop can then be estimated to be proportional to the product of the effective 
anisotropy and maximum magnetization. This product was higher for BNF-Water (8.3 
J/kg) when compared to BNF-lipiodol (6.7 J/kg). Conversely, for JHU-Water this was 








Figure 6.14 Lipiodol formulations of BNF have lower saturation magnetization compared to aqueous formulations. Normalized 
hysteresis loops for BNF-water and BNF-lipiodol nanoparticles at temperatures 2 K – 300 K. The magnetic moments were normalized 





Figure 6.15 Lipiodol formulations of JHU have lower saturation magnetization compared to aqueous formulations. Normalized 
hysteresis loops for JHU-water and JHU-lipiodol nanoparticles at temperatures 2 K – 300 K. The magnetic moments were normalized 





Figure 6.16  Area enclosed decreases with increase in temperature for both aqueous and lipiodol formulations of BNF nanoparticles. 
Magnified view of measured of normalized hysteresis loops for BNF-water and BNF-lipiodol nanoparticles at temperatures 2 K – 300 





Figure 6.17  Area enclosed decreases with increase in temperature for both aqueous and lipiodol formulations of JHU nanoparticles. 
Magnified view of measured of normalized hysteresis loops for JHU-water and JHU-lipiodol nanoparticles at temperatures 2 K – 300 





Figure 6.18 Lipiodol formulations have lower maximum magnetization compared to 
aqueous formulations Maximum magnetization of lipiodol and aqueous formulations of (a) 








Figure 6.19 Lipiodol and aqueous formulations of BNF and JHU nanoparticles have similar 
coercivity Coercivity of lipiodol and aqueous formulations of BNF and JHU nanoparticles 
measured at temperatures 2 K – 300 K. 
 
 
Figure 6.20 Approach to saturation for lipiodol and aqueous formulations of BNF and JHU 





6.3.5 In vivo heating simulation results 
To estimate the heating of aqueous and lipiodol formulations of nanoparticles in 
tissues, simulations were carried out using the spherical tumor-healthy tissue model 
described in section 6.2.9. The mean values of thermal properties of tumor after injection 
of BNF-water and BNF-lipiodol, were calculated using equations 6.3 - 6.5, and shown in 
Table 6-3. The thermal diffusivity αt defined as the ratio of thermal conductivity and 
volumetric heat capacity, for tumor injected with BNF-lipiodol was lower (0.121 mm2/s) 
when compared to BNF-water (0.140 mm2/s). A higher thermal diffusivity will result in 
enhanced heat diffusion leading to more transfer of heat away from the heat sources 
(nanoparticles) in the tumor into the surrounding healthy tissue.  
Temperatures achieved at various distances from the center of the tumor after 20 
minutes of heating at constant power of 20 kA/m was shown in Figure 6.23 (a). Higher 
temperatures were achieved in tumor injected with BNF-lipiodol nanoparticles in 
comparison to BNF-water nanoparticles. The maximum temperature achieved in the tumor 
with BNF-lipiodol nanoparticles was 54.03 °C compared to 48.34 °C (10.5% lower) for 
tumor with BNF-water nanoparticles. The decrease in thermal diffusivity of the tumor 
results in higher temperatures leading to increased thermal damage and decreased survival 
as can be seen in Figure 6.23 (b). Volume of tumor with αt = 0 is higher for BNF-lipiodol 






Figure 6.21 Anisotropy field estimation using the Langevin function Difference in the 
measured magnetization and magnetization determined from fitting a Langevin function to 
the measured data for BNF-water and BNF-lipiodol  
 
Figure 6.22 Anisotropy field estimation using the Langevin function Difference in the 
measured magnetization and magnetization determined from fitting a Langevin function to 









Figure 6.23 Higher intra-tumor temperatures and thermal damage are achieved in tumors 
with BNF-lipiodol compared to tumors with BNF-water nanoparticles Computed (a) 
temperatures, (b) degree of survival at various distances from the tumor center after 20 min 






Table 6-3 Thermal properties of tumor with BNF-water and BNF-lipiodol nanoparticles 
 Tumor with BNF – 
Water 
Tumor with BNF-Lipiodol 
Thermal conductivity, k1 
(W/m-K) 
0.561 0.378 
Density, ρ1 (kg/m3) 1039.5 1109.5 




Magnetic nanoparticles have demonstrated increasing importance for medical 
applications such as in vivo imaging and therapy [38]. Magnetic nanoparticle hyperthermia 
has advanced for treatment of solid tumor cancers with magnetic iron oxide nanoparticles 
(MIONs) following favorable demonstrations of their biocompatibility and ability to 
generate hysteresis heating with an applied alternating magnetic field (AMF) [37]. Lipiodol 
is an iodinated oil, approved and preferentially used in many clinical image-guided 
procedures, both as an imaging agent and carrier fluid for active targeting of anti-cancer 
chemotherapy agents [206]. Formulations containing nanoparticles and lipiodol were 
previously used for intra-arterial therapies [66,128,129,202–205] but little efforts were 
made to understand the effect of lipiodol on the thermal and magnetic properties of these 
nanoparticles. The aim of the current study was to characterize the thermal and magnetic 




increased change in temperatures previously observed and using simulations to accurately 
estimate the temperatures that can be achieved inside tissue.  
TEM images of nanoparticles allow us to estimate the size and organization of the 
nanoparticles in its aqueous and lipiodol formulations. Size of nanoparticles is an important 
physicochemical property which can influence their use in imaging and therapeutic 
applications [217]. The size of the nanoparticle core and formation of complex structures 
such as chains, or clusters, has an influence on the overall heating power of these 
nanoparticles [51,60,216]. Complex structures can result from dipole-dipole interactions 
and can modulate the time-dependent relaxations of the magnetic domains as well as 
changes in anisotropy (colloidal anisotropy vs magnetocrystalline anisotropy) [51]. These 
can affect the overall heating efficiency of these nanoparticles. TEM images of aqueous 
formulations of BNF and JHU nanoparticles were consistent with previous results [57,66]. 
Surrogate samples of BNF-lip and JHU-lip nanoparticles show large particle clusters with 
central dark core of nanoparticles and a coating of lipiodol. However, the alteration of 
lipiodol formulations of BNF and JHU nanoparticles to make them tractable for TEM 
imaging limits the interpretation of the results obtained from these images. Cryo-TEM 
imaging also turned out to be futile as the lipiodol formulation sample was too thick for the 
beam to pass through. Additional measurements will be needed to verify and quantify these 
clusters but it is to be understood that lipiodol presents a significant challenge to use various 
measurement techniques. 
Heating rates of nanoparticle formulations are generally estimated by taking a 
sample of nanoparticle formulation in a tube, placing it in an AMF coil using an insulated 




[56,60,218]. The measured temperature rise of the sample is a measure of the change in 
internal energy of the sample. The rate of change in internal energy normalized to the mass 
of the nanoparticles depends on both the amount of heat generated by the nanoparticles and 
the volumetric heat capacity (product of density and specific heat capacity) of the 
formulations. Most of the formulations used for biological applications are generally water-
based and hence the effect of these thermal properties (density, specific heat capacity) on 
the heating rate and determination of SLP were generally neglected [218].  
 Rise in temperatures of BNF-lipiodol were consistently higher (Figure 6.5) 
compared to BNF-water across all the fields tested (8 – 32 kA/m) and were consistent with 
those reported by Attaluri et al. [66]. But a similar comparison of temperature rise for JHU-
water and JHU-lipiodol do not show a similar trend (Figure 6.5 and Figure 6.6). At lower 
amplitudes (8 – 16 kA/m), JHU-lipiodol has higher rise in temperatures compared to JHU-
water but at higher amplitudes (20 – 32 kA/m) this gradually decreases and eventually 
becomes lower than that of JHU-water. Increased particle sizes (below a specific size) 
result in higher heat generation by magnetic iron oxide nanoparticles [51]. While TEM 
images for both BNF-lipiodol and JHU-lipiodol show formation of large clusters, the 
measured heating rates for JHU-lipiodol were lower (at higher amplitudes) and do not show 
a clear trend as expected. As explained previously, the TEM imaging was conducted on 
concentrated surrogate formulations of BNF-lip and JHU-lip, which although can give a 
general idea of the particle sizes however limits the interpretation of these results.  
The volumetric heat capacity of the formulation is the product of density and 
specific heat capacity of the formulation. Under otherwise similar conditions, for a given 




temperature rises [218]. The density of lipiodol is 1280 kg/m3 [206], which is 1.28 times 
that of water. The specific heat capacity of lipiodol was measured to be 1394 J/kg K, which 
is ~3 times lower than that of water (4180 J/kg K). Thus, the volumetric heat capacity of 
lipiodol is ~2.3 times lower than that of water. Hence, the increased rise in temperatures 
observed for BNF-lip compared to BNF-water can be partly explained by the lower 
volumetric heat capacity of BNF-lip (2381460 J/m3-K) compared to that of BNF-water 
(418000 J/m3-K). However, the lack of replication of a similar trend by JHU-lip in 
comparison to JHU-water despite having a similar lower volumetric heat capacities 
suggests possible changes in the heat generated (SLP) by the nanoparticles.  
Interestingly, SLPs of lipiodol formulations of both BNF and JHU nanoparticles 
were lower when compared to their corresponding aqueous formulations (Figure 6.8). The 
difference in SLP between the lipiodol and aqueous formulations of both BNF and JHU 
nanoparticles increased with increasing amplitude of applied magnetic field. Statistical 
analysis of the SLPs for both aqueous and lipiodol formulations signify a statistical 
difference for the both the BNF and JHU nanoparticles (Figure 6.10 and Figure 6.11). This 
shows that there is a significant change in the magnetic properties of the nanoparticles 
when they are suspended in lipiodol. For BNF nanoparticles, the difference in SLP between 
BNF-water and BNF-lip reduces from ~33% at 8 kA/m to ~17% at 24 kA/m and increases 
to ~29% at 32 kA/m. This reduction in difference in SLP between BNF-water and BNF-
lip combined with lower volumetric heat capacity results in higher rise in temperatures for 
BNF-lip compared BNF-water (Figure 6.6). The slight decrease in temperature rise for 




unwanted solvent heating due to heat transfer from the coil through the styrofoam [56], as 
evidenced by the measured background temperatures at those fields.  
The reduction in SLP for lipiodol formulation of JHU (average 31.6%) compared 
to JHU-water was significantly higher than that of BNF nanoparticles (average 25.8%). 
Also, in contrast to BNF nanoparticles, the difference in SLP between JHU-lip and JHU-
water increases consistently from ~17% at 8 kA/m to ~42% at 32 kA/m. This reduction in 
SLP with increasing amplitude results in higher temperatures for JHU-lip at lower 
amplitudes (8 – 16 kA/m)  and lower temperatures at higher amplitudes (20 – 32 kA/m) 
despite having lower volumetric heat capacity, compared to JHU-water. These results show 
that while lower volumetric heat capacity of lipiodol formulations can enhance the rate of 
rise in temperatures, significant reduction in SLP could result in overall lower rate of rise 
in temperatures. This is further confirmed with the computed change in temperatures 
(Figure 6.12 and Figure 6.13) for the nanoparticle formulations using the computational 
model described in 6.2.7. 
The magnetic properties of the aqueous and lipiodol formulations of BNF and JHU 
nanoparticles were characterized by measuring the hysteresis loops at temperatures ranging 
between 2 K and 300 K. Maximum magnetization of BNF-lip and JHU-lip were 
significantly lower than the corresponding aqueous formulations of BNF and JHU 
nanoparticles at all measured temperatures. For BNF nanoparticles, the average maximum 
magnetization for BNF-lip was ~36.1 % lower than that of BNF-water. This significant 
difference in magnetization suggests that the nanoparticle cores of the two formulations 
are different. The difference of SLP that was obtained from temperature measurements can 




nanoparticles, the average maximum magnetization for JHU-lip was ~24% lower than that 
of JHU-water. This is lower than the average difference in SLP (~31.6 %) for JHU-lip 
which suggests that this observed difference cannot be attributed to reduction in 
magnetization alone. Change in magnetic anisotropy and size of nanoparticles can also 
significantly impact the heating efficiency of these nanoparticles [51,57]. Suspending the 
nanoparticles in lipiodol had little effect on the coercivity of the nanoparticles (Figure 
6.19). The approach to saturation for the lipiodol and aqueous formulations of BNF and 
JHU nanoparticles shows distinct variations (Figure 6.20). These differences can be 
attributed to different magnetic anisotropies or changes in interactions or change in crystal 
structure/compositions [57,58]. The estimated effective anisotropies showed that the 
lipiodol formulations have higher anisotropy compared to aqueous formulations for both 
BNF and JHU nanoparticles. The area enclosed by M-H loop which is proportional to the 
product of saturation magnetization and effective anisotropy can be used to qualitatively 
compare the observed differences in SLP. For BNF nanoparticles, this product was 
significantly lower (~18.6 %) for lipiodol formulation compared to aqueous formulation. 
This is similar to the observed differences in SLP (average ~ 25.8% lower) for BNF-lip 
compared to BNF-water. However, for JHU nanoparticle formulations, this product was 
slightly higher (~3%) for JHU-lip compared to JHU-water. Thus, while DC bulk magnetic 
measurements can be helpful in determining the saturation/maximum magnetization for 
the nanoparticle formulations, the energy dissipated by these nanoparticle formulations 
depends critically on the internal magnetic structure and further measurements would need 




The higher temperature rates observed with BNF-lipiodol compared to BNF-water 
translated to higher intra-tumor temperatures in simulations carried out on a spherical 
tumor-healthy tissue model. SLP of nanoparticles in vivo can vary significantly depending 
on multiple factors such as aggregation of particles, interparticle interactions, protein/cell-
nanoparticle interactions [48,216,219]. Hence, the same SLP (142 W/g Fe @ 20 kA/m) for 
BNF and BNF-lipiodol was taken to understand the effect of solvent on the temperature 
distribution inside the tumor. As expected, BNF-lip results in higher intratumor 
temperatures and thermal damage compared to BNF-water. This was consistent with the 
enhanced heating observed by Attaluri et al. [66] in their in vivo experiments. The lower 
volumetric heat capacity of lipiodol results in lower thermal diffusivity, helping 
concentrate the heat inside the tumor, resulting in higher intratumor temperatures. Also, 
lipiodol can also introduce biological effects such embolization [206] which can result in 
decrease of blood perfusion. As blood perfusion acts as a heat sink, the reduction in blood 
perfusion can lead to further increase in intratumor temperatures and thermal damage.  
The methods for estimating the SLPs of the formulations have some limitations. 
Despite the water cooling of the coil, the temperature inside the coil surface rises 
significantly during the experiment. The styrofoam used as the sample holder is not 
completely insulating and this results in heat transfer from the coil to the sample. With the 
relative change in specific heats of formulations, subtraction of background blanks itself 
will not compensate for the heat transfer from the coil. This can lead to error in estimation 
of SLPs for the formulation. The shape of the sample tube and volume of sample can also 
have an effect on the estimated SLPs [218]. Using a spherical shaped bottom sample and 




model used for estimating the effects of lipiodol on intratumor temperatures has some 
limitations. First, the assumption of homogeneous distribution of nanoparticles is 
impractical. In reality, the nanoparticle distribution inside the tumor is highly 
heterogeneous. Further, a porous tumor model would be more realistic representation of 
the tumor compared to the current model considered. Additionally, the effect of lipiodol 
on the vascular structure and thereby on blood perfusion should be considered.  
 
6.5 Conclusion 
In this chapter, the thermal and magnetic properties of lipiodol and aqueous 
formulations of BNF and JHU nanoparticles were determined. The rise in temperatures of 
the nanoparticle formulations was measured at different fields and compared. The 
enhanced rise in temperatures observed for BNF-lip in comparison to BNF-water is mainly 
attributed to the change in thermal properties of solvent. SLP of lipiodol formulations of 
both BNF and JHU nanoparticles was lower than the corresponding aqueous formulations. 
Bulk magnetization measurements showed a significant reduction in magnetization for 
both BNF-lip and JHU-lip compared to their respective aqueous formulations. These 
results show that both heat generation, which is governed by magnetic properties, and heat 
transfer, which is governed by the thermal properties, of the formulation need to be 
considered to estimate the heating performance of nanoparticle formulations to ensure 
optimal heating with imaging features. Additional physical and magnetic characterization 
would further allow us to understand the effect of lipiodol on the core of these nanoparticle 







Chapter 7  
Thesis summary and future work 
 
7.1 Thesis summary 
With cancer becoming one of the leading causes of death worldwide, extensive 
research efforts are being focused to understand the disease and develop treatments for it. 
Current standard of care treatments such as surgery, chemotherapy, and radiation therapy 
have not been effective for all cancers and have been known to have a significant effect on 
patient’s quality of life. Many efforts are currently being undertaken across the world to 
come up with alternative treatment strategies to improve the efficacy of these treatments 




selectively raising tissue temperatures to inflict thermal damage to cancer cells and 
sensitize them to traditional treatments such as chemotherapy and radiation therapy. Of the 
different hyperthermia treatment modalities, magnetic nanoparticle hyperthermia has 
emerged as one of the most promising because of its ability to selectively heat causing 
precise and localized thermal damage. The potential to deliver tumor specific heating while 
minimizing surrounding healthy tissue heating makes it the most attractive hyperthermia 
modality. Principal challenges for magnetic nanoparticle hyperthermia to become a 
treatment modality are intratumor nanoparticle distribution, nanoparticle targeting, and 
minimizing off-target eddy current heating. This thesis has been an attempt to address these 
challenges by developing strategies and new computational tools. Using heat transfer 
analysis, computational and experimental efforts were carried out to develop an 
understanding of the above challenges and present strategies for optimization.  
Nanoparticle distribution inside tumor following direct intratumor injection is 
influenced by injection parameters and by tumor physiological and mechanical properties. 
This leads to limited control of the nanoparticle distribution inside the tumor. In chapter 2, 
we first studied the effect of nanoparticle distribution on the temperatures generated inside 
the tumor using a spherical tumor model with two distributions – uniform and concentrated. 
Constant power simulations were conducted to understand and highlight the temperature 
distributions achieved. We then conducted modulated power heating based on temperature 
feedback at three different locations and showed that modulating power using temperature 
feedback from the tumor-healthy tissue boundary can deliver therapeutic dose to the tumor 




In chapter 3, this modulated power heating was then improved and implemented in 
both 2D and 3D computational models for a range of distributions including those derived 
from animal models. Temperature effects on perfusion were included by modeling it as a 
function of thermal damage. The modulated power heating method presented in chapter 2 
was further improved by implementing a PID controller with temperature feedback from 
tumor-healthy tissue boundary. It was shown that PID controlled modulated power heating 
can deliver therapeutic thermal doses to the tumor with minimal surrounding healthy tissue 
damage. We then compared modulated power heating with constant power heating to show 
that, with modulated power heating effective thermal damage can be achieved with overall 
lower temperatures and more temperature homogeneity. Overall, controlling the 
temperatures achieved at the tumor-healthy tissue boundary with modulated power heating 
can deliver effective thermal dose to the tumor while simultaneously minimizing healthy 
tissue damage, compensating for nanoparticle distributions.  
We then conducted an in vivo pilot study to implement the modulated power heating 
in subcutaneous xenograft models of liver cancer in mice. Subcutaneous tumors were 
generated by injecting HepG2 cells on the right thigh of tumor. When the tumor reached 
the target treatment volume, nanoparticles were injected using two injection methods, 2-
pt, and 3-pt with a syringe pump. This was done to generate two intratumor nanoparticle 
distributions. Using Prussian blue staining combined with image analysis, we generated 
3D nanoparticle distributions for the tumors. The generated 3D nanoparticle distributions 
show that in spite of using controlled nanoparticle injection methods, achieving similar 
distributions is not possible. For animals in the AMF treatment group, we then manually 




tissue interface, to achieve a target temperature of 43.5 ± 0.5 °C. Our results showed that 
effective control of temperature at the tumor-healthy tissue interface can be achieved for 
both the distributions consistently. However, treatment resulted in ablation of tumors and 
skin damage, restricting our study to determine the therapeutic potential. We then carried 
out a computational study to compare and understand the results from the animal 
experiments. Results from our simulations predict ablation and skin damage as observed 
in experiments. This shows that the chosen subcutaneous models, despite their advantages 
for ease of nanoparticle delivery and tumor measurements, are unsuitable to test our 
modulated power heating strategy. Additionally, qualitative agreement can be observed 
between our animal experiments and computational simulations. 
Chapter 5 included a rigorous verification and validation of a computational model 
incorporating both electromagnetic and heat transfer physics. We first developed a 
computational model which can be used to simultaneously solve for both electromagnetic 
and heat transfer physics allowing us to understand and model both nanoparticle heating 
and off-target eddy current heating. The model was first verified with the analytical model 
and then validated by temperature measurements in agar gel phantom with no nanoparticles 
exposed to an alternating magnetic field. After this, we developed a 3D model of rabbit 
liver from CT scan images and computed the temperature distribution due to off-target 
eddy current heating. Our results showed that hyperthermic temperatures can be achieved 
at the edges of the liver which can result in significant thermal damage. These models may 
possibly be used for treatment planning to determine the optimum field parameters for 




Magnetic nanoparticles suspended in lipiodol can offer dual imaging capabilities in 
addition to combined chemotherapy and hyperthermia. In chapter 6, we determined the 
heating efficiency of these dual contrast magnetic nanoparticle formulations used for 
image-guided magnetic nanoparticle hyperthermia. We measured the specific heat for the 
lipiodol nanoparticle formulations to be half that of aqueous nanoparticle formulations. 
With this we showed that the observed higher rise in temperatures for lipiodol nanoparticle 
formulations was due to reduced specific heat compared to aqueous formulations. 
Additionally, we also showed that the suspending nanoparticles in lipiodol reduces their 
heating efficiency compared to aqueous suspensions. Using simulations, we showed that 
the observed difference in rise in temperatures for BNF and JHU nanoparticle formulations 
was due to a combined effect of change in specific heat capacity and decreased heating 
efficiency. Additionally, bulk magnetic measurements also showed a reduction in 
maximum magnetization for lipiodol formulations compared to aqueous formulations 
confirming the observed reduced heating efficiency. 
 
7.2 Future work 
The temperature control modulated power heating strategy presented in this thesis 
relies on temperature feedback from single location on the tumor-healthy tissue boundary. 
With the advent of real-time 3D temperature mapping, temperature feedback from multiple 
locations on the tumor can be utilized to design a more robust control heating method which 
can further improve the efficacy of modulated power heating. This becomes important for 
tumors near sensitive organs such as brain, where the allowance for healthy tissue damage 




the tumor can enable us to employ more realistic and accurate bioheat transfer models, 
some of which were introduced in chapter 1. This would lead to a better understanding of 
the role of blood perfusion in the temperature distributions generated both inside the tumor 
and in its vicinity. It is also important to include the role of large blood vessels and artery-
vessel pairs when modeling tissues located closer to them. When quantifying thermal 
damage computationally, it is important to include the thermal sensitivity of that individual 
cell line instead of using a generic model [29].  
Experimental investigation of modulated power MNPH should be carried out in 
deep seated orthotopic tumor models in large animals. Our in vivo experiments clearly 
show that subcutaneous mouse tumor models are unsuitable for testing modulated power 
MNPH due to ablation. Also use of imaging resources such as CT imaging for nanoparticle 
distribution and ultrasound for temperature probe placement would be required and critical 
for accurately testing this treatment strategy. Additionally, large animal models also allow 
us to test the limits of power modulation hyperthermia as eddy current heating effects 
become significant for large animals. This would then require a careful improvement of 
the temperature control modulated heating strategy to ensure maximizing tumor thermal 
damage and minimizing healthy tissue heating both due to nanoparticle heating and eddy 
currents. The combined electromagnetic and heat transfer model developed in chapter 5 
can be used to for further improving the modulated power heating strategy to include non-
specific eddy current heating effects. The interplay between maximizing tumor thermal 
dose while ensuring minimal heating of healthy tissue with increases in healthy tissue 




with realistic tissue-tumor models generated from CT images (as presented in chapter 5) 
can be used to develop treatment strategies that can be readily translated to the clinic.  
The methods developed for generating 3D nanoparticle distribution using Prussian 
blue images can be used as relatively cheaper method for determining the nanoparticle 
distribution for labs with limited access to imaging facilities. However, care should be 
taken for registration of individual tissue slides to ensure that the generated nanoparticle 
distributions represent the real intratumor nanoparticle distribution. For lipiodol 
nanoparticle formulations, further magnetic characterization need to be conducted to 
understand the internal structure of the particles. Small angle neutron scattering 
experiments can be conducted to determine the internal magnetic structure of these 
formulations. However, it should be noted that the presence of lipiodol can make 
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